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Akirin1 is a small (191 amino acid) ubiquitously expressed protein, which 
belongs to a family of highly conserved nuclear proteins called akirins. Due to 
its nuclear localization and propensity to interact with other proteins, Akirin1 
is speculated to regulate transcription of its target genes as a cofactor. Previous 
studies have shown that Akirin1 is a downstream target of myostatin, which is 
a negative regulator of myogenesis. Akirin1 was expressed at higher levels in 
mice lacking myostatin and consistent over-expression of Akirin1 induced 
hypertrophy in C2C12 myotubes in vitro.  
To further elucidate the function of Akirin1 in striated muscle (skeletal muscle 
and cardiac muscle), an Akirin1 knock-out mouse model was used in this 
study. The results of this study show that Akirin1 knock-out mice did not 
show any obvious phenotypic change when compared to wild-type mice. The 
molecular analysis of important myogenic genes performed on Akirin1 knock-
out skeletal muscle revealed that levels of myogenic genes were unchanged 
apart from myogenin.  
Molecular analysis of sarcomeric genes like α-actin, Myosin heavy chain and 
troponins showed that Akirin1 knock-out skeletal muscle showed reduced 
levels of these proteins compared to the wild-type. Lack of Akirin1 also leads 
to reduced levels of certain cytoskeletal proteins like desmin and poly-
glutamylated tubulin compared to the wild-type. These results indicate that 
Akirin1 plays an important role in maintaining the structural integrity in 
skeletal muscle.  
One other important protein that helps in maintaining the sarcomere stability is 
MuRF1. Molecular analysis of MuRF1 in Akirin1 knock-out muscle showed 
xii 
 
that MuRF1 mRNA and protein levels were down-regulated. Similarly, 
Akirin1 knock-out primary myoblast cultures also showed reduced MuRF1 
mRNA and protein levels during differentiation. The results showed that 
Akirin1 regulates MuRF1 level in skeletal muscle. To determine how Akirin1 
regulates MuRF1, we analyzed the promoter region of MuRF1. The promoter 
analysis showed FoxO3 and CREB-1 binding sites on MuRF1 promoter. 
Indeed, FoxO3 and CREB-1 protein levels were down-regulated in Akirin1 
knock-out muscle compared to the Wild-type. Consistently, the levels of 
MuRF1, CREB-1 and FoxO3 were up-regulated when Akirin1 was over-
expressed in C2C12 myoblasts. Promoter-reporter assay results indicated that 
Akirin1 might be regulating the transcription of MuRF1 through CREB-1 and 
FoxO3.    
One of the molecules important for maintaining the post-natal muscle mass 
and myoblast differentiation is serum response factor (SRF). We saw 
increased SRF levels in differentiating primary cultures compared to the wild-
type. It is likely that Akirin1 negatively regulates SRF during differentiation 
because SRF, being a target of MuRF1, is not degraded due to lower MuRF1 
levels.  
Gene expression analysis showed that Akirin1 transcriptionally regulates the 
expression of different types of Myh genes. As a result of which, lack of 
Akirin1 makes the muscle less oxidative due to increase in Myh2, thus an 
increase in type IIa muscle fibers and decrease in Myh7, thus a decrease in 
type I muscle fibers. This shows a novel role of Akirin1 in maintaining the 
muscle fiber type and in turn regulating the metabolic activity of the muscle.  
xiii 
 
Akirin1 was found to have an interesting function in cardiac muscle. 
Histological analysis of Akirin1 knock-out heart showed larger ventricular 
cavity as seen in left ventricular hypertrophy (LVH). Absence of Akirin1 was 
shown to post-transcriptionally up-regulate serum response factor (SRF), 
which is known to affect the gene expression of cardiac hypertrophy inducing 
genes like β-MyHC and atrial natriuretic peptide (ANP) and miR-1. Our 
results showed that β-MyHC and ANP were transcriptionally up-regulated and 
miR-1 level was transcriptionally down regulated in Akirin1 knock-out 
cardiac muscle compared to the wild-type cardiac muscle. Thus, proposing 
that Akirin1 regulates SRF, which in turn maintains cardiac mass through 
regulating miR-1 expression. In summary, we speculate that Akirin1 regulates 
skeletal muscle metabolism and cardiac hypertrophy through different 
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OVERVIEW OF THE THESIS 
 
Akirin1 is one of the relatively unstudied molecules in muscle biology, in 
terms of its potential role and the various facets that are still left to be 
explored. This small nuclear protein is evolutionarily conserved and known to 
be ubiquitously expressed in all the tissues. As Akirin1 has been previously 
established as an important pro-myogenic factor in myogenic cells (Marshall 
et al., 2008), our study involves understanding the role of Akirin1 in fully 
differentiated striated muscle (both skeletal and cardiac muscle).  
As the emphasis of this study is in skeletal and cardiac muscle, relevant 
literature about skeletal and cardiac muscle structure, development and 
function and the various factors involved in these processes has been reviewed 
in chapter 1. The various materials and methods used in this study have been 
explained in chapter 2. The novel findings of this study are divided into three 
chapters in which the possible role of Akirin1 in myogenic differentiation, 
skeletal muscle and cardiac muscle has been discussed respectively. 
Through this study we have established a novel role of Akirin1 in regulation 
of genes involved in maintenance of sarcomere structure and function. 
Additionally, we have shown an important function of Akirin1 in maintaining 
fiber-type composition and metabolic homeostasis in skeletal muscle. 
Furthermore in cardiac muscle, our results indicate an important role of 
Akirin1 in maintaining cardiac muscle mass via regulating miR-1 biogenesis. 
In summary, our study indicates a novel function of Akirin1 in both skeletal 
muscle and cardiac muscle albeit through different mechanisms.   
















































1. REVIEW OF LITERATURE 
1.1 Skeletal muscle 
Skeletal muscle is a highly contractile tissue derived from the mesodermal 
layer of embryonic germ cells. Skeletal muscle makes up to 40-50 % of the 
total body weight making it one of the largest organs. Vertebrates have three 
types of muscle tissue: skeletal, cardiac and smooth muscle. Skeletal and 
cardiac muscle are striated muscle while smooth muscle is non–striated.  
Although the three types of muscle share similar features, they vary from each 
other in their location, microscopic structure and how they are influenced by 
the nervous system. Skeletal muscle is controlled by somatic nervous system 
and thus is voluntarily controlled. This tissue is mostly attached to the skeleton 
via bundles of collagen fibers called tendons that aid in locomotion, stabilizing 
joints and posture maintenance. However, there are a few skeletal muscles that 
assist in the movement of other skeletal muscles or movement of certain 
internal organs. Skeletal muscle is metabolically active tissue playing a major 
role in carbohydrate and lipid metabolism and maintaining the energy 
homeostasis of the body.  
1.1.1. Skeletal muscle structure 
Skeletal muscle is a highly organized tissue composed of several distinct 
compartments of muscle fibers. An individual skeletal muscle is contained 
within a layer of connective tissue called the epimysium (Seeley et al., 2006) 
(Figure 1.1A). Skeletal muscle is further divided into smaller compartments by 
the perimysium called fascicle. In turn, a fasciculus contains bundles of 
muscle fibers encased by a layer of connective tissue called endomysium.  
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Each muscle fiber is a multinucleated single cell, enclosed by sarcolemma, 
and is predominantly made up of myofibrils (Seeley et al., 2006) (Figure 
1.1B).  Each myofibril in turn is made up of various types of proteins that 
form the contractile element of muscle called sarcomere (Seeley et al., 2006) 
(Figure 1.1C). Myofibrils basically contain three categories of proteins which 
function jointly leading to the contraction of the muscle: 1) Structural proteins, 
which give the frame work and elasticity to the muscle like titin and desmin; 
2) Contractile proteins, which provide force during contraction of the muscle 
like actin and myosin; 3) Regulatory proteins, which regulate the process of 
contraction and relaxation of the muscle like troponins (Martini, 2006). The 
detailed structure of sarcomere will be later discussed in detail in section 
1.1.1.1.    
Apart from myofibrils, muscle fibers contain vital organelles like 
mitochondria, sarcoplasmic reticulum and myonuclei in sarcoplasm. 
Sarcoplasmic reticulum is made up of numerous transverse tubules and 
terminal cisterns filled with interstitial fluid. Two terminal cisterns and a 
transverse tubule form a triad, which invaginates from the sarcolemma to the 






       
Figure 1.1 Skeletal muscle structure (A) Skeletal muscle is made up of 
fascicles, which are enclosed in the perimycium. The entire skeletal muscle is 
enclosed in the epimycium. (B) Fascicles are made up of muscle fibers, which 
are enclosed in the endomycium. (C) Muscle fiber is made up of myofibrils, 
which are in turn made up of sarcomeres enclosed in sarcolemma. Sarcomeres 
are mainly composed of actin and myosin filaments. Figure freely downloaded 
at http://commons.wikimedia.org/wiki/File:1007_Muscle_Fibes_%28large% 
29.jpg (Anatomy & Physiology, Connexions Web site. http://cnx.org/content/ 












1.1.1.1. Sarcomere structure 
Sarcomere is the basic structural and functional element of skeletal muscle. It 
is defined by borders made of dense line of protein called Z-line. In between 
the Z line are series of thick and thin protein filaments, along with proteins 
that regulate the movement of thick and thin filaments. The thin actin 
filaments are 1-2 µm long and 8 nm in diameter, while thick myosin filaments 
are 1-2 µm long and 16 nm in diameter. Regular arrangement of these thick 
and thin filaments gives striated appearance to the muscle fiber. Due to 
differences in the density of thick and thin filaments, sarcomere shows dark A 
band at the center consisting of predominantly thick filaments and light I band 
at the periphery consisting of thin filaments. The center of the dark A band is 
bisected by M line of proteins which hold the thick filaments together. Under 
resting conditions, dark A band consists of two zones- H zone, which is the 
portion on either side of the M line consisting only of thick filaments; Zone of 
overlap, which is the portion where thick and thin bands overlap.  During 
muscle contraction, due to increased overlapping of thick and thin filaments, 
the dark A band increases in size while light I band and H zone decreases, 
resulting in the shortening of the sarcomere (Campbell, 1996; Martini, 2006; 
Wakabayashi et al., 2010) (Figure 1.2A). The thick filament is predominantly 
made of rod-shaped protein called myosin. Each myosin molecule is made up 
of two myosin heavy chains (MyHC) and four myosin light chains (MLC). 
Myosin heavy chain protein has two catalytic globular heads at one end that 
binds to ATP, a regulatory neck region at the center made up of a pair of MLC 
and a tail at the other end. About 300 myosin molecules polymerize at the tail 
region to form the thick filament and the globular heads protrude from the 
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thick filament. The thin filament is predominantly made of globular proteins 
called actin. Many actin molecules polymerize and form long double helical 
structure called the thin filament. The globular heads of myosin interact with 
the actin filaments and lead to sliding of the filaments along each other 
eventually leading to contraction of the sarcomere. Apart from the structural 
proteins, a sarcomere contains regulatory proteins associated with the 
myofibrils that play important role in regulation of sarcomere contraction- 
Tropomyosin and troponin complex. Tropomyosin is a long myofibrillar 
protein that fits into the groove of two actin filaments and anchors Troponin 
complex. Troponins are a complex of three proteins- Troponin C, Troponin T 
and Troponin I.  Troponin C contains a Ca
2+
 binding domain, troponin T 
interacts with tropomyosin and troponin I blocks the interaction of myosin and 
actin filaments (Figure 1.2B).  When nerve impulses reach the neuromuscular 
junction, Ca
2+
 is released from the sarcoplasmic reticulum of the muscle fiber. 
Interaction of Ca
2+ 
with Troponin C leads to conformational change in 
Troponin I as a result of which Troponin T is able to interact with tropomyosin 
and this allows interaction of myosin heads with actin filaments (Bagshaw, 
1993; Campbell et al., 1996). According to sliding filament theory of muscle 
contraction, myosin head binds to adenosine triphosphate (ATP) and 
hydrolyzes ATP to adenosine diphosphate (ADP) and a phosphate ion. The 
energy released activates the myosin heads to interact with active site on the 
actin filaments creating a cross-bridge between thick and thin filaments. The 
hinge region of myosin molecule consisting of MLC acts as a regulatory lever 
for the myosin head domain. Myosin head then releases the ADP and 
phosphate ion while pulling the thin filament along. ADP on the myosin head 
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is recharged with ATP leading to dissociation of Myosin and actin bond, thus 
preparing for the next cycle. Many myosin heads together ‘walk’ on the actin 





Figure: 1.2 Sarcomere structure and function. (A) Structure of sarcomere 
showing different regions during contraction. Figure freely downloaded from 
http://commons.wikimedia.org/wiki/File:Sarcomere.gif on 29.12.2014. (B) 
Sarcomere is mainly made up of actins, myosins and troponins that work in 
consort leading to the contraction of the sarcomere. Figure freely downloaded 
from http://commons.wikimedia.org/wiki/File:Myofilament.svg (Häggström, 
Mikael. "Medical gallery of Mikael Häggström 2014". Wikiversity Journal of 






1.1.1.2. Sarcomeric proteins and their function 
During muscle contraction, the highly organized assembly of hundreds of 
actin and myosin filaments of the sarcomere is anchored at the Z-line and M-
band by important sarcomeric proteins. Some of the important sarcomeric 
proteins that anchor the actin and myosin filaments are discussed in the 
following paragraphs.  
Titin is a giant protein that stabilizes the whole structure of the sarcomere by 
interacting with majority of the proteins at the Z-line and M-line 
(Tskhovrebova et al., 2003). It has been shown that myogenic cells lacking the 
titin protein have defective sarcomeric assembly (Person et al., 2000; Van der 
Ven et al., 2000). Obscurin, another important giant protein interacts with titin 
in the Z-line and ankyrin-1 in the sarcoplasmic reticulum, thus anchoring the 
myofibrillar assembly to the sarcoplasmic reticulum (Young et al., 2001; 
Kontrogianni-Konstantopoulos et al., 2003; Bagnato et al., 2003).  
Muscle specific RING–finger proteins (MuRFs) belong to the family of 
RING/B box/Coiled coiled (RBCC) proteins consisting of three homologous 
MuRF genes i.e., MuRF1, MuRF2 and MuRF3 (Centner et al., 2001). The 
MuRF proteins are expressed in a tissue-specific manner and also homo- or 
heterodimerize through their coiled-coiled domain (Centner et al., 2001; Pizon 
et al., 2002).  MuRF1 and MuRF2 are known to interact with titin protein at 
the M-line. Also, MuRF1 and MuRF3 interact with the sarcomeric proteins at 
the Z-line (Centner et al., 2001; Pizon et al., 2002). Thus, indicating that 
MuRF may be providing protein-protein interaction to various sarcomeric 
proteins in holding the sarcomere together. MuRFs have also been shown to 
interact with glutamylated tubulin present in the microtubules of the sarcomere 
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(Spencer et al., 2000; Pizon et al., 2002). Thus, it was shown that reduced 
MuRFs levels resulted in defective myofibrillar assembly and instability of the 
M-line structure of the sarcomere in cultured skeletal myocytes (Pizon et al., 
2002; McElhinny et al., 2004). MuRFs have another distinct function of 
ubiquitinating the target proteins. It was shown that mice lacking MuRF1 are 
resistant to muscular atrophy and showed reduced E3 ubiquitin ligase activity 
in vitro (Fielitz et al., 2007; Bodine et al., 2001).  
Desmin is an intermediate filament protein present specifically in striated 
muscle.  This protein forms a scaffold in the Z-line connecting the sarcomere 
organelles together. Thus, desmin provides structural and mechanical stability 
to the myofibrillar assembly and the sarcomere in the muscles (Fuchs et al., 
1994). It has been shown that lack of desmin leads to myofibrillar myopathy 
and muscular dystrophy (Fuchs et al., 1998) (Figure 1.3). There are other 
important sarcomeric proteins, which will not be discussed as they are beyond 



















Figure 1.3 Important proteins in the sarcomere. Apart from actins and 
myosins, a sarcomere is made up of various structural, contractile and 
regulatory proteins which have specific function in the sarcomere. Figure 
freely downloaded and modified from 
http://commons.wikimedia.org/wiki/File:Sarcomere.svg (Richfield, David. 
"Medical gallery of David Richfield 2014". Wikiversity Journal of Medicine 1 








1.1.2. Muscle fiber types 
Individual skeletal muscle is stimulated by numerous motor units, which is the 
functional unit of motor system. However, a motor unit controls a group of 
muscle fibers that have similar structural and functional properties within a 
muscle. Mammalian skeletal muscle is made up of different types of muscle 
fibers. This heterogeneity of muscle fibers is based on three structural and 
functional characteristics i.e., contraction speed due to nerve activity, type of 
MyHC expressed and density of mitochondria (type of metabolism). Muscle 
fibers that are controlled by smaller motor units and have low contraction 
speed are called slow twitch or type I fibers. As the slow twitch fibers contract 
less forcefully, they are highly resistant to fatigue. Slow twitch fibers have 
high mitochondrial density and thus are aerobic in nature. These fibers appear 
red in colour due to myoglobin, an oxygen carrying protein in the 
mitochondria.  Type I fibers use triglycerides as energy source. Type I fibers 
express myosin isoform Myh7 which is also expressed in cardiac muscle as 
cardiac beta MyHC (Talmadge et al., 1993; Lompre et al., 1984). Type II 
fibers are divided into type IIa and type IIb fibers. Both of these fibers are 
controlled by bigger motor units and have high contraction speed, thus 
generating greater force compared to type I fibers. Type IIa fibers have 
moderately high contraction speed and are anaerobic in nature and thus fairly 
resistant to fatigue. Type IIa fibers also have high density of mitochondria 
with increased oxidative potential; however they can metabolize glycogen and 
creatine phosphate as energy source. Type IIa fibers predominantly contain 
myosin isoform Myh2 in mammals. Type IIb fibers have very high contraction 
speed and are anaerobic in nature, thus have low resistance to fatigue. Type 
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IIb fibers have low mitochondrial density and predominantly use glycogen and 
creatine phosphate as energy source. They are white in color due to lower 
amounts of myoglobin. Type IIb fibers predominantly contain myosin isoform 
Myh4. Muscle fibers that are neither Type IIa nor Type IIb fibers are called 
Type IIx or Type IId and have high expression in the diaphragm. These fibers 
have high contraction speed and low oxidative potential, with moderate 
mitochondrial density. Type IIx fibers contain myosin isoform Myh1 
(Westerblad et al., 2010, Schiaffino et al,. 1994).  Fiber type switches occur 
with a change in function like, a change in murine masseter muscle to entirely 
type IIb fibers when the pups progress from suckling to mastication upon 
weaning (Gojo et al., 2002). Changes in fiber type also have been shown to 
occur with different training regimes in humans like type IIb fibers convert to 
type I in response to endurance training, however when training ceases these 
fibers revert back to Type IIb fibers. Thus heterogeneity of the muscle fibers 
in the skeletal muscle allows the same muscle to perform different tasks as per 
the requirement of the body.  
1.1.3. Skeletal muscle function 
Mammalian skeletal muscles exhibit different properties depending on their 
functional requirement. They have four important properties. 1. Contractility- 
ability to contract when stimulated by action potential. 2. Excitability- ability 
to respond to stimuli by producing electrical impulses. 3. Extensibility- ability 
to stretch without damage. 4. Elasticity- ability to return to its original length 
and shape after contraction and extension. Skeletal muscle can be divided into 
two classes depending on whether they are affected by gravitational pull or 
not. 1. Gravity muscles- which create movement and functions in the presence 
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of gravitational pull of the Earth through repeated cycles of contraction and 
relaxation like muscles required for locomotion e.g., tibilas anterior. 2. Anti-
gravity muscles- which function even in the absence of gravitational pull 
through sustained contraction like muscles required for posture maintenance 
and breathing e.g., Gluteus maximus and diaphragm respectively (Martini, 
2006). Apart from locomotion and posture maintenance, skeletal muscle has a 
role in thermogenesis, as contraction of muscle is a critical homeostatic 
mechanism for maintenance of normal body temperature. It is also important 
for the movement of substances within the body like contraction of skeletal 
muscle causes flow of lymph and helps in return of venous blood to the heart. 
Moreover, studies have revealed a novel function of skeletal muscle in 
maintaining the energy metabolism homeostasis (Wallimann et al., 1996).  
1.2 Cardiac muscle  
The heart wall is made up of three layers; the outer connective tissue called 
epicardium, the middle cardiac muscle tissue region called the myocardium 
and the inner simple squamous epithelium layer called endocardium. Cardiac 
muscle cells (cardiocytes), which form the myocardium, are uni-nucleated 
striated involuntary cells present only in the heart. Like skeletal muscle cells, 
cardiocytes also contain myofibrils i.e., the actin and myosin filaments, 
organized into sarcomeres (Figure 1.4). Cardiocytes are highly branched cells 
that are interconnected to each other by intercalated discs. These discs are 
made up of cell membranes of adjacent cardiocytes locked together by 
desmosomes, intercellular matrix and gap junctions. Electric impulses are 
uniformly and quickly conducted through these intercalated discs and help in 
coordinated contraction of the cardiocytes. Also, the intercalated discs hold the 
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cardiocytes together in place during contraction, thus maintaining the three-
dimensional structure of the heart tissue (Martini, 2006).  
 Although cardiac muscle is a striated muscle, it is different from skeletal 
muscle in many ways. Some of the striking differences are as follows. 1. 
Cardiocytes are relatively smaller in size.  2. Unlike skeletal muscle cells, 
cardiocytes have very limited ability to repair and regenerate. Although 
cardiocytes are capable of dividing after a heart injury, the repair is usually 
insufficient leading to loss in cardiocyte function (Martini, 2006). 3. Cardiac 
muscles are involuntary in nature i.e., cardiac muscle is not controlled by 
somatic nervous system. But they have specialized cells called pacemaker 
cells that provide electric impulses and maintain a constant rate of contraction. 
4. The cardiocytes contains T tubules that are short and broad and are not 
arranged in triads. 5. Cardiocytes are predominantly aerobic, as they need 
continuous supply of energy for uninterrupted contraction. Cardiocytes 
contain relatively large numbers of mitochondria and utilize glycogen and 
lipids as the main energy source. 6. Cardiocyte contraction lasts approximately 
10 times longer than the skeletal muscle cell contraction and thus cardiocytes 







Figure 1.4 Cardiac muscle structure. Cardiac muscle sarcomeres are similar 
to skeletal muscle sarcomeres in their struture and function. Each cardiocytes 
is seperated by specialised membrane structures called intercalated discs that 
help in the conduction of electric impulses across the heart. Figure freely 
downloaded from http://commons.wikimedia.org/wiki/File:Blausen_0470_ 
HeartWall.png (Blausen.com staff. "Blausen gallery 2014". Wikiversity 









1.2.1. Cardiac Hypertrophy 
Cardiac muscle has the tendency to undergo structural changes in response to 
stress factors like hemodynamic load and/or cardiac injury. The process of 
cardiac muscle undergoing the structural changes, which eventually changes 
the dimension and function of the heart is termed as cardiac remodeling. 
Depending on the type of cardiac remodeling, the cardiac muscle can either 
increase in mass (hypertrophy) or decrease in mass (atrophy). Cardiac 
hypertrophy can be broadly classified into two types based on the type of 
hypertrophic stimulus- physiological hypertrophy and pathological 
hypertrophy (Cohn et al., 2000) (Figure 1.5). Physiological hypertrophy is a 
beneficial hypertrophy that occurs in response to physiological stimuli like 
exercise training or during pregnancy (Mone et al., 1996). When there is a 
hemodynamic load on the heart walls due to chronic physical exercise, the 
cardiomyocytes are stretched which leads to synthesis of new contractile 
proteins and usually the new sarcomeres are arranged in parallel. This 
increases the muscle thickness of the heart wall, thereby increasing the 
contractile ability and eventually the cardiac output (Wakatsuki et al., 2004). 
Thus, physiological hypertrophy is a compensated growth to normalize the 
wall stress and usually reverts back to normal on cessation of exercise regime 
(Zak et al., 1984).  Physiological hypertrophy can be further subdivided into 
two categories depending on the type of hemodynamic overload. In case of 
aerobic exercises like running and swimming exerts volume load on the heart 
walls. This stimulates the addition of new sarcomeres next to each other in the 
cardiomyocytes leading to dilation of the heart walls. This kind of hypertrophy 
is called eccentric hypertrophy. On the contrary, during static exercise like 
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weight lifting, pressure load is exerted on the heart wall. This stimulates 
addition of new sarcomeres parallel to each other in the cardiomyocytes, 
increasing the thickness of the heart walls. This type of hypertrophy is called 
concentric hypertrophy (Pluim et al., 2000; Zak et al., 1984). Physiological 
hypertrophy is mainly induced by IGF1-phosphoinositide-3 kinase pathway. 
IGF-1 growth factor released in response to exercise training interacts with its 
receptor IGF1R. This further activates the PI3-K leading to activation of 
protein synthesis pathway resulting in cardiac cell growth (Toker et al., 1997). 
Mice having increased cardiac IGF-1/PI3-K have normal life span but develop 
physiological hypertrophy with increased cardiac output (Reiss et al., 1996; 
Shioi et al., 2000). On the contrary, mice with reduced IGF-1/PI3-K signaling 
show reduced heart size (Shioi et al., 2000; Luo et al., 2005).     
A different kind of cardiac remodeling occurs in response to hemodynamic 
overload due to cardiomyopathies and chronic heart diseases like aortic 
stenosis and hypertension. This type of hypertrophy is known as pathological 
hypertrophy (Zak et al., 1984). In this kind of hypertrophy, the heart muscle 
wall increases in thickness due to the hemodynamic stress along with 
pathological stimuli such as production of collagen by cardiac fibroblasts, 
inflammation and apoptosis/necrosis of cardiomyocytes (Volders et al., 1993).  
All these factors together affect the contractility of the cardiac muscle and 
eventually the cardiac output. These changes are irreversible and eventually 
lead to heart failure and increased mortality (Olivetti et al., 1997). Re-
expression of fetal genes like Atrial natriuretic peptide (ANP), βMyHC and 
skeletal alpha-actin are usually seen during pathological hypertrophy and not 
during physiological hypertrophy. In pathological hypertrophy, the 
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compensatory growth is eventually decompensated leading to dilated 
cardiomyopathy and heart failure (Pluim et al., 2000; Fagard et al., 1997). 
During pathological hypertrophy, chronic heart conditions like hypertension 
and aortic stenosis exerts pressure overload on the heart walls resulting in 
concentric hypertrophy (Grossman et al., 1975). Chronic heart condition like 
aortic regurgitation exerts volume overload on the heart walls leading to 
eccentric hypertrophy (Grossman et al., 1975; Pluim et al., 2000). Pathological 
hypertrophy is mainly induced through Gαq receptor belonging to G-protein-
coupled receptors (GPCR) family of cell surface receptors (Seidman et al., 
2001). Pathological stimulus induces secretion of cardiac factors like 
endothelin (ET)-1, angiotensin (Ang) II and noradrenaline leading to 









protein kinases (MAPK) pathway together leading to 
pathological hypertrophy. Transgenic mice over-expressing Gαq receptor 
showed cardiac dysfunction and premature death (D’Angelo et al., 1997; Hein 
et al., 1997). On the contrary, mice lacking Gαq receptor in the cardiomyocytes 
failed to develop pathological hypertrophy even with pressure overload 
(Akhter et al., 1998; Wettschureck et al., 2001).  
As pathological hypertrophy is of more clinical relevance, it has been 
extensively studied using artificial sympathomimetics drugs that mimic the 
effect of cardiac factors like ET-1, Ang II etc. Most widely used 
sympathomimetic drug is isoproterenol (ISO). It is clinically used to treat 
bradycardia (slow heart rate) and heart block. ISO is structurally similar to 
adrenaline and acts as a beta-adrenergic receptor agonist and induces 
pathological hypertrophy (Tse et al., 1979). However, it is also seen that there 
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can be crosstalk between these two main signaling pathways in developing 
either type of cardiac hypertrophy.  
 Studies have shown that myostatin is expressed in heart predominantly in the 
purkinje fibers and cardiomyocytes (Sharma et al., 1999). Myostatin is a well-
studied negative growth factor and will be discussed in detail in section 
1.6.3.1. Previous studies have shown that myostatin inhibits IGF-1 induced 
physiological hypertrophy in the heart, thus acting as a chalone for heart organ 
development (Shyu et al., 2005).  Rodgers et al., on the contrary showed that 
myostatin null mice exhibited physiological hypertrophy and loss of myostatin 
induced eccentric hypertrophy with enhanced cardiac output (Rodgers et al., 
2009). Also aged myostatin null mice have heavier hearts compared to the 
wild-type counterparts and showed physiological cardiac hypertrophy 



















Figure 1.5 Types of cardiac hypetrophy. (A) Figure representing 
pathological cardiac hypertrophy. Figure freely downloaded from 
http://commons.wikimedia.org/wiki/File:Blausen_0166_Cardiomyopathy_Hy
pertrophic.png (Blausen.com staff. "Blausen gallery 2014". Wikiversity 
Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762) on 
29.12.2014 (B) Image showing different stimuli responsible for physiological 





1.3 Skeletal Myogenesis 
Skeletal muscle development is a highly coordinated event involving many 
factors functioning at specific time. This process of skeletal muscle formation 
is termed as myogenesis. There are two types of myogenesis depending on the 
time of development they occur, 1. Embryonic myogenesis- muscle 
development during embryogenesis 2. Post-natal myogenesis- muscle 
development after birth and also due to exercise training.   
1.3.1. Embryonic myogenesis 
In mammals, myogenic cells that are responsible for formation of muscle cells 
are derived from somites. Somites are bilaterally symmetric structures that are 
transiently formed from paraxial mesoderm of the embryo. They develop on 
either side of the neural tube and notochord in a rostro-caudal fashion 
(Buckingham et al., 2001). Initially somites are made of outer epithelium and 
mesenchymal core. However later, somites undergo the process of de-
epithelialization to give rise to sclerotome ventrally and dermomyotome 
dorsally (Buckingham, 2001). The dorsal dermomyotome gives rise to skeletal 
muscles of body and limb while the ventral sclerotome gives rise to bone and 
cartilage of the body. Furthermore, the medial portion of dermomyotome, i.e., 
the epaxial dermomyotome, gives rise to deep back muscles and the lateral 
portion of dermomyotome i.e., the hypaxial dermomyotome, gives rise to rest 
of the musculature of the body and limbs (Figure 1.6). The first muscle mass 
to form in an embryo is the myotome, a layer of longitudinally arranged 
muscle cells between the dermomyotome and the sclerotome. Later, this mass 
of muscle cells is integrated into the trunk musculature. The uncommitted 
muscle precursor cells undergo delamination from the epithelium of the 
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dermomyotome and migrate to the limb buds, where they proliferate and 
differentiate to form skeletal muscles (Emerson, 1993).  
 
 
Figure 1.6 Embryonic myogenesis. Formation of skeletal muscle during 
embryogenesis. The dermomyotome gives rise to the epaxial myotome, which 
in turn gives rise to back musculature, and hypaxial myotome, which gives 
rise to limbs and body musculature.  
 
 
1.3.1.1. Transcriptional factors involved in embryonic myogenesis 
Myogenic Regulatory Factors (MRFs) and Myocyte enhancer factor-2 (MEF2) 
are two important classes of transcription factors that together orchestrate a 
highly regulated process of embryonic myogenesis.  
MRFs are a group of four muscle-specific basic helix-loop-helix (bHLH) 
transcription factors namely MyoD, Myf5, myogenin and MRF4/ herculin/ 
Myf-6 that can convert non-myogenic cells to myogenic lineage when 
expressed ectopically (Choi et al., 1990; Miner at al., 1990; Edmondson et al., 
1989). Studies in mice show that Myf5 is the first bHLH transcription factor to 
be expressed during embryonic myogenesis and act upstream of MyoD along 
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with Pax3 (Tajbakhsh et al., 1997). MyoD expression is followed by myogenin 
and lastly MRF4 expression (Sassoon et al., 1989; Wright et al., 1989; Hannon 
et al., 1992). Mutations in MyoD gene results in delayed myogenesis with 
almost complete loss of muscle formation (Kablar et al., 1997), while 
mutations of Myf5 gene results in normal musculature with slight reduction in 
muscle fiber size and muscle mass (Kablar et al., 1997). But when both MyoD 
and Myf5 are mutated, mice show complete absence of skeletal muscle 
formation (Rudnicki et al., 1993). This indicates that MyoD and Myf5 
functionally compensate for each other during embryonic myogenesis. 
Furthermore, mutations in myogenin show myoblasts that migrate normally 
but incapable of differentiation to form multinucleated myotubes (Venuti et 
al., 1995). Thus myogenin is indispensable for differentiation of skeletal 
muscle.  
MRFs contain conserved bHLH domain with N-terminal and C-terminal 
transcriptional activation domains. It is the bHLH domain that binds to the 
DNA and dimerises with ubiquitously expressed E proteins to confer its role in 
skeletal myogenesis (Murre et al., 1989). The important E proteins expressed 
in skeletal muscle are E47, E12 and HEB. The MRFs characteristically bind to 
consensus sequence CANNTG called E-box, commonly found in the 
promoters of muscle specific genes like MLC1 and 3, desmin, creatine kinase, 
cardiac alpha actin, thus transactivating the downstream target genes (Li and 
Capetanaki, 1994; Amacher et al., 1993; Wentworth et al, 1991; Sartorelli et 
al., 1990).  
MEF2 is another important class of transcription factors affecting the process 
of embryonic myogenesis. MEF2 is a family of MADS-box transcription 
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factors consisting of four members, MEF2A, MEF2B, MEF2C and MEF2D 
(Breitbart et al., 1993; Hidaka et al., 1995). The expression of MEF2 isoforms 
overlaps with MRFs expression in skeletal muscle although MEF2 is 
expressed in other tissues such as heart and brain (Edmondson et al., 1994; 
Molkentin et al., 1996). MEF2C is the predominantly expressed isoform in 
skeletal muscle (Edmondson et al., 1994).  
The MADS- box of MEF2 proteins bind to conserved A/T-rich element in the 
promoters of muscle specific genes (Cserjesi and Olson, 1991; Gossett et al., 
1989). MEF2 binding sites and E-boxes usually co-exist in the promoters of 
muscle specific genes (Black et al., 1995; Wan and Moreadith, 1995; Naidu et 
al., 1995; Edmondson et al., 1992). Thus MRFs and MEF2 family together 
influence the process of embryonic myogenesis. For example, MRF4 promoter 
in rat contains an E-box and a MEF2 binding site and both these sites are 
required for the maximum expression of MRF4 to drive the muscle specific 
expression (Black et al., 1995; Naidu et al., 1995). However in some instances, 
MRF and MEF2 can synergistically activate a promoter. For example, 
myogenin can interact with MEF2-DNA complex and transactivate muscle 
specific genes, even when the E-box is mutated. Thus mutation of the E-box 
does not eliminate the synergy between myogenin and MEF2 (Naidu et al., 
1995). When both MRFs and MEF2 binding occurs in a promoter region, there 
appears to be a geometric restriction on the association of the two factors, with 
the two sites being found closely associated in the promoters of muscle 
specific genes (Fickett et al, 1996). Thus the synergistic interaction between 
the MRFs and MEF2 is an important mechanism for induction of muscle 
specific gene expression.  
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The ability of MRFs and MEF2 to activate muscle specific transcription is also 
regulated by their post-translational modification, specifically acetylation. 
MRFs and MEF2 can associate with histone acetyltransferases (HATs) and 
histone deacetylases (HDACs) which control the acetylation state of histones 
and therefore the condensation and accessibility of chromatin (Mal et al., 
2001; Puri et al., 2001). Also, MyoD is known to can act as a substrate for 
HATs and HDACs (Mal et al., 2001; Puri et al., 2001; McKinsey et al., 2001; 
Eckner et al., 1996). Acetylation by HATs of histones results in the relaxation 
of nucleosomal structure allowing the access of transcriptional machinery into 
the chromatin (Garrett and Grisham, 1999). HAT activity is affected by 
numerous transcriptional activators such as p300 with CREB binding protein 
(CBP) and GRIP-1 (Eckner et al., 1996; Puri et al., 1997). 
Deacetylated histones are associated with transcriptionally silent genes 
(Garrett and Grisham, 1999). There are two classes of HDACs containing 
eight known HDACs in humans; ubiquitously expressed Class I (-1, -2, -3, and 
-8); and Class II (-4, -5, -6, and -7) HDACs are highly expressed in adult 
heart, skeletal muscle and brain tissue (McKinsey et al., 2001; Zhou et al., 
2000). HDAC act antagonistically to the function of HATs, and also influence 
the myogenic differentiation of C2C12 myoblasts.  The class I HDAC, HDAC-
1, can target MyoD directly. HDAC1 binds to MyoD in undifferentiated cells, 
and can deacetylate MyoD, inhibiting its activity (Mal et al., 2001). The 
interaction of HDAC1 with MyoD is disrupted as the cell cycle regulatory 
protein pRb becomes hypo-phosphorylated during myogenic differentiation.  
Hypo-phosphorylated pRb forms a complex with HDAC1.  A point mutation 
in pRb, making it incapable of binding HDAC1, prevents the disruption of the 
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MyoD-HDAC1 complex and inhibits muscle gene expression and myogenic 
differentiation (Puri et al., 2001; Lu et al., 2000). HDAC4, -5 and -7 associate 
with MEF2, via a HDAC class II specific domain in the amino-terminus, and 
inhibit MEF2 dependent transcription, suppressing myogenic differentiation 
(Zhang et al., 2002; Dressel et al., 2001; Lu et al., 2000). The interaction of 
HDACs with MEF2 mediates the inhibition of MyoD, as MyoD dependent 
transcription was affected when the E-box binding site was in close 
association with a MEF2 binding site (Lu et al., 2000). These studies indicate 
that HAT and HDAC proteins have the potential to play an important role in 
the regulation of transcription factors involved in embryonic myogenesis. 
1.3.1.2. Growth factors involved in myogenesis 
Along with transcription factors, various growth factors like Hepatocyte 
growth factor (HGF), Fibroblast growth factor (FGF), Bone morphogenetic 
protein (BMP) and Transforming growth factor β (TGFβ) play important role 
in both embryonic and post-natal myogenesis. HGF acts as a chemo-attractant 
and aids in migration of muscle precursor cells towards the limb bud. 
Mutations in either HGF or its receptor, c-met, results in failure of migration 
of muscle precursor cells eventually leading to absence of skeletal muscle in 
limbs (Francis-West et al., 2003; Bladt et al., 1995). HGF also suppresses the 
expression of myogenic regulatory factors like Myf5, MyoD and myogenin, 
and the muscle contractile protein Myosin heavy chain (MyHC) such that the 
migrating muscle precursor cells do not differentiate until they have reached 
the limb buds (Gal-Levi et al., 1998).   
FGFs are other important factors required for the process of delamination and 
migration of myogenic precursor cells. FGFs including FGF-2,-4,-8 are 
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upstream of HGF expression. FGFs like HGF function as a chemo-attractant 
and help in the migration of myogenic precursor cells to the limb buds (Webb 
et al., 1997). FGFs also inhibit the expression of myogenic regulatory factors 
like Myf5 and MyoD to inhibit the differentiation of myogenic precursor cells 
until they have reached their appropriate destination. When the myogenic 
precursor cells have migrated to the limb buds, the predominant FGF receptor, 
FGF receptor 1 (FGFR1) is lost, followed by expression of myogenic 
regulatory factors like Myf5 and MyoD leading to the initiation of 
differentiation of myogenic cells (Itoh et al., 1996). 
BMPs, BMP-2, -4 and -7 belong to TGFβ superfamily and inhibit myogenic 
differentiation. BMPs are produced in the developing limb bud and have 
varied function depending on their concentration. At low levels, BMPs induce 
and maintain the expression of Pax3 and inhibit the expression of MyoD. 
However at high concentrations, these BMPs prevent both Pax3 and MyoD 
expression and induce apoptosis (Amthor et al., 1998). The actions of BMPs 
are antagonized by Noggin, which is induced by Wnt signals from the dorsal 
neural tube (Reshef et al., 1998). It is the balance in expression of BMPs and 
Noggin that determine the expression of the myogenic regulatory factor genes 
such as Myf5 and MyoD (Emerson et al., 2000). Myostatin, another TGFβ 
superfamily member, also has important role in regulation of myogenesis. 
Myostatin, also known as Growth and Differentiation Factor-8 (GDF-8), is 
expressed in muscle precursors in the somite and this expression is continued 
into adult muscle (McPherron et al., 1997). Myostatin is shown to inhibit both 
proliferation and differentiation of myogenic precursor cells (Thomas et al., 
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2000; Langley et al., 2002). The role of myostatin will be discussed in detail 




Figure 1.7 A schematic diagram showing the roles of certain important 
proteins during embryonic myogenesis used in this thesis.   
 
1.3.2. Post-natal myogenesis 
Once the muscle has formed, the myonuclei present in the myofibers are 
unable to divide to allow muscle maturation, growth and repair. For this 
purpose, skeletal muscle has a population of muscle precursor cells called 
satellite cells (SCs) that proliferate and provide growth and regenerative 
property to adult skeletal muscle. Satellite cells are mono-nucleated, quiescent 
precursor cells located between the basal lamina and the sarcolemma of the 
myofibers. SCs are usually in a quiescent state and possess a small cytoplasm 
and condensed chromatin. Thus they have a high nuclear to cytoplasmic ratio 
with minimum intracellular organelles (Bischoff, 1994; Muir et al., 1965). 
However, in case of myo-trauma, SCs are activated and migrate from their 
niche to the region of muscle injury. After reaching the area of injury, they re-
enter the cell cycle, proliferate and either contribute myonuclei to the damaged 
myofibers or fuse among themselves to give rise to a nascent myofibers and 
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replace the damaged myofiber thus aiding in muscle regeneration and growth 
(McKinnell et al., 2004; Hawke et al., 2003). Simultaneously, the SCs also 
undergo the process of self-renewal to replenish the population of SCs within 
the muscle (Bischoff, 1994; Hawke et al., 2001; McCroskery et al., 2005) 
(Figure 1.8).  
SCs express certain bona fide markers in response to activation. Quiescent 
SCs specifically express proteins like M-cadherin, CD34, Pax7, c-met, Sox8, 
Msx1 and myostatin (McCroskery et al., 2005; Fukada et al., 2004; Sajko et 
al., 2004; Cornelison et al., 2000; Cornelison et al., 1997) (Figure 1.8).  
Studies have shown that Pax7 is expressed in quiescent SCs and upon 
activation Pax7 expression is down-regulated. Thus, Pax7 has an important 
role in maintaining quiescence in SCs and maintaining the SC pool in skeletal 
muscle (Olguin et al., 2004). Mice lacking Pax7 showed a drastic reduction in 
SC number and muscle regenerative capacity. However, the postnatal muscle 
growth is not affected (Oustanina et al., 2004; Charge and Rudnicki et al., 
2004). Upon activation, SCs begin to express Myf5, MyoD and desmin 
proteins, which are the markers of myogenic precursor cells (Cornelison et al., 
1997). Mice studies have revealed that MyoD expression in SCs is critical for 
muscle regeneration, and MyoD null mice showed reduced muscle 






Figure 1.8 A schematic diagram depicting post-natal myogenesis. SCs 
normally exist in a quiescent state and are activated upon injury or 
myotrauma. Quiescent SCs express CD34, Pax7, Myf5 and β-gal. However, 
upon activation, MyoD expression is up-regulated along with the expression 
of Pax7. The SCs committed to differentiation express myogenin and fuse into 
myotubes and further mature into myofibers. 
 
1.4 Muscle regeneration 
Following post-natal muscle growth, satellite cells remain quiescent within the 
muscle. However in case of muscle trauma such as prolonged exercise or 
muscle injury, SCs are activated to regenerate and replenish the damaged 
muscle tissue. The process of skeletal muscle regeneration is divided into three 
phases- degeneration, regeneration and remodeling (Grefte et al., 2007).  Due 
to muscle injury, the sarcolemma covering the myofibers is disrupted and 
myofibrils organization is lost.  As a result, the intracellular muscle protein 
such as creatine kinase is released into the blood stream, which can be 
detected in the serum. The membrane damage also leads to influx of Ca
2+
 into 
the cell, stimulating the Ca
2+ 
dependent proteases such as calpains that degrade 
the myofibrillar and cytoskeletal proteins. This necrotic muscle tissue releases 
chemotactic factors that initially recruit inflammatory neutrophils followed by 
macrophages to the injury site (McLennan, 1996; Tidball, 1995). The 
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macrophages phagocytose the necrotic tissue, allowing the muscle 
regeneration to occur. This phase of clearing the necrotic tissue is called 
degeneration. The inflammatory cells present at the site of injury, release 
cytokines and growth factors like HGF, FGF and TGFβ that activate and 
attract the SCs underneath the basal lamina from the distant uninjured sites to 
the site of injury (Schultz et al., 1985; Bischoff, 1997; Robertson et al., 1993). 
The activated SCs re-enter cell cycle and proliferate to increase in number and 
become myoblasts (McKinnell et al., 2004; Hawke et al., 2003). These SC 
derived myoblasts either fuse among themselves to form nascent myofibers or 
with the damaged myofiber, thus repairing or replacing myofibers. This phase 
of replenishing the damaged muscle tissue is called regeneration. The nascent 
myofibers show characteristic centrally located myonuclei and express 
embryonic MyHC (eMyHC). Upon maturation, the myofiber increase in size 
moving the myonuclei to the periphery of the myofiber. Thus, the regenerated 
myofibers become indistinguishable from the undamaged myofibers. 
Fibroblasts also infiltrate the site of injury and produce connective tissue 
resulting in scar tissue formation (Sato et al., 2003). This results in fibrosis in 
the muscle tissue, which affects the efficiency of muscle contraction 
(Fukushima et al., 2001; McCroskery et al., 2005). This phase of myofiber 
maturation followed by fibrosis is called remodeling. 
1.5 Skeletal muscle metabolism 
The fundamental role of skeletal muscle is to provide movement by 
contraction. Energy required for this contraction is obtained by metabolizing 
high-energy molecules like glucose, lipids, glycogen and phosphocreatine to 
release ATP (Sahlin et al., 1998). Skeletal muscle predominantly uses glucose 
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as the main energy source, which is stored in the form of polysaccharide chain 
of glucose molecules called glycogen (Graham et al., 2010).  However, when 
glycogen reserves are low, the muscle fibers utilize fatty acids and amino 
acids to derive energy. During muscle activity, glycogen is broken down to 
release glucose and this catabolic process is termed as glycogenolysis. 
Glucose released is used as a substrate to generate ATP by two main processes 
1) Anaerobic glycolysis in the cytoplasm 2) Aerobic oxidative metabolism in 
mitochondria. Firstly, glucose released from glycogen is anaerobically broken 
down into two pyruvate molecules in the cytoplasm, generating two molecules 
of ATP. This catabolic process is called glycolysis. Two pathways can 
metabolize the pyruvate formed through glycolysis:  
1) Pyruvate can stay in the cytoplasm and continue to be broken down 
anaerobically to generate ATP and lactic acid. During strenuous exercise, ATP 
is predominantly generated anaerobically, and the lactic acid formed diffuses 
out of the muscles into the bloodstream, which is subsequently absorbed by 
the liver. Furthermore, the lactic acid in the liver can be converted back to 
pyruvate with the help of liver enzymes, thus providing substrate to generate 
more ATP. However, some of the lactic acid remaining in the muscle cell 
contributes to muscle fatigue.  
 2) Pyruvate enters mitochondria and is aerobically broken down by aerobic 
oxidative phosphorylation to generate almost 95% of the ATP demand of the 
contracting skeletal muscle.  
Although the ATP requirement of the resting muscle is low, the muscle fibers 
absorb glucose, fatty acids and oxygen from the bloodstream.  This leads to 
generation of excess amounts of ATP, as there is no limitation in oxygen 
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availability for the oxidative phosphorylation to occur in the mitochondria. 
These extra ATP molecules build up the glycogen and creatine phosphate 
reserves in the muscle fibers. At moderate levels of muscle activity, the ATP 
demand increases, which is met by breakdown of glycogen reserves followed 
by oxidative phosphorylation in the mitochondria. However, during high 
levels of muscle activity, the demand for ATP is very high which leads to 
inability of the mitochondria to cater to the demand. Thus, additional ATP is 
generated through anaerobic pathway discussed earlier.  
1.6 Factors regulating post-natal skeletal muscle mass 
Post-natally, skeletal muscle mass development is affected by various growth 
factors leading to either skeletal muscle atrophy or hypertrophy. These growth 
factors affect different stages of myogenesis leading to variation in skeletal 
muscle mass. Some growth factors have an impact on the rate of myoblast 
proliferation, which eventually determines the number of myoblasts present to 
undergo differentiation. Other growth factors influence the process of 
differentiation, affecting the timing and extent of myotube formation. Skeletal 
muscle undergoes wear and tear during its use. Growth factors play an 
important role in the regulation of skeletal muscle regeneration as well. Some 
of the important factors are discussed below.  
1.6.1. Insulin-like growth factors (IGFs) 
IGF family of growth factors consists of secreted proteins that positively 
regulate myogenesis. Two types of IGFs, IGF1 and IGFII are secreted by a 
wide variety of tissues including liver and skeletal muscle (Bondy et al., 1993; 
Alexandrides et al., 1989; Beck et al., 1988).  IGF-I and -II have been shown 
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to enhance the proliferation and differentiation of myoblasts. Myoblasts 
treated with IGF-I show enhanced proliferation rates and cell survival (Lawlor 
et al., 2000; Semsarian et al., 1999); Engert et al., 1996). Expression of IGF-I 
and IGF-II increases during myoblast differentiation, indicating IGFs role in 
skeletal muscle differentiation (Yoshiko et al., 2002). As myoblasts 
differentiate, IGF-I enhances the differentiation process by inducing p21, 
MyoD and myogenin expression (Yang and Goldspink, 2002; Engert et al., 
1996; Greene and Allen, 1991). This can lead to myotube hyperplasia- when 
myoblasts fuse and form new myotubes; as well as myotube hypertrophy- 
when myoblasts fuse with existing myotubes (Semsarian et al., 1999). Mice 
lacking IGF-I are significantly smaller compared to the wild type littermates 
and the muscle tissue is under-developed. In some strains of mice, lack of 
IGF-I results in death shortly after birth due to inability to breathe (Liu et al., 
1993; Powell-Braxton et al., 1993). Conversely, overexpression of IGF-I 
(IGF-IEa) results in an increase in muscle mass (Mathews et al., 1989) and in-
vivo, over-expression of IGF-I prevents muscle atrophy and induces exercise-
induced muscle hypertrophy (Sacheck et al., 2004; Alzghoul et al., 2004; Paul 
and Rosenthal, 2002; Barton-Davis et al., 1998). There are two main isoforms 
of IGF-I expressed in skeletal muscle, IGF-IEa (mIGF-I) and MGF (IGF-IEc), 
both of which are splice variants of IGF-I gene.  These two IGF-I splice 
variants appear to play different roles in skeletal muscle. MGF increased 
myoblast proliferation and inhibited myogenic differentiation, while IGF-IEa 
increased cell density and induced myoblasts to fuse to form myotubes 
(Goldspink et al., 2003; Yang and Goldspink, 2002). 
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IGF-II expression is necessary for myoblast survival and differentiation. Over-
expression of IGF-II leads to up-regulation of myogenic markers such as 
myogenin, and an enhanced differentiation phenotype (Kaliman et al., 1998). 
Conversely, myoblasts lacking IGF-II undergo rapid cell death when switched 
to low mitogen media.  The addition of IGF-I prevented this apoptosis, 
indicating that both IGF-I and IGF-II promote survival and differentiation of 
myoblasts (Lawlor and Rotwein, 2000).  
IGFs bind to cell surface receptors to initiate signalling cascades to elicit their 
effect.  There are three known receptors that bind IGFs.  The insulin receptor, 
which predominantly binds insulin, can also bind related IGF-II and IGF-I to a 
far lesser extent. IGF-I and IGF-II appear to signal predominantly through the 
IGF-I receptor.  
 IGF-II receptor binds IGF-II with high affinity and can bind IGF-I to a much 
lesser extent.  This IGF-II receptor is also known as the cation-independent 
mannose 6-phosphate receptor (Kiess et al., 1988).  
IGF-II signaling via PI3K and Akt can activate the mTOR pathway and this 
signaling leads to skeletal muscle hypertrophy and inhibition of skeletal 
myogenic differentiation (Erbay et al., 2003; Sarker and Lee, 2004). Elevated 
IGF-II expression results in the phosphorylation of 4E-BP1 (PHAS1) and 
p70
S6K
 via activation of the PI3K/Akt/mTOR pathway. Both 4E-BP1 and 
p70
S6K
 are important factors required for translation. 4E-BP1 binds to 
eukaryotic initiation factor 4E in its un-phosphorylated state.  Phosphorylation 
of 4E-BP1 by the PI3K/Akt/mTOR pathway results in the release of E4 in turn 
stimulating translation.  The PI3K/Akt/mTOR can activate p70
S6K
, which is a 
serine threonine protein kinase and phosphorylates and activates ribosomal 
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protein S6.  The role of the ribosomal protein S6 is to recruit mRNAs to the 
ribosome and destine the proteins they encode to be expressed (Shah et al., 
2000). Thus the phosphorylation of 4E-BP1 and p70
S6K
 by IGFs via the 
PI3K/Akt/mTOR pathway results in increased translation within target cells.  
This in turn, results in increase in skeletal muscle protein synthesis over DNA 
synthesis leading to skeletal muscle hypertrophy.  
1.6.2. Ca2+ signaling 
Ca
2+
 released from the sarcoplasmic reticulum of skeletal muscle cells is 
required for skeletal muscle contraction. However, higher intracellular 
Ca
2+
levels can trigger Ca2+/Calmodulin dependent protein phosphatase 
signaling called calcineurin signaling. Calcineurin is a cytoplasmic serine 
threonine protein phosphatase, which is made up of a heterodimer of 59kD 
catalytic subunit (CNA) and an auto-inhibitory 19kD Ca
2+
 binding regulatory 
subunit (CNB). At sustained higher intracellular Ca
2+
 levels, calcineurin binds 
to Ca
2+
 and is activated. Active calcineurin then binds to members of NFAT 
family of transcription factors and dephosphorylate them. This de-
phosphorylation enables the translocation of NFAT transcription factors 
(NFATc1-c4) to the nucleus and affects the transcription of downstream target 
genes by interacting with factors like MEF2, GATA2 and AP-1 (Schulz and 
Yutzey, 2004; Olson and Williams, 2000; Musaro et al., 1999; Chin et al., 
1998). Activation of calcineurin in myoblasts leads to up-regulation of slow 
fiber specific genes like slow MyHC, slow fiber specific troponin I and 
myoglobin (Delling et al., 2000; Chin et al., 1998). On the contrary, 
inactivation of calcineurin promotes fiber type switch from slow fibers to fast 
fibers (Chin et al., 1998). Calcineurin also has a role in IGF-1 induced skeletal 
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muscle hypertrophy (Musaro et al., 1999; Zheng et al., 2004). Increased 
phosphatase activity of calcineurin leads to interaction of GATA2 
transcription factor with NFATc1 in the nucleus. This results in transcriptional 
up-regulation of hypertrophy-associated genes contributing to IGF-1 induced 
skeletal muscle hypertrophy (Semsarian et al., 1999; Musaro et al., 1999). 
NFAT proteins translocate to the nucleus at different times in skeletal muscle 
formation, indicating a specific role for each in the process of myogenesis.  
NFATc3 is expressed in the nuclei of myoblasts, NFATc2 is localized in the 
nucleus in nascent myotubes, and NFATc1 is found in the nuclei of nascent 
and mature myotubes (Schulz and Yutzey, 2004; Delling et al., 2000). 
NFATc2 null mice show reduced muscle size due to decrease in muscle fibre 
cross sectional area. NFATc3 null mice also show reduced skeletal muscle 
mass but this is due to decrease in myofibre number, indicating different 
NFATs play different roles in myogenesis (Kegley et al., 2001).  
1.6.3. Transforming Growth Factor s (TGF) 
TGF is a superfamily of growth factors consisting of nearly 30 members that 
play important roles in the process of myogenesis affecting the skeletal muscle 
mass. Some of the important TGF superfamily members are TGFs, BMPs, 
Growth and Differentiation Factors (GDFs), Activins and Inhibins. TGF 
family of secreted signaling molecules mainly affects determination, 
proliferation, differentiation, adhesion, apoptosis and migration of skeletal 
muscle. TGF superfamily members possess certain characteristic features. 
They contain a secretion signal at the amino-terminal of the protein, followed 
by a latency-associated peptide (LAP) that which can be cleaved at the RSRR 
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cleavage site present in the carboxyl-terminal of the protein making it active as 
a signaling molecule. The carboxyl-terminal portion of the molecule contains 
nine conserved cysteine residues that form the cysteine knot structure typical 
of the superfamily (Mehra and Wrana, 2002; Massague et al., 2000; Vitt et al., 
2001; 2001; Gaddy-Kurten et al, 1995; Daopin et al., 1993). TGF1 and 2 can 
inhibit myoblast proliferation and induce or inhibit differentiation depending 
on culture conditions (Liu et al., 2001; Cusella-De Angelis et al., 1994; Greene 
and Allen, 1991). TGF prevents myoblast proliferation by up-regulating a 
cell cycle inhibitor, p21 (Li et al., 1995). TGF in low serum media inhibits 
terminal differentiation of myoblasts by inhibiting the activity and expression 
of MyoD and myogenin (Liu et al., 2001; Vaidya et al., 1989; Massague et al., 
1986). However in high serum media, TGF can induce the differentiation of 
myoblasts (Zentella and Massague, 1992). TGF also induces embryonic stem 
cells into myogenic lineage (Slager et al., 1993). During skeletal muscle 
myogenesis, TGF appears to be required for the mediation of signals from 
the neural tube that is required for myogenesis (Pirskanen et al., 2000). In 
addition, TGF can act as a chemotactic factor for satellite cells in 
regenerating muscle (Bischoff et al, 1997). Thus TGF appears to play an 
important role in the regulation of the skeletal muscle mass both pre- and post-
natally.  
1.6.3.1. Myostatin 
Myostatin also known as Growth and Differentiation Factor-8 (GDF-8) was 
discovered in 1997 in mice as a TGF- superfamily member that specifically 
regulates skeletal muscle growth (McPherron et al., 1997). Myostatin is 
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expressed in skeletal muscle and acts as a negative regulator of both 
proliferation and differentiation of myoblasts (McCroskery et al., 2005; 
Langley et al., 2004; Langley et al., 2002; Thomas et al., 2000; Kambadur et 
al., 1997; McPherron et al., 1997). Furthermore, myostatin also acts as a 
negative regulator of muscle regeneration and hypertrophy, thus regulating all 
stages of muscle myogenesis. Thus myostatin becomes one of the key players 
in the regulation of myogenesis of skeletal muscle. Apart from skeletal 
muscle, myostatin has been detected in adipose tissue (McPherron et al., 1997) 
and in cardiomyocytes and purkinje fibers of the heart (Sharma et al., 1999). 
But the function of myostatin in other tissues is largely unknown.  
Mutations in myostatin, as in myostatin null mice and cattle, results in 2-3 fold 
increased muscle mass than wild type, termed as “double-muscling” 
phenotype (Schuelke et al., 2004; Lee and McPherron, 1999; Kambadur et al., 
1997). This increase in muscle mass is due to both muscle fiber hypertrophy 
and hyperplasia (McPherron et al., 1997).  Moreover, myostatin null mice 
showed increased proportion of type II or glycolytic fibers (Girgenrath et al., 
2005).  In addition to targeted disruption of Mstn in mice, several naturally 
occurring mutations have been identified in other species including the 
double-muscled cattle breeds such as Belgian Blue (Figure 1.9) and 
Piedmontese (Grobet et al., 1998; Kambadur et al., 1997; McPherron et al., 
1997) and the whippet racing dog breed (Mosher et al., 2007).   Mstn mutation 
has been discovered in humans that resulted in dramatic hypertrophy of 






Figure 1.9 Double muscling phenotype. Natural mutations in myostatin lead 
to lack of functional myostatin resulting in double muscling phenotype in 
cattle. Figure freely downloaded from http://commons.wikimedia.org/ 
wiki/File:GEURTZ16.JPG#filelinks (privates Foto auf einem deutschen 
Zuchtbetrieb, wo ich einen Bullen gekauft habe, dieses Foto wurde von mir 
selbst gemacht, summer 2005) on 29.12.2014.   
 
 
Like other TGF superfamily members, myostatin is synthesized as a 52kD 
inactive precursor protein (pre-proprotein). After synthesis, the precursor 
protein consists of a homodimer linked by disulphide bonds. The precursor 
myostatin undergoes two proteolytic cleavage events to generate the mature 
protein. In the first cleavage, the 24 amino acid amino terminal signal peptide 
is cleaved which targets the protein for secretion from the Golgi complex (pro-
protein). In the second cleavage, the proprotein is cleaved at the RSRR 
proteolytic cleavage site to give rise to 12.5kD carboxy terminal mature 
myostatin protein and 26kD amino terminal Latency associated protein (LAP) 
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(Lee and McPherron, 2001; Sharma et al., 2001; Thomas et al., 2000). The 
mature myostatin contains nine conserved cysteine residues, out of which 
eight cysteine residues form disulphide bond within the protein and the ninth 
residue forms a covalent bond between the homodimers. The bonding between 
these cysteine residues forms a typical structure of TGF superfamily called 
as the cysteine knot.  This cysteine knot is required for the functioning of the 
mature myostatin protein (McPherron et al., 1997).   
 TGF superfamily members elicit its biological response by binding to serine 
threonine kinase receptor activin type IIB (ActRIIB) (Rebbapragada et al, 
2003). Mice over-expressing dominant negative form of ActRIIB showed 
increased muscle mass comparable to myostatin null mice (Lee and 
McPherron et al., 2001). Another study showed that the mstn-mediated 
activation of ActRIIB receptor leads to phosphorylation of the type I receptors, 
i.e., activin receptor-like kinase 4 (ALK4) or ALK5 (Rebbapragada et al., 
2003). Once Mstn binds to Type II and Type I receptors, downstream 
molecules like Smad2 and/or Smad3 are activated (Rebbapragada et al., 2003). 
Smad 2/3 binds to co-smad called smad4 and together translocates to the 
nucleus and regulates expression of various downstream target genes 
(Rebbapragada et al., 2003). Thus, mstn signals canonically through Smads to 
affect the skeletal muscle mass.  In addition, it is also reported that Mstn can 
signal via non-canonical pathways through p38 mitogen activated protein 
(MAPK), ERK1/2, c-Jun N-terminal Kinase (JNK) and Wnt signaling 
(Allendorph et al., 2006; Elkasrawy and Hamrick, 2010; Huang et al., 2007).  
It was shown that myostatin induces p38 MAPK phosphorylation through 
TGF activated kinase-1 (TAK1) in myoblasts and has been proposed to be 
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involved in myostatin mediated myoblast growth inhibition (Philip et al., 
2005). Thus, the regulation of skeletal muscle mass by myostatin is attributed 
mainly to these above-mentioned pathways.  
It had clearly been established that myostatin is a negative regulator of skeletal 
muscle formation and muscular hypertrophy (Grobe et al., 1997; Kambadur et 
al., 1997; McPherron et al., 1997). Addition of myostatin protein to C2C12 or 
primary bovine myoblasts in culture results in an inhibition of proliferation in 
a dose dependent manner.  Furthermore, this inhibition did not result in overt 
myotube formation, did not result in increased apoptosis and was reversible 
(Thomas et al, 2000).  Treatment of myoblasts with myostatin results in an up-
regulation of the Cyclin dependent kinase inhibitor (CKI), p21, without 
altering the levels of other CKIs (Rios et al., 2001; Thomas et al., 2001; 
Thomas et al., 2000). Thomas et al. (2000) proposed that the mechanism of 
this cell cycle inhibition involves the up-regulation of p21.  p21, in turn 
inhibits the activity of the Cyclin-cdk2 complex, in addition a slight down-
regulation of cdk2 expression occurs, overall this results in an inhibition of 
cdk2 activity.  This loss of cdk2 activity results in hypo-phosphorylation of the 
retinoblastoma protein (Rb). This active hypo-phosphorylated Rb inhibits cell 
cycle progression from G1-S phase, thus stalling the myoblasts at G1 phase 
resulting in reduced number of myoblasts (Thomas et al., 2000).   
It has been well established that myostatin regulates skeletal myogenesis by 
inhibiting differentiation of myoblasts in a dose dependent manner (Langley et 
al., 2002; Rios et al., 2002; Joulia et al., 2003). Furthermore, myostatin was 
shown to signal through smad3 protein and down-regulate MyoD protein 
expression as well as activity (Langley et al., 2002).  
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In addition to regulating skeletal muscle mass, myostatin also has an important 
role in muscle repair and regeneration. The process of muscle regeneration is 
described in section 1.4. Myostatin was shown to negatively regulate 
regeneration by keeping satellite cells quiescent until necrosis and 
inflammation has occurred and in the absence of myostatin the regenerative 
process is accelerated (McCroskery et al., 2005).   
It has been shown that antagonists to myostatin could be potentially useful 
pharmalogical treatments for disorders associated with overt degeneration and 
regeneration such as muscular dystrophies (McCroskery et al., 2005; Bartoli et 
al., 2007; Ohsawa et al., 2007). Treatment of mdx mice, a model for Duchenne 
muscular dystrophy (DMD), with myostatin inactivating antibody lead to an 
increase in body weight, muscle size and muscle strength alleviating the 
dystrophic phenotype (Bogdanovich et al., 2002). Also, similar improvement 
in muscle strength was seen in mdx mice crossed into myostatin null lineage 
(Wagner et al., 2005). Myostatin is also shown to inhibit satellite cell 
migration and proliferation during muscle regeneration.   Thus inactivation of 
myostatin could be used as a potential therapeutic target to alleviate muscular 
dystrophy symptoms. Recently, a novel myostatin antagonist, human ActRIIb 
antibody called Bimagrumab (BYM338) was developed.  This antibody binds 
to human myostatin and Activin A and blocks the canonical signaling 
pathways of myostatin, thus stimulating differentiation of primary human 
myoblasts leading to hypertrophy. BYM338 is also shown to inhibit 
glucocorticoid-induced muscle wasting and induce muscle hypertrophy in 
mice (Lach-Trifilieff et al., 2014). Similarly, it was shown that short-term 
antagonism of myostatin with truncated myostatin protein called mstn-ant1, 
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improved the muscle regeneration after muscle injury during sarcopenia 
(Siriett et al., 2007). Inhibition of myostatin resulted in increased activation of 
satellite cells with MyoD expression and enhanced regeneration after muscle 
injury in sarcopenic muscle (Siriett et al., 2007).  This suggests that 
antagonism of myostatin can act as a potential therapeutic strategy to 
ameliorate sarcopenia.  
In addition to inhibiting the process of myogenesis, myostatin has been 
implicated in the induction of muscle wasting. Increased myostatin expression 
has been detected in atrophic conditions like sarcopenia (Schulte and 
Yarasheski, 2001; Yarasheski et al., 2002); muscle disuse, including chronic 
human muscle disuse atrophy (Reardon et al., 2001; Zachwieja et al., 2000), 
hind limb unloading (Carlson et al., 1999) and space flight (Lalani et al., 2000) 
and during progression of cachexia (Zimmers et al., 2002). Ma et al., (2003) 
demonstrated that injection of a glucocorticoid like dexamethasone in rats 
induces skeletal muscle atrophy and elevated myostatin RNA and protein 
expression. Furthermore, inhibition of dexamethasone by a glucocorticoid 
agonist RU-486, resulted in down-regulation of myostatin levels and 
alleviating muscle wasting (Ma et al., 2003). 
In addition to an associative role during various skeletal muscle wasting 
pathologies, myostatin has been directly demonstrated to induce cachexia in 
mice. Specifically, injection of CHO cells over-expressing myostatin into the 
mice resulted in 33% reduction in total body weight within 16 days compared 
to the control mice (Zimmers et al., 2002). Furthermore in the same study it 
was demonstrated that the severe body mass loss was alleviated by injection of 
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myostatin antagonists like follistatin or myostatin pro-peptide (Zimmers et al., 
2002). 
Myostatin-induced skeletal muscle wasting has been shown to result in down-
regulation of myogenic gene expression. Over-expression of myostatin results 
in reduced expression of myogenic structural genes like MyHC and desmin 
(Durieux et al., 2007). Furthermore, myostatin–mediated muscle wasting 
resulted in down-regulation of MRFs including MyoD and myogenin (Durieux 
et al., 2007; McFarlane et al., 2006). A reduction in these MRFs would further 
worsen the muscle wasting phenotype by potentially impairing post-natal 
myogenesis and muscle regeneration. Concomitant with the down-regulation 
of MRFs, myostatin via smad3 signaling stimulates the activity of FoxO 
transcription factors to induce the transcription of atrophy-related genes like 
atrogin-1, MuRF1 and E214K which degrade the sarcomeric proteins through 
ubiquitin-proteasome pathway (McFarlane et al., 2006; Ge et al., 2011; 
Lokireddy et al., 2011). Furthermore, it was demonstrated that treatment of 
C2C12 myotubes with recombinant myostatin protein inhibited PI3-K/Akt 
phosphorylation by down-regulating the IGF-I/PI3-K/Akt pathway thereby 
inhibiting the protein synthesis and inducing muscle atrophy (Trendelenburg 
et al., 2009). These evidences show myostatin as a potent inducer of skeletal 
muscle wasting.   
Myostatin has also shown to induce increased production of reactive oxygen 
species (ROS) by activating TNF alpha signaling pathway thus inducing 
skeletal muscle wasting phenotype in skeletal muscle cells (Sriram et al., 
2011). It was also shown that increased ROS in turn induces increased 
myostatin expression in a feed-forward mechanism and increased myostatin 
47 
 
levels in turn activate the ubiquitin-proteasome pathway leading to sarcomeric 
protein degradation (Sriram et al., 2011).    
Recently, another important ubiquitin ligase protein called Mul1 was shown to 
induce loss of mitochondria as a response to muscle wasting in mice 
(Lokireddy et al., 2012). Furthermore, it was shown in the same study that 
during muscle wasting, Mul1 targets an important mitochondrial biogenesis 
protein called Mfn1 to ubiquitin-proteasomal degradation resulting in 
mitochondrial fission and eventually mitophagy (Lokireddy et al., 2012). 
1.7 Akirin1  
To understand the function of myostatin in skeletal muscle, novel downstream 
signaling molecules of myostatin have been identified. Suppressive 
subtraction hybridization of mRNA expressed between wild type and 
myostatin knockout muscle identified a novel gene called mighty (Marshall et 
al., 2008). Later this gene was renamed as Akirin1. The gene name ‘akirin’ is 
taken from a Japanese phrase ‘akiraka ni suru’ meaning ‘making things clear’ 
due to presence of a strong nuclear localization signal (NLS) at the N terminus 
of the protein. Due to the presence of clear NLS, akirin family of proteins is 
shown to be highly conserved nuclear proteins (Goto et al., 2008). Akirin1 is a 
191 amino acid protein with a molecular weight of 21 kD and isoelectric point 
of 9.05 (Macqueen et al., 2009; Yang et al., 2011). Akirin1 is ubiquitously 
expressed in all the tissues, but is negatively regulated by myostatin in skeletal 
muscle (Marshall et al., 2008). Evolutionarily, akirin gene underwent a gene 
duplication event in vertebrates to give rise to two homologues, Akirin1 and 
Akirin2 (Macqueen et al., 2009). Akirin2 is similar to Drosophila Akirin 
(DmAkirin) and has a role in providing innate immunity against gram-
48 
 
negative bacteria (Goto et al., 2008). In rats, Akirin2 was shown to interact 
with 14-3-3 repressor-protein complex and promote carcinogenesis 
(Macqueen et al., 2009). 
It was shown that when Akirin1 is over expressed in C2C12 cells, the 
myoblasts withdraw from cell cycle and show increased fusion of myoblasts 
compared to the control C2C12 myoblasts. This increased fusion of myoblasts 
results in hypertrophy of myotubes (Marshall et al., 2008). The hypertrophy 
phenotype is contributed by premature expression of MyoD with increased 
production of IGF-II (Marshall et al., 2008). Akirin1 expression was up 
regulated in myostatin null muscle compared to the wild type muscle 
(Marshall et al., 2008). On the contrary, differentiated C2C12 myotubes that 
were treated with myostatin showed reduced levels of Akirin1 expression 
(Marshall et al., 2008). Furthermore, expression of Akirin1 in mdx mice 
resulted in muscle fibers with increased myofiber size (Marshall et al., 2008). 
Thus showing that Akirin1 is an important pro-myogenic protein that 
functions downstream of myostatin (Marshall et al., 2008). During muscle 
regeneration, Akirin1 is expressed earlier i.e., after two days of muscle injury 
and is shown to have a role in satellite cell activation (Salerno et al., 2009). 
Also, over expression of Akirin1 led to increased chemotactic efficiency of 
myoblasts and macrophages during muscle regeneration (Salerno et al., 2009). 
Thus it was shown that Akirin1 has a very prominent role during the process 
of skeletal muscle regeneration. 
 Contemporarily, a few research groups were independently studying akirin 
under different aliases in different animal models like fly, ticks and fish. In 
drosophila, when genome–wide high-throughput RNA interference (RNAi) 
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screen was performed to identify new components of Imd pathway, a novel 
gene called DmAkirin was identified (Goto et al., 2008). DmAkirin (also 
called bhringi), functions along with NF-κB transcription factor in Imd 
pathway to provide innate immunity to drosophila by producing attacin, an 
antibacterial protein that acts against gram-negative bacteria (Goto et al., 
2008). Nowak et al. discovered another important function of akirin as a 
cofactor in drosophila. It was shown that Akirin physically interacts with 
muscle transcription factor twist, and regulate transcription of twist-regulated 
genes in drosophila. Akirin protein also co-localizes with Brahma SWI/SNF 
complex subunits which is a chromatin remodeling complex. Thus, akirin is 
predicted to link twist and chromatin remodeling complex resulting in 
remodeling of chromatin assembly, affecting the expression of twist-regulated 
genes (Nowak et al., 2012).   
Akirin was discovered in ticks as well. It was shown that when ticks were 
infected with bacterial pathogens, they produce a protective protein called 
subolesin. This protein was identified to be similar in structure and function to 
Akirin (Zivkovic et al., 2010).  
Evolutionarily, Akirin gene underwent a few gene duplication events in teleost 
lineage to give rise to eight homologues of Akirin (Macqueen et al., 2009). In 
Atlantic salmon fish, the various homologues of Akirin have been shown to 
play significant roles in myoblast proliferation and differentiation (Macqueen 
et al., 2010). Akirin in Scophthalmus maximus (turbot) was identified as a 
nuclear-localized protein that was expressed ubiquitously in all the tissues 
with maximum expression in the brain and spleen (Yang et al., 2011). Also, 
Scophthalmus maximus Akirin1 (SmAkirin1) was identified as a member of 
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NF-κB signaling pathway induced in response to bacterial and viral infection 
(Yang et al., 2011).  
Recently Dong et al. showed that Akirin1 was down regulated by increased 
expression of myostatin in dexamethasone-induced muscle atrophy in mice 
(Dong et al., 2013).  Furthermore, reduced Akirin1 levels affected the 
proliferation and differentiation of satellite cell both in-vitro and in-vivo, 
contributing to muscle atrophy during dexamethasone treatment. On the 
contrary, when myostatin was down regulated in dexamethasone-treated mice, 
both Akirin1 levels and satellite cell activation increased, leading to improved 
skeletal muscle regeneration and growth. Also, when Akirin1 was over 
expressed in dexamethasone-treated myoblasts, satellite cell activation 
improved leading to up-regulation of myogenic markers like MyoD and 
myogenin. Thus, by inducing Akirin1, a pro-myogenic factor, dexamethasone-
induced satellite cell dysfunction and muscle atrophy could be alleviated 













1.8 Aims and Objectives 
Akirin1 is one of the new exciting molecules in Muscle biology, in terms of its 
potential role and the various facets that are still left to be explored. A number 
of research groups have studied the roles of Akirin as a transcriptional co-
activator in invertebrates, namely Drosophila, and vertebrates such as Atlantic 
salmon fish. Akirin gene has two homologues (Akirin1 and Akirin2) in mice. 
Previous work from our lab showed a novel role of Akirin1 as a pro-myogenic 
protein in differentiating C2C12 myotubes. Therefore, to delineate the exact 
function of Akirin1 in fully differentiated striated muscle (skeletal and cardiac 
muscle), we have used Akirin1 gene knock-out mice. Through this study, we 
aim to achieve the following: 
1. Understand the function of Akirin1 during skeletal myogenesis. 
As over-expression of Akirin1 in C2C12 myoblasts lead to enhanced 
differentiation of myoblasts, we wanted to study the effect of lack of 
Akirin1 during myogenic differentiation using Akirin1 knock-out mice. 
2. Characterize the skeletal muscle phenotype in Akirin1 knock-out mice. 
Previous work showed that Akirin1 over-expression increased the protein 
synthesis leading to hypertrophy of myotubes. So we wanted to study the 
skeletal muscle phenotype of Akirin1 knock-out mice by exploring 
important aspects in fully differentiated skeletal muscle such as the levels 
of various skeletal muscle sarcomeric proteins and myogenic genes that 
are important for myogenesis and energy metabolism. 
3. Characterize the cardiac muscle phenotype in Akirin1 knock-out mice. 
Knowing that cardiac muscle is a highly oxidative tissue and Akirin1 may 
have a role in energy metabolism, we wanted to study the effect of Akirin1 
in cardiac muscle by studying the cardiac muscle sarcomeric proteins and 







































2. MATERIALS AND METHODS 
 
This chapter details the general materials and methods used in this thesis, 
which includes reagents, chemicals, solutions, oligonucleotides, antibodies 
and relevant protocols.   
2.1 Materials 
This section provides the general materials used in this thesis.  
2.1.1. Oligonucleotides 
All oligonucleotides used in this thesis were synthesized by Sigma-Aldrich, 
Singapore. The stock solutions (100µM) were stored at -20
o
C. The working 
concentration of primers used was 2.5 µM for Reverse Transcriptase- 
quantitative Polymerase Chain Reaction (RT-qPCR) and 10 µM for 
genotyping PCR. The oligonucleotides used are listed in table 2.1 and 2.2.      
Table 2.1 RT-qPCR primers 
Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
Myh1 CACGCTGGATGCTGAGATTA AGGTGCAGCTGAGTGTCCTT 
Myh 2 CTCGTTTGCCAGTAAGGGTCT GGCCTCGATTCGCTCCTTT 
Myh4 CAAGTCATCGGTGTTTGTGG GGCCATGTCCTCAATCTTGT 
Myh7 GCTGGCACTGTGGACTACAA CTTTCTTTGCCTTGCCTTTG 
MuRF1 ACGAGAAGAAGAGCGAGCTG CTTGGCACTTGAGAGGAAGG 
PGC1α GAGAGACAACCCTGGGATCA GTGGCCAGCATTATTTCACAG 
U6 CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT 
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Pri- miR-1 GGTGGGCTGCTTCATGTT TTTCCTTTAGCTTCTTCTTGGC 
Myogenin TGGTACCCAGTGAATGCAACTC GGACCAAACTCCAGTGCATTG 


























mt DNA CCTATCACCCTTGCCATCAT GAGGCTGTTGCTTGTGTGAC 
nu DNA ATGGAAAGCCTGCCATCATG TCCTTGTTGTTCAGCATCAC 
α-actin CTGAGCGTGGCTATTCCTTGTGC GCAGCGGTGGCCATCTCATTCT 
Desmin GTCCTCCTACCGCCGCACCTT CGTGCGCGACACCTGGTACAC 
AMPKα2 CGCCTCTAGTCCTCCATCAG ATGTCACACGCTTTGCTCTG 
PPARα GGACCTTCGGCAGCTGGT TCGGACTCGGTCTTCTTGATG 
HDAC4 CAGATGGACTTTCTGGCCG CTTGAGCTGCTGCAGCTTC 
MEF2C CCATCAGCCATTTCAACAAC GATGGCGGCATGTTATGTAG 
FoxO3 AGCCGTGTACTGTGGAGCTT TCTTGGCGGTATATGGGAG 
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MyHC CATCGCCGCAGACTTTGG GGGCCTCCTTCTGGGATGCCT 
p21/WAF1 CGGTGGAACTTTGACTTCGT CAGGGCAGAGGAAGTACTGG 
MyoD GACAGGGAGGAGGGGTAGAG TGCTGTCTCAAAGGAGCAGA 
CREB-1 TCTAGTGCCCAGCAACCAAG ACGCCATAACAACTCCAGGG 
SRF TACCAGGTGTCGGAGTCTGACA GGCAGGTTGGTGACTGTGAA 
 
Table 2.2 Genotyping primers 















All antibodies used in this project were purchased from the following 
companies: Santa Cruz Biotechnology Inc (Santa Cruz Biotechnology Inc, 
Santa Cruz, CA), Developmental Studies Hybridoma Bank (DSHB, Iowa City, 
IA), Cell Signaling (Cell Signaling Technology, Inc. Danvers, MA), BD 
Pharmingen (BD Pharmingen, San Diego, CA, R&D System (R&D Systems 
Inc, Minneapolis, MN, USA, Abnova (Taipei City, Taiwan), Abcam 
(Cambridge, UK Dako (Dako, Glostrup, Denmark), Sigma (Sigma, St. Louis, 
MO), mouse anti-MuRF1 and rabbit anti-atrogin-1 antibodies were gifted from 
Regeneron Company, USA.   
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The primary and secondary antibodies used in this project are listed in table 
2.3. 
Table 2.3 Western antibodies and dilutions 
Antibody Catalogue No. Source Dilution used 
4eBP1 sc-9977 Santa Cruz 1:500 
Akirin1  Ab 77074 Abcam 1:250 
Akt sc-8312 Santa Cruz 1:2000 
AMPKα 2550 Cell signaling 1:500 
ANP sc-80686 Santa Cruz 1:500 
Atrogin-1 Gift Regeneron 1:2000 
Atrogin-1 PAB15627 Abnova 1:3000 
Cardiac troponin I TI-1 DSHB 1:1000 
Cardiac troponin T CT3 DSHB 1:1000 
Cdk4 sc-601 Santa Cruz 1:200 
CREB-1 sc-240 Santa Cruz 1:500 
Cyclin D1 sc-8396 Santa Cruz 1:200 
Desmin D76 DSHB 1:500 
FoxO3 sc-11351 Santa Cruz 1:400 
GAPDH sc-166545 Santa Cruz 1:10000 
GSK3β 612312 BD Pharmingen 1:500 
57 
 
HDAC4 2072 Cell signaling 1:500 
IGF-1 sc-9013 Santa Cruz 1:300 
Cyclin E sc-481 Santa Cruz 1:400 
MEF2C sc-13266 Santa Cruz 1:200 
mTOR 2983 Cell signaling 1:300 
MuRF1  Gift Regeneron 1:200 
MuRFI sc-27642  Santa Cruz 1:200 
MyHC MF20 DSHB 1:5000 
MyoD sc-304 Santa Cruz 1:400 
Myogenin sc-576 Santa Cruz 1:400 
p-ERK1/2 
(thr202/tyr204) 
sc-16982 Santa Cruz 1:500 
p-4eBP1 (ser65/thr70) sc-12884 Santa Cruz 1:500 
p-Akt (ser473-R) sc-7985-R Santa Cruz 1:500 
p-CREB-1 (ser133) sc-7978 Santa Cruz 1:500 
p-FoxO3 (ser253) sc-101683 Santa Cruz 1:100 
p-GSK3β (ser9) 9336 Cell signaling 1:500 
p-MEF2C (thr300) sc-130201 Santa Cruz 1:200 
p-mTOR (ser2448) 2971 Cell signaling 1:300  
p-p38 MAPK 
(T180/Y182) 





4228 Cell signaling 1:200 
p21(WAF1/CDK 
inhibitor-1) 
556430 BD Pharmingen 1:400 
P38 MAPK 4292 Cell signaling 1:2000 
p-JNK (T183/Y185) 9251 Cell signaling 1:1000 
PGC1α sc-13067 Santa Cruz 1:500 
JNK 9252 Cell signaling 1:400 
PI3Kp85 4292 Cell signaling 1:500 
Polyglutamylated 
tubulin 
T9822 Sigma 1:3000 
PPARα sc-9000 Santa Cruz 1:500 
SRF 5147 Cell signaling 1:1000 
Troponin C sc-48347 Santa Cruz 1:200 
Troponin I TI-4 DSHB 1:500 
Troponin T-SS sc-8122 Santa Cruz 1:500 
Ubiquitin sc-8017 Santa Cruz 1:10000 
ERK1/2 sc-94 Santa Cruz 1:500 
α-actin sc-58670 Santa Cruz 1:1000 
α-Myh (cardiac) Ab50967 Abcam 1:100 
α-tubulin T9026 Sigma 1:10000 
β-Myh (cardiac 
MYH7) 




Table 2.4 Primary antibodies used for Immunohistochemistry (IHC) 
Antibody Catalogue no. Source Dilution used 
Myh fast 2A 2F7 DSHB 1:25 
Myh fast 2B 10F5 DSHB 1:25 
Myh slow (type I) A4.840 DSHB 1: 25  
 








Alexa Fluor 488 (AF 
488) donkey anti-
mouse lgG 
A-21202 Invitrogen 1:400 IHC 
Goat anti-mouse lgG 
HRP conjugate 
170-6516 Bio-Rad 1:5000 Western blot 
Goat anti-rabbit lgG 
HRP conjugate 
170-6515 Bio-Rad 1:5000 Western blot 
Goat anti-rat lgG HRP 
conjugate 
sc-2006 Santa Cruz 1:2000 Western blot 
 
2.1.3. Reagents and chemicals 
Sigma-Aldrich, St. Louis, MO, USA: Methylene blue, Collagenase type 1A, 
Aprotinin, Bovine serum albumin (BSA), low-gelling temperature agarose, 
PVP (Polyvinylpyrrolidone), PEG (Polyethylene glycol), DMSO (Dimethyl 
sulphoxide).    
PAA Laboratories: DMEM (Dulbecco’s Modified Eagle Medium). 
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BD Biosciences, Franklin Lakes, New Jersey, USA: Matrigel. 
HyClone Laboratories, Inc., Logan, Utah, USA: Fetal Bovine Serum (FBS) 
and HEPES pH 7.8 
Gibco, Carlsbad, CA, USA: Penicillin/Streptomycin (P/S), Trypsin-EDTA 
and HS (Horse serum). 
US Biologicals, Swampscott, MA, USA: Chick embryo extract (CEE) and 
Dithiothreitol (DTT). 
Bio-Rad Laboratories: Bradford assay reagent, Ssofast Evagreen and 
nitrocellulose membrane. 




 Base Pte. Ltd.: EDTA (Ethylenediaminetetraacetic acid). 
GE Healthcare Life Sciences: Nucleic acid blotting nylon membrane 
(Hybond-N+). 
Fluka, St. Louis, MO, USA: lgepal (NP-40). 
Merck & Co, Inc., NJ, USA:  Ethanol, Formaldehyde, HCl, methanol, 
acetone. 
Invitrogen: NSS (Normal sheep serum) and DAPI (4',6-diamidino-2-
phenylindole).  
2.1.4. Enzymes 
All restriction enzymes were acquired from New England Biolabs (NEB, 
USA) or Fermentas (Maryland, USA).  All restriction enzyme buffers were 
supplied by the respective companies.  The remaining enzymes used in this 
study are listed in table 2.6. 
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Table 2.6 Enzymes 
Enzymes Source 
Proteinase K Invitrogen 
iScript Reserve Transcriptase Biorad 
Taq DNA polymerase Fermentas 
2.1.5. Plasmid DNA 




C in either TE buffer or Milli-Q water. 
Bacterial stocks were maintained in 25% autoclaved glycerol and stored at -
80
o
C. Plasmid DNA constructs and their sources are given in the table 2.7.  
Table 2.7 Plasmid constructs 
Construct name Vector backbone source 
Akirin1 pcDNA3.1 pcDNA3.1 Invitrogen 
pRL-TK Renilla Promega 
MuRF1-Luc pGL4.1 Gift 
 
2.1.6.  Solutions 
The solutions used in this project are listed in table 2.8.  









37% Formaldehyde - 250 ml 
NaC1-8.7g 
Milli-Q water - 750 ml 
Sodium borate buffer 0.01 M (pH 8.7) 
Sodium tetraborate - 7.63g 
Milli-Q water - 2 L 
Adjust pH to 8.7 
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Methylene blue stain 
1% methylene 
blue 
Methylene blue - 1g 
0.01 M borate buffer  
(pH 8.5)- 100 ml 
1 M HC1 1 M 
37% fuming HCl - 8.33 ml  
Milli-Q water - 100 ml 
HC1:Ethanol 
1:1 0.1 M HC1: 
Ethanol 
Absolute ethanol - 500 ml 
1 M HC1 - 50 ml 




Absolute ethanol - 87 ml 
37% Formaldehyde - 8.7 ml 
Glacial acetic acid - 4.3 ml 
0.1% HC1 0.1% 
37% fuming HC1 - 0.1 ml 
Milli-Q water  - 99.9 ml 
Scott’s tap water - 
Sodium bicarbonate - 3.5 g 
MgSO4. 7H2O - 20g 
Milli-Q water - 1 L 
Collagenase 1A solution 0.2% 
Collagenase 1A (490U) - 40mg 




Matrigel - 0.4 ml 
Cold DMEM - 3.6 ml 
RIPA buffer 
Aprotinin 
1.5 mM Sodium 
vanadate 
2 mM NaF 
5 mM Na2-EDTA 
1X protease 
inhibitor stock 
2 mM PMSF (add 
just before using) 
1.7 mg/ml Aprotinin- 0.4 ml 
700 mM Sodium vanadate- 30 
µl  
500 mM NaF- 1.4 ml 
0.5 M EDTA- 140 µl 
50 X protease inhibitor stock- 
400 µl 
Make up to14 ml with Milli-Q 
water 




Solutions for cytoplasmic and nuclear extract isolation (freshly prepared): 
Lysis buffer 50 mM KCl 
0.5% Igepal-NP-40 
25 mM HEPES  
(pH 7.8) 
- 
125 µM DTT 
1 mM PMSF 
1 M KCl - 250 µl 
Igepal-NP-40 - 25 µl 
1 M HEPES (pH 7.8) - 125 µl 
1.7 mg/ml Aprotinin - 58.8 µl 
250 mM DTT - 2.5 µl 
100 mM PMSF - 50 µl 
Milli-Q water - 4.48 ml 
Wash buffer 50 mM KCl 
25 mM HEPES  
(pH 7.8) 
- 
125 µM DTT 
1 mM PMSF 
1 M KCl - 250 µl 
1 M HEPES (pH 7.8) - 125 µl 
1.7 mg/ml Aprotinin - 58.8 µl 
250 mM DTT - 2.5 µl 
100 mM PMSF - 50 µl 
Milli-Q water - 4.51 ml 
Extraction 
buffer 
0.5 M KCl 




125 µM DTT 
1mM PMSF 
1 M KCl – 2.5 ml 
1 M HEPES (pH 7.8) - 125 µl 
50% glycerol - 1 ml 
1.7 mg/ml Aprotinin - 58.8 µl 
250 mM DTT - 2.5 µl 
100 mM PMSF - 50 µl 






































































Milli-Q water- 4.1 ml 
Separating 















Milli-Q water- 8.1 ml 
Separating 
protein gel 














Milli-Q water- 5.4 ml 
MES-SDS 
running buffer 
1X 20X MES-SDS - 50 ml 






- Tris - 3.03 g 
Glycine - 14.4 g 
Methanol - 200 ml 
Make up to 1000 ml with Milli-Q 
water.  Store at 4°C. 
TBS (Tris 
buffered saline) 
0.05 M Tris-HC1 (pH 
7.5) 
150 mM NaCl 1X 
1 M Tris-HCl (pH 7.5) = 50 ml 
5 M NaCl = 30 ml  
Make up to 1000 ml with Milli-Q 
water. 
TBS-T (1X) 0.05 M Tris-HC1 (pH 
7.5) 
150 mM NaCl 
0.1% Tween-20 
1 M Tris-HCl (pH 7.5) - 50 ml 
5 M NaCl - 30 ml 
Tween 20 - 1 ml 




5% non-fat milk in 1X 
TBS-T 
Non-fat milk powder - 5 g 
1X TBS-T - 100 ml 
Western blot 
BSA blocker 
5% BSA in 1X TBS-T BSA - 5 g 
1X TBS-T - 100 ml 




0.5X 10X TBE - 100 ml 
Make up to 2000 ml with Milli-Q 
water.  Freshly prepared. 
5% TBE gel - 30% Acrylamide - 1.66 ml 
10X TBE - 0.5 ml 
10% Ammonium persulfate (freshly 
prepared) - 0.1 ml 
TEMED - 10 µl 
Make up to 10 ml with Milli-Q water. 
Binding buffer 100 mM Tris 
500 mM KCl 
10 mM DTT 
Tris - 60.57 mg 
KCl - 186.32 mg 
DTT - 7.71 mg 
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pH 7.5 Milli-Q water - 5 ml 
Adjust pH to 7.5. Store at -20°C. 
DNA Loading 
dye 
5X Bromophenol blue - 25 mg 
Xylene cyanol - 25 mg 
0.2 M Na2-EDTA - 5 ml 
30% glycerol - 3 ml 
Make up to 10 ml with Milli-Q water.  




1X 10X TAE - 100 ml 
Make up to 1000 ml with Milli-Q 
water. 
Sodium acetate  3 M (pH 5.0) Sodium acetate – 2.460 g 
Milli-Q water - 10 ml 
Adjust pH to 5.0 
DNA extraction 
buffer 
0.1 M NaCl 
1 mM Na2-EDTA 
1% SDS 
 
NaCl- 292.2 mg 
Na2-EDTA- 18.61 mg 
10% SDS- 5 ml 
Make up to 50 ml with 10 mM Tris-
HCl (pH 8.0) 
DAPI 0.2 µg/ml DAPI in 
1 X PBS 
1 mg/ml DAPI - 2 µl 
Make up to 10 ml with 1X PBS. 
Proteinase K 5 µg/ml Proteinase K  
20 mM Tris and 
1 mM Na2-EDTA 
pH 7.5 
19.2 mg/ml Proteinase K - 2.6 µl 
Tris - 24.2 mg 
Na2-EDTA - 3.7 mg 
Make up to 10 ml with Milli-Q water. 
Adjust pH to 7.5. 
PBS-T 1X PBS 
0.05 % Tween-20 
1X PBS - 10 ml 
Tween-20 - 5 µl 
Na2-EDTA 0.5 M Na2-EDTA - 18.6 g 
Milli-Q water - 100 ml 
 
2.1.7 Cell lines 
The cell lines used in this project are listed in the table 2.9. 
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Table 2.9 Cell lines 
Cell line Species Cell type Source 
C2C12 Mouse Myoblast 
ATCC (Yaffe and 
Saxel, 1977). 
Clone 7 (Akirin1 
over-expressing 
stable clone) 
Mouse Myoblasts Marshall et al., 2008 
2.2 Methods 
This section describes the basic protocols employed in the thesis. 
2.2.1. Mice breeding 
Heterozygote and homozygous breeding pairs of Akirin1 knock-out and wild-
type mice (C57BL/6 and SV129 mixed strain background) used in this project 
were obtained from Dr. Kazufumi Matsushita (Osaka University, Japan). Mice 
were housed at the Nanyang Technological University (NTU) Animal House, 
Singapore and maintained on standard chow diet at a constant temperature 
(20°C) under a 12/12 hour artificial light/dark cycle with unlimited access to 
water. All experiments were performed as per the approved protocols of 
Institutional Animal Ethics Committee (IACUC), Singapore.   
2.2.2. Genotype analysis 
Genotype analysis of the Akirin1 transgenic mice was performed according to 
Ge et al., 2011.  A 0.2 x 0.2 cm² section of mouse ear tissue was digested in 
300 µl of tissue lysis buffer containing 10 mM Tris-HCl (pH 8.0), 100 mM 
Na2EDTA, 0.5% SDS and 100 µg/ml Proteinase K for 2 hour at 56°C. The 
tissue digest was centrifuged at 13,000 rpm at room temperature for 10 
minutes.  The supernatant was transferred to a new tube and 500 µl of 
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isopropanol was added followed by 1 ml ice-cold 70% ethanol.  The mixture 
was centrifuged at 13,000 rpm at room temperature for 10 minutes.  The 
supernatant was decanted and DNA pellet was washed with 1 ml of 70% 
ethanol.  After air-drying, the pellet was re-suspended in 100 µl of 10 mM 
Tris-HCl (pH 8.0) for 5 minutes at 65°C.  Semi-quantitative PCR was 
performed to identify wild type, heterozygous, Akirin1 homozygous knock- 
out alleles using the oligonucleotides listed in table 2.2. PCR reaction 
conditions were as follows: 5 minutes at 94°C, 35 amplification cycles (30 
seconds at 94°C, 1 minute at 67°C, and 1 minute at 72°C) and 10 minutes at 
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C.  PCR products were separated on 1% agarose gel in 1X TAE running 
buffer.  
2.2.3. DNA gel electrophoresis 
Agarose gels (0.8-2% depending on the size of the fragments to be separated) 
were made in 1X TAE buffer.  Ethidium bromide was added for visualization 
of the DNA bands. DNA samples were mixed with 5X DNA loading dye 
before loading and run in 1X TAE running buffer.   DNA molecular markers 
were run beside the DNA samples.  Electrophoresis was carried out at 100 V 
until the desired separation of bands was obtained.  The separated DNA was 
then visualized under ultraviolet (UV) light using the Gel Doc system 
(G:BOX, Syngene, Synoptics Ltd., England) and photos were printed. 
2.2.4. Isolation of primary myoblasts 
Primary myoblasts were cultured from hind-limb muscles using a modified 
method published by McCroskery et al., 2003. Muscles were minced in PBS 
and centrifuged at 3000 rpm for 10 minutes to remove PBS.  The minced 
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muscles were digested in 0.2% collagenase type 1A in Dulbecco’s Modified 
Eagle Medium (DMEM; Invitrogen, USA) at 37°C with shaking (70 rpm) for 
90 minutes and then centrifuged at 3000 rpm for 10 minutes.  The pellet was 
re-suspended in 12 ml PBS and passed through 100 µm filter (BD falcon 100 
µm nylon cell strainers) and then centrifuged at 3000 rpm for 10 min.  The 
pellet was re-suspended in 8 ml of warm primary myoblasts proliferation 
media containing 20% Fetal Bovine Serum (FBS), 10% Horse Serum (HS), 
1% chicken embryo extract (CEE), 100 units/ml penicillin and 100 µg/ml 
streptomycin in DMEM (Invitrogen, USA), and pre-plated on uncoated 10 cm 
plates for 3 hours at 37°C and 5% CO2 to remove fibroblasts.  After 3 hours 
primary myoblasts were transferred to 10% Matrigel (BD Biosciences, USA) 
coated 10 cm plates and incubated for 12 hours at 37°C and 5% CO2.  Isolated 
primary myoblasts were later washed with PBS and maintained for subsequent 
experiments. 
2.2.5. Cell culture 
The established ATCC mammalian (murine) cell line C2C12 myoblasts were 
used (Yaffe and Saxel 1977). The cell stocks were stored in C2C12 
proliferation media Dulbecco’s Modified Eagle Medium (DMEM) (PAA 
Laboratories, Inc., Pasching, Austria), 10% Fetal Bovine Serum (FBS) 
(HyClone Laboratories, Inc., Logan, Utah, USA), 1% Penicillin / 
Streptomycin (P/S) (Gibco, Carlsbad, CA, USA) media with 5% Dimethyl 
Sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) in liquid nitrogen.  
The cells were passaged in proliferation media and differentiated in C2C12 low 
serum differentiation media: DMEM, 2% Horse Serum (HS) (Gibco, Carlsbad, 
CA, USA), 1% P/S was used to differentiate the myoblasts to myotubes. 
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2.2.6. Myoblast proliferation assay 
Myoblast proliferation was assessed as described according to Thomas et al, 
2000.  Myoblasts were seeded on 96-well plates at a density of 1,000 cells per 
well and incubated at 37°C and 5% CO2. Proliferating myoblasts were 
subsequently fixed at 24-hour intervals in 100 µl formal saline fixative (10% 
Formaldehyde, 0.9% NaCl).  Proliferation was assessed using the methylene 
blue photometric end-point assay (Oliver et al., 1989).  Briefly the fixative 
was removed and myoblasts were washed with 1X PBS for two times.  Then 
myoblasts were incubated at room temperature for 30 minutes in 100 µl 
methylene blue stain (1% methylene blue in 0.01 M sodium tetraborate, pH 
8.5). Each well was washed four times with 200 µl of borate buffer to remove 
excess stain. Following this, 200 µl of 0.1 M HC1: 70% ethanol (1:1) was 
added and the absorbance of the cells was read on xMark Microplate 
Absorbance Spectrophotometer (Bio-Rad, USA) reader at 655 nm.  The 
absorbance is directly proportional to final myoblast number. 
2.2.7. Myoblast differentiation assay 
Primary myoblasts from wild-type and Akirin1 knock-out were seeded in 6-
well plates (for protein and RNA) or on Thermanox coverslips (for 
Hematoxylin and Eosin staining) coated with 10% Matrigel (BD Biosciences) 
at a density of 25,000 cells/cm² in proliferation medium containing DMEM, 
20% FBS, 10% HS, 1% CEE, 100 units/ml penicillin and 100 µg/ml 
streptomycin at 37°C and 5% CO2.  After an overnight attachment period, 
myoblasts were induced to differentiate in low serum media containing 
DMEM, 2% HS, 100 units/ml penicillin and 100 µg/ml streptomycin.  
Myotubes in 6-well plates were washed twice with 1X PBS and collected in 
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TRIzol for RNA or RIPA buffer for total protein respectively.  Myotubes on 
the coverslips were fixed at 24-hour intervals in 0.5 ml fixative containing 
70% ethanol; formaldehyde; acetic acid (20:2:1) for 30 seconds and washed 
with 1X PBS three times for Hematoxylin and Eosin (H & E) staining.  
2.2.8. Muscle sample collection  
Mice were terminated by CO2 asphyxiation and the muscles were dissected 
and frozen in liquid nitrogen.  Body weights and the weights of individual 
muscles, including M tibialis anterior, M gastrocnemius, M soleus, M 
quadriceps, heart, masseter and diaphragm were recorded before sample 
collection.   
2.2.9. Protein lysate isolation and quantitation 
The myoblasts or myotubes were collected in appropriate volume of RIPA 
buffer and homogenized by passing through 27G gauge needle at least 20 
times. The lysate was incubated for 15 minutes on ice and centrifuged at 
12,000 rpm for 15 minutes.  Skeletal muscle protein lysates were prepared by 
homogenizing muscles in RIPA buffer (1 ml buffer for 50 mg muscle tissue) 
using the Yellowline 1KA DI 25 Base Homogenizer (Fisher Scientific, USA) 
at 9,500 - 24,000 rpm for 1 minute at each speed keeping on ice. The protein 
lysate was kept on ice for 15 minutes and then centrifuged at 12,000 rpm for 
15 minutes at 4°C.  The supernatant was collected and the protein 
concentration was measured using Bradford’s protein assay reagent (Bio-Rad, 
USA) against BSA standard (Bio-Rad, USA) detected at 595 nm.  
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2.2.10. Cytoplasmic and nuclear fraction extraction 
C2C12 and Clone7 cells were differentiated and collected at respective time-
points. The cells were trypsinized and centrifuged at 1,500 rpm for 5 minutes 
at 37°C following 1X PBS was twice.  The cell pellets were stored at -80°C to 
be processed later or were processed immediately for isolation of cytoplasmic 
and nuclear extracts as previously described (Ye et al. 1996). Wild-type and 
Akirin1 knock-out quadriceps muscle samples were homogenized in ice-cold 
1X PBS and processed immediately for isolation of cytoplasmic and nuclear 
extracts as previously described (Ye et al., 1996).   To the cell pellet or muscle 
homogenate, 300 µl of lysis buffer was added, mixed well and incubated on 
ice for 4 minutes.  The tubes were then centrifuged at 10,000 rpm for 1 minute 
at 4°C.  The supernatant was collected as cytoplasmic extract (CE).  The pellet 
in the tubes were washed with 300 µl of wash buffer followed by 
centrifugation at 10,000 rpm for 1 minute at 4°C.  The supernatant was 
discarded and the pellet was re-suspended in appropriate volume (100 µl for 
cells; 250 µl for muscles) of extraction buffer.  The pellet was pipetted up and 
down several times in the extraction buffer.  The mixture was centrifuged at 
14,000 rpm for 5 minutes at 4°C.  The supernatant was collected as nuclear 
extract (NE).  The protein concentrations of the nuclear and cytoplasmic 
extracts were measured by Bradford’s assay (Bradford 1976) (Bio-Rad). 
2.2.11. SDS-PAGE and western blotting 
 Equal amount of proteins, usually 20-30 µg, were mixed with 4X protein 
loading dye (Invitrogen, CA, USA) with β-Mercaptoethanol (βMe) (loading 
dye:βMe = 3:1, V:V) .  The mixed protein samples were boiled at 100°C for 5 
min and separated in SDS-PAGE (NuPage 4-12% gradient Bis-Tris pre-cast 
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polyacrylamide gels, Invitrogen, USA) at 200V (125mA). After 
electrophoresis, SDS-PAGE gels were transferred to TransBlot (Bio-Rad, 
USA) nitrocellulose membrane by electroblotting using Xcell II blot module 
(Invitrogen). The membranes were then stained with Ponceau S (Fluka, 
Sigma-Aldrich) to determine equal protein loading and transfer efficiency.  
After de-staining in 1X TBS-T, membranes were blocked overnight with 5% 
milk in TBS-T at 4°C, or blocked in PVP blocker or BSA blocker for 1 hour at 
room temperature.  Blocking was followed by incubation with specific 
primary (3 hours for milk and BSA blocker or overnight in PVP blocker) and 
secondary antibodies (1 hour).  Membranes were washed with 1X TBS-T for 5 
times (5 minutes each) after each incubation.  Primary and secondary 
antibodies used in this project are listed in table 2.3 and 2.5 respectively.  HRP 
activity was detected using Western Lighting™ Chemiluminescence Reagent 
Plus (NEL104; PerkinElmer Life Sciences, Waltham, MA, USA).  Films 
(Kodak) were exposed to the membranes and the developed films were 
analyzed using Quantity One imaging software (Bio-Rad, USA). 
2.2.12. RNA extraction and electrophoresis 
Total RNA from cells or skeletal muscle tissue was isolated using TRIzol 
(Invitrogen, CA, USA) according to the manufacturer’s protocol.  1 ml of 
TRIzol was used for 100 mg muscle or 1 million cells.  After homogenization, 
samples were incubated for 5 minutes at room temperature and centrifuged for 
10 minutes at 4°C (12,000 rpm).  After mixing with chloroform (200 µl for 1 
ml TRIzol), samples were vigorously shaken for 15 seconds.  Following 3 
minutes incubation at room temperature, samples were centrifuged for 15 
minutes at 12,000 rpm.  The aqueous phase was transferred into fresh tubes 
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and mixed with isopropanol (500 µl for 1 ml TRIzol) for RNA precipitation.  
Total RNA was collected by centrifuging (12,000 rpm) for 10 minutes, and the 
resulting pellet was washed with 75% ethanol and then re-suspended in 
DEPC-treated H2O (0.1% diethylpyocarbonate). The re-suspended RNA was 
incubation at 55°C for 10 minutes aided the solubilisation of RNA.  After 
quantification with NanoDrop® spectrophotometer (ND-1000; NanoDrop 
Technologies Inc., DE, USA), RNA samples were stored at -80°C.  RNA 
quality was checked by electrophoresis.  Equal amount of RNA samples (1 
µg), mixed with 2X RNA loading dye, were separated in 1.5% agarose gel 
(UltraPure™, Invitrogen, USA) in 1X MOPS running buffer with 
formaldehyde. 
2.2.13. cDNA synthesis and quantitative PCR analysis 
One µg of RNA was used for cDNA synthesis using iScript™ cDNA 
Synthesis Kit (Bio-Rad, USA) according to the manufacturer’s instruction.  
RNA samples were mixed with 5X iScript reaction buffer and 1 µ1 of iScript 
reverse transcriptase (RT).  The reaction mixture was incubated for 5 minutes 
at 25°C, followed by 30 minutes at 42°C and finally for 5 minutes at 85°C.  
After incubation, synthesized cDNA was stored at -20°C prior to use.  
Quantitative real time PCR was carried out in triplicates using SsoFast™ 
EvaGreen supermix and CFX96 Real Time System (Bio-Rad, USA).  PCR 
reaction conditions were as follows: 3 minutes at 98°C and 45 amplification 
cycles (3 seconds at 98°C, 10 seconds at 60°C, and 10 seconds at 72°C).  Gene 
expression levels were analyzed as fold change using the ∆∆CT (threshold 
cycle) method, normalized to cyclophilin expression. Details about the 
oligonucleotides used in this project are listed in table 2.1.   
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2.2.14. Tissue preparation for cryosectioning for histological analysis 
Muscle tissue processing was performed according to Ge et al., 2011. For 
histological analysis, muscles and whole heart were embedded with liquid 
Optimal Cutting Temperature (OCT) compound and then frozen in isopentane 
cooled with liquid nitrogen.  Transverse sections of 10 µm thick were cut 
using Rotary Cryostat Microtome (RM2265, Leica) and mounted on slides for 
further histological analysis. 
2.2.15. Hematoxylin and Eosin (H&E) staining of primary cultures 
Hematoxylin and Eosin staining of mouse muscle primary cultures was 
performed according to McFarlane et al., 2008. Wild-type and Akirin1 knock-
out primary myoblasts were seeded on 10% Matrigel (BD Biosciences) coated 
Thermanox coverslips (Thermo Scientific, USA) at a density of 25,000 
cells/cm².  After overnight incubation at 37°C and 5% CO2, myoblasts were 
induced to differentiate in low Serum differentiation medium for 96 hours.  
Myotubes were subsequently fixed at 24-hour intervals in 70% ethanol 
formaldehyde: acetic acid (20:2:1) for 30 seconds and washed with 1X PBS 
three times, and then stained with Hematoxylin solution (Merck Chemicals, 
Germany) for 3 minutes and rinsed in 0.1% HCl solution for 2 seconds. 
Myotubes were then washed in Scott’s tap water for 5 times (1 minute each), 
and stained in Eosin solution (Merck Chemicals, Germany) for 3 minutes. 
After Eosin incubation, slides were dehydrated in 100% ethanol three times (5 
minutes each) and mounted with DPX solution (Merck Chemicals, Germany).  
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2.2.16. Measurement of myotube number, myotube area and fusion index 
To assess if Akirin1 knock-out primary myoblasts differentiate differently 
compared to the wild-type primary myoblasts, the cells were first seeded on 
Thermanox coverslips (Thermo Scientific, USA) at a density of 25,000 
cells/cm². Primary myoblasts were induced to differentiate in DMEM with 2% 
horse serum and 1% penicillin/streptomycin. At the indicated time points, the 
cultures were fixed with ethanol:formaldehyde:glacial acetic acid (20:2:1) and 
stained with Hematoxylin and 1% Eosin. Myotubes containing two, three or 
more than three myonuclei were considered for measuring the myotube 
number using the Image-Pro Plus analysis software package (Media 
Cybernetics, Bethesda, MD, USA). Fusion index was determined by counting 
the number of nuclei within myotubes over the total number of nuclei 
(represented as percentage). Myotubes containing equal or more than three 
myonuclei were considered for measuring the myotubes number and area. The 
myotubes area was represented as µm
2
. Myotube number myotubes area and 
fusion index were assessed in six random images taken from two coverslips 
each per genotype. 
2.2.17. Hematoxylin and Eosin (H & E) staining of muscle sections 
Firstly, 10 µm thick sections were cut at the mid-belly region of tibialis 
anterior muscle and then Hematoxylin and Eosin staining was performed. The 
sections were stained in Hematoxylin solution for 1 minute and rinsed in tap 
water until sections were clear. This was followed by rinsing the sections in 
Scott’s tap water for 2 minutes and then rinsed with tap water. The muscle 
sections were further stained with Eosin solution for 2 minutes and rinsed with 
tap water until the sections were clear. The sections were serially dehydrated 
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in 50% ethanol three times, 70% ethanol three times, 90% ethanol for 2 
minutes and 100% ethanol for 2 times (2 minutes each). The stained sections 
were cleared in xylene two times (5 minutes each) and air-dried. The dry 
sections were mounted using DPX mounting solution and allowed to dry 
overnight at room temperature. Images were captured using the Leica CTR 
6500 microscope, equipped with the Leica DFC 310 FX camera and Image 
Pro Plus software (Media Cybernetics, Bethesda, MD).  
2.2.18. Succinate dehydrogenase (SDH) and α-glycerophosphate 
dehydrogenase (GPD) staining on tibialis anterior sections 
SDH and α-GPD activity was measured by a colorimetric assay described by 
Masuda et al., 2009 with slight modification. In brief, for SDH staining, 
sections were air-dried for 30 minutes and then incubated in pre-warmed PBS 
buffer containing 50nM sodium succinate and 0.6 mM Nitro Blue Tetrazolium 
(NBT) (Sigma N5514) for 30 minutes at 37
o
C. For a-GPD staining, the 
sections were incubated in pre-warmed 0.2 M Tris-HCl buffer (pH7.4) 
containing 9.3 mM rac-glycerol-1-phosphate disodium salt hexahydrate 
(Sigma G6014) and 0.24 mM NBT for 45 minutes at 37
o
C after air-drying. 
The reaction was terminated by thoroughly rinsing the sections with Milli-Q 
water. After dehydration and clearance by xylene, the sections were mounted 
by DPX (Sigma). Images were captured using the Leica CTR 6500 
microscope, equipped with the Leica DFC 310 FX camera and Image Pro Plus 
software (Media Cybernetics, Bethesda, MD). The enzyme activities were 
measured for the mean grey value by Image J software (National Institute of 
Health, USA) and expressed as the mean optical density (OD) of the entire 
tibialis anterior section.       
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2.2.19. Fiber typing of tibialis anterior sections 
10 µm thick tibialis anterior sections were cut and blocked with blocking 
mixture made of 0.5% Triton X-100, 0.2% BSA and 10% normal sheep serum 
(NSS) in 1X PBS for one hour at room temperature with shaking. Further, the 
sections were treated with appropriate primary myosin heavy chain type 
antibody in a diluent made of 0.2% BSA, 5% normal sheep serum and 0.1% 
PBS-Tween 20 at 4
o
C overnight with shaking. The primary antibody dilution 
used for the various myosin heavy chain types is listed in table 2.4. Next day, 
the sections were washed with 1X PBS three times for five minutes each. The 
primary antibody staining was fixed by treating the sections with 10% 
buffered formalin for 5 minutes and then washed three times with 1X PBS for 
five minutes each. Further, sections were treated with secondary antibody 
diluent containing biotinylated sheep anti-mouse IgG antibody in 1:200 
dilution along with 0.2% BSA, 5% normal sheep serum in 0.1%PBS-Tween 
20 for one hour at room temperature with shaking followed by washing thrice 
with 1X PBS for five minutes each. Tertiary antibody streptavidin anti-mouse 
IgG Alexa Fluor 488 (AF 488) was used at 1:400 dilution along with 0.2% 
BSA and 0.1% PBS-Tween 20 for one hour at room temperature in dark. Then 
the sections were washed with 1X PBS thrice for five minutes each. 
Myonuclei were stained with DAPI made in 1X PBS at 1:10,000 dilution for 
five minutes and then rinsed with 1X PBS and air-dried. The dry sections were 
mounted using ProLong Gold Antifade solution (Invitrogen) and allowed to 
dry overnight at room temperature. Images were captured using the Leica CTR 
6500 microscope, equipped with the Leica DFC 310 FX camera and Image 
Pro Plus software (Media Cybernetics, Bethesda, MD).     
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2.2.20. Transformation of competent cells and isolation of single bacterial 
colonies 
Transformation of DH5α competent cells was achieved by addition of 5-10 ng 
of plasmid DNA to 50 µl of the competent cells.  The DNA competent cell 
mixture was incubated on ice for 20 minutes, followed by a heat shock at 42°C 
for 48 seconds, then further 2 minute incubation on ice.  Following this, 950 µl 
of room temperature LB broth (without antibiotic) was added to the 
transformed cells and incubated at 37°C for 90 minutes with gentle shaking 
(~150 rpm).  The culture was spread over LB agar plates, which contained the 
appropriate antibiotic, and grown for 16-24 hours at 37°C.  Single colonies 
were seeded in 4 ml (for miniprep) or 100 ml (for maxiprep) of LB broth with 
the appropriate antibiotic.  The cultures were grown at 37°C with shaking 
(~250 rpm) for 12-18 hours. 
2.2.21.  Plasmid isolation 
Plasmid DNA used in this study was isolated using two procedures explained 
below. 
2.2.21.1. Miniprep plasmid isolation 
Plasmid DNA was extracted and purified using the QIAprep spin miniprep 
system (Qiagen), according to the manufacturer’s protocol.  Bacteria were 
harvested by centrifugation at 3500 rpm for 5 minutes in a 1.5 ml eppendorf 
tube.  The bacterial pellet was re-suspended in 250 µl of Buffer P1 followed 
by 250 µl of Buffer P2, the sample was then mixed by inverting four-six times 
and allowed to incubate at room temperature for no more than 5 minutes.  
After incubation 350 µl of Buffer P3 was added.  After the addition of Buffer 
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P3, the tube was again inverted four-six times to mix.  The extract was 
centrifuged (20,000 x g for 10 minutes) and the supernatant transferred to a 
QIAprep spin column.  The spin column was centrifuged at 20,000 x g for 1 
minute, washed with 0.75 ml Buffer PE and centrifuged twice to remove any 
traces of Buffer PE.  Plasmid DNA was eluted in 50 µl Buffer EB by 
centrifugation (20,000 x g for 1 minute). 
2.2.21.2. Maxiprep plasmid isolation 
Large-scale purification of plasmid DNA was performed using the Qiagen 
Plasmid Maxi kit (Qiagen) as per the protocol. Firstly, 250 ml of overnight 
culture was harvested by centrifugation at 6,000 x g for 15 minutes.  The pellet 
was then re-suspended in 10 ml of buffer P1, mixed with 10 ml of Buffer P2 
and incubated on ice for 20 minutes on addition of Buffer P3.  The mix was 
then centrifuged for 30 minutes at 20,000 x g followed by a second spin at 
20,000 x g for 15 minutes to remove any contaminants.  The plasmid DNA 
containing supernatant was passed through a pre-equilibrated Qiagen-column 
by gravity flow.  Plasmid DNA bound to the column was washed twice with 
Qiagen Buffer QC and eluted with Qiagen elution buffer.  The eluted DNA 
was precipitated with 0.7 volumes of isopropanol and pelleted by 
centrifugation at 20,000 x g for 10 minutes.  The pellet was washed twice with 
70% ethanol, dried and re-suspended in an appropriate volume of TE buffer. 
2.2.22. Transfection and Luciferase assay 
C2C12 myoblasts were plated at a density of 15,000 cells/cm² in 6 well plates.  
Following overnight attachment, the C2C12 myoblasts were transfected with 
either pGL4.1 or rat MuRF1 promoter construct along with pcDNA3.1 or 
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pcDNA3.1-Akirin1 expression vector together with the control Renilla 
Luciferase vector pRL-TK using Lipofectamine 2000 (Invitrogen) as per the 
manufacturer’s guidelines.  Following overnight transfection, the medium was 
replaced with fresh differentiation medium and the cells were incubated and 
collected at respective time points. The cells were lysed using 1X passive lysis 
buffer (Promega, USA). Luciferase assays were performed using the Dual 
Luciferase Assay System, as per the manufacturer’s protocol (Promega).  
Relative luciferase activity in each of the extracted protein samples was 
measured in triplicate using the Fluoroskan Ascent Microplate Fluorometer 
and Luminometer (Thermo Fisher Scientific Inc.,). 
2.2.23. Electrophoretic Mobility Shift Assay (EMSA) 
 Oligonucleotides which contain the CREB-1 consensus binding site 5’-
TGACATTA-3’ on rat MuRF1 promoter i.e., forward oligonucleotide 
5’-CGTGGTGGTGACTGGGGGTGTGTAGTGACATTATTTTGT-3’ and 
reverse oligonucleotide 5’-ACAAAATAATGTCACTACACACCCCCAGTC 
ACCACCACG-3’ were hybridized and labeled at the 3’ end with Biotin 
Tetraethyleneglycol (TEG) (Sigma-Aldrich, St. Louis, MO, USA).  The 
EMSA was performed using the Lightsift Chemiluminescent EMSA kit 
(Thermo Scientific Pierce Biotechnology, Rockford, IL, USA).  Nuclear 
extracts obtained from wild-type and Akirin1 knock-out quadriceps muscle 
and Clone 7 cells were incubated with the biotin labeled probe (working 
concentration 1nM) in final volume of 20 µl containing binding buffer (100 
mM Tris, 500 mM KC1, 10 mM DTT, pH 7.5), glycerol, MgC12, poly (dl-dC) 
and NP-40.  After 20 minutes of incubation at room temperature, samples 
were subjected to electrophoresis on a 5% acrylamide gel containing Tris-
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Borate-EDTA (TBE) (Promega Corporation, Madison, W1, USA) at 80V at 
4ºC.  The samples were then transferred to a nylon membrane at 200 mA for 2 
hours at 4ºC and UV-crosslinked after transfer.  The membrane was probed 
with stabilized Streptavidin-Horseradish Peroxidase conjugate and developed 
using the Lightshift Chemiluminescent EMSA kit (Thermo Scientific Pierce 
Biotechnology, Rockford, 1L, USA). 
To confirm the presence of CREB-1 protein in the shifted complex, nuclear 
extracts from cells and quadriceps muscle were pre-incubated for 20 minutes 
at room temperature with 4 µg of CREB-1 (sc-240) antibody before incubation 
with the labeled probe for another 20 minutes at room temperature. The 
samples were then subjected to EMSA as mentioned above. 
2.2.24. Genomic and mitochondrial DNA isolation from differentiating 
primary myoblasts 
Primary myoblasts were seeded in 6-well plates and differentiated in low 
serum differentiation media. Myotubes were collected at 24-hour intervals in 
100 µl of DNA extraction buffer per well. Then the cells were digested with 
10mg/ml Proteinase K for 1.5 hours at 56
o
C with shaking. The volume of the 
digested sample was made to 500 µl using DNA extraction buffer. From this 
mixture, 250 µl was taken for DNA extraction by phenol-chloroform method. 
One volume of Phenol:Chloroform:Isoamyl alcohol (25:24:1) (Invitrogen, 
USA) was added to the digested mixture and shaken well followed by 
centrifuging at 14,000 rpm for 5 minutes. The top aqueous phase containing 
the DNA was collected in a new tube and precipitated by adding 2 volumes of 
100% ethanol. To this, 1/10 volume of 3 M sodium acetate (pH 5) was added 
and centrifuged at 14,000 rpm for 10 minutes. The DNA pellet was washed 
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with 150 µl of 70% ethanol and then air-dried. The DNA pellet was re-
suspended in 50 µl of 10 mM Tris–HCl (pH 8) and the DNA concentration 
was checked using NanoDrop® spectrophotometer (ND-1000; NanoDrop 
Technologies Inc., DE, USA).    
2.2.25. Mitochondrial DNA (mtDNA) copy number per nuclear DNA 
(nuDNA) ratio quantification by qPCR 
Relative copy number of mitochondrial DNA (mtDNA) per nuclear DNA 
(nuDNA) ratio was measured using a protocol described by Chen et al., 2010. 
The set of primers for mtDNA, forward primer: 5’-CCTATCACCCT 
TGCCATCAT-3’; reverse primer: forward primer: 5’-CCTATCACCCT 
TGCCATCAT-3’; reverse primer: 5’GAGGCTGTTGCTTGTGTGAC-3’ and 
for nuDNA, forward primer: 5’-ATGGAAAGCCTGCCATCATG-3’; reverse 
primer: 5’-TCCTTGTTGTTCAGCATCAC-3’ were used. Quantification of 
the relative ratio of mtDNA per nuDNA was analyzed using the threshold 
cycle ∆∆CT method. 
2.2.26. cDNA synthesis and quantitative real time PCR analysis of  
mature miR-1  
One µg of RNA was used for cDNA synthesis using Taqman® MicroRNA 
Reverse Transcription Kit (Applied Biosystems®, USA) according to the 
manufacturer’s instruction. Quantitative real time PCR was carried out in 
duplicates using Taqman® PCR Kit protocol as per manufacturer’s instruction 
in CFX96 Real Time System (Bio-Rad, USA).  PCR reaction conditions were 
as follows: 2 minutes at 50°C, 10 minutes at 95
o
C and 40 amplification cycles 
(15 seconds at 95°C and 1 minute at 60°C).  Gene expression levels were 
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analyzed as fold change using the ∆∆CT (threshold cycle) method, normalized 
to U6 expression. Details about the oligonucleotides used in this project are 
listed in table 2.1.   
2.2.27. Statistical analysis 
Statistical analysis was performed using one–way ANOVA, two-tailed 
Student’s t-test Results were considered significant at p<0.05 (*), p<0.01 (**), 
or p<0.001 (***). Results were expressed as mean ± SE of 3 or 4 independent 
experiments. Non-parametric Mann-Whitney U test was used to calculate the 
level of significance for ± SE n=2 experiments and the results were considered 


































3. ROLE OF AKIRIN1 IN MYOGENESIS 
 
This chapter explains the results that help us in understanding the role of 
Akirin1 during myogenesis. The materials and methods used in this chapter 
are discussed in chapter 2 of this thesis.    
RESULTS 
3.1 Identification of Akirin1 knock-out mice by genotyping and 
confirming the absence of Akirin1 in these mice. 
In this study, Akirin1 knock-out mice were used as the animal model to 
understand the in-vivo function of Akirin1. Akirin1 knock-out mice was 
generated by deleting exon 1 of Akirin1 gene in C57BL6J/SV129 mouse 
embryos by loxP-cre system (Goto et al., 2008). C57BL6J/SV129 (wild-type) 
mice were used as controls in this study. Mice were bred and genomic DNA 
was isolated from the ear tissue. To identify the wild-type and Akirin1 knock-
out pups, semi-quantitative PCR was performed with specific primers (Table 
2.2). Wild-type mice were identified by an amplicon band of 413 base pairs 
while Akirin1 knock-out mice were identified by an amplicon band of 650 
base pairs (Figure 3.1A).  
To confirm the absence of Akirin1 gene in Akirin1 knock-out mice, real time-
quantitative PCR was performed on wild-type and Akirin1 knock-out 
quadriceps RNA using Akirin1 specific primers (Table 2.1). The Akirin1 Ct 
values were normalised to cyclophilin Ct values. This result clearly indicated 
that Akirin1 gene is indeed significantly down-regulated in Akirin1 knock-out 





Figure 3.1 Identification of Akirin1 knock-out mice by genotyping and 
confirming the absence of Akirin1 in these mice. (A) Agarose gel 
electrophoresis was performed on the PCR amplification products from 
Akirin1 knock-out and wild-type ear explants. 1 kb plus ladder was loaded as 
reference (Lane 1). Wild-type allele was identified by the amplicon product 
size at 413 base pairs (lane 2). Akirin1 knock-out allele was identified by the 
amplicon product size at 650 base pairs (lane 3). (B) Confirmation of absence 
of Akirin1 in Akirin1 knock-out muscles. The mRNA expression for Akirin1 
was determined in quadriceps muscle obtained from Akirin1 knock-out and 
wild-type mice. The values are mean ± S.E. of four different animals. 
***p<0.001 denotes significant fold change difference in Akirin1 mRNA 




3.2 Absence of Akirin1 leads to reduced proliferation of primary 
myoblasts.  
Marshall et al., showed that over-expression of Akirin1 in C2C12 myoblasts led 
to increased proliferation compared to the control C2C12 myoblasts (Marshall 
et al., 2008). So, we wanted to see if the rate of proliferation was affected in 
the absence of Akirin1 in skeletal muscle. To investigate this, methylene blue 
photometric end-point assay was performed on proliferating Akirin1 knock-
out and wild-type primary myoblasts. Methylene blue stains the myoblasts in 
the culture dish and the optical density obtained at 655nm will be proportional 
to the number of myoblasts in the culture dish.    
The results revealed that Akirin1 knock-out primary myoblasts cultures 
showed significantly reduced number of primary myoblasts at 24, 36, 48 hour 






































Figure 3.2 Absence of Akirin1 leads to reduced proliferation of primary 
myoblasts. (A) Akirin1 knock-out and wild-type primary myoblasts were 
allowed to proliferate and fixed at the indicated time point and methylene blue 
photometric end-point assay was performed (*p<0.05, **p<0.01 and 
***p<0.001) (n=4, where n is the number of primary myoblast culture 
isolations done and for each primary myoblast culture isolation four mice per 







3.3 Lack of Akirin1 alters the levels of cell cycle regulators during 
proliferation.  
As Akirin1 knock-out primary myoblasts proliferated slower than the wild-
type, we analyzed the protein level of an important cyclin–dependent kinase 
inhibitor (CKI), p21 also known as WAF1/CDK inhibitor-1. p21 binds and 
inhibits the activity of cyclin-cdk complexes thus inhibiting G1-S phase 
transition (Gartel et al., 2005). Akirin1 knock-out and wild-type primary 
myoblasts were allowed to proliferate and cells were collected at 24-hour 
intervals. Protein lysates were subjected to western blotting with anti-p21 
antibody. The results showed that proliferating Akirin1 knock-out primary 
myoblasts have significantly higher level of p21 protein compared to the wild-
type primary myoblasts (Figure 3.3A and B).  
Next, we wanted to investigate the levels of various cell cycle regulators that 
play important roles in different stages of cell cycle progression. Cyclins and 
cyclin dependent kinases (Cdk) are the important regulators of cell cycle 
checkpoint progression. Proliferating Akirin1 knock-out and wild-type 
primary myoblast protein lysates were subjected to western blotting with anti-
cyclin D1, anti-cyclin E and anti-cdk4 antibodies. Proliferating Akirin1 knock-
out primary myoblasts showed significantly higher protein levels of cyclin E, 
cyclin D1 compared to the wild-type primary myoblasts (Figure 3.3A, C and 
D). However, cdk4 levels were not significantly up-regulated (Figure 3.3A 









Figure 3.3 Lack of Akirin1 alters the levels of cell cycle regulators during 
proliferation. Western blotting analysis was performed on Akirin1 knock-out 
and wild-type proliferating primary myoblasts protein lysates. (A) A 
representative immunoblot showing protein level of p21, cyclin D1, cyclin E 
and Cdk4. α-tubulin was used as the internal control for equal protein loading 
on the gel.  (B), (C), (D) and (E) Corresponding densitometry graph of p21, 
cyclin D1, cyclin E and Cdk4 in Akirin1 knock-out and wild-type primary 
myoblasts during proliferation. Level of significance was calculated by non-
parametric Mann-Whitney U test (*p<0.05 and **p<0.01) (n=2, where n is the 
number of primary myoblast culture isolations done and for each primary 
myoblast culture isolation four mice per genotype were used). 
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3.4 Proliferating Akirin1 knock-out primary myoblasts have increased 
levels of Serum response factor (SRF) protein.  
Serum response factor (SRF) is a MADS box containing transcription factor 
that binds to serum response element (SRE) on the promoters of target genes 
and stimulates their transcription. It has been shown that SRF is indispensable 
for myoblast proliferation (Soulez et al., 1996). Therefore, protein lysates from 
Akirin1 knock-out and wild-type proliferating primary myotubes were used to 
perform western blotting with anti-SRF antibody. The results showed that 
Akirin1 knock-out primary myoblasts showed significantly increased levels of 
SRF protein when compared to wild-type myoblasts at 24, 48, 72 and 96 hours 




































Figure 3.4 Proliferating Akirin1 knock-out primary myoblasts have 
increased levels of Serum response factor (SRF) protein. Western blotting 
analysis was performed on Akirin1 knock-out and wild-type primary 
myoblasts protein lysates. A(i) A representative immunoblot showing protein 
level of SRF in proliferating Akirin1 knock-out and wild-type primary 
myoblasts. GAPDH was used as the internal control for equal protein loading 
on the gel. A(ii) Corresponding densitometry graph of SRF showing 
significant increase in the protein content in Akirin1 knock-out primary 
myoblasts at 24, 48, 72 hours of proliferation. Level of significance was 
calculated by non-parametric Mann-Whitney U test (*p<0.05 and **p<0.01) 
(n=2, where n is the number of primary myoblast culture isolations done and 




3.5 Akirin1 knock-out primary myoblasts show increased myoblast 
fusion. 
 Previous results have shown that over-expression of Akirin1 in C2C12 
myoblasts led to enhanced differentiation compared to the control C2C12 
myoblasts (Marshall et al., 2008). So, we wanted to see if the rate of 
differentiation was affected in the absence of Akirin1 in skeletal muscle. To 
investigate this, Akirin1 knock-out and wild-type primary myoblasts were 
allowed to differentiate in low serum media and collected at 24-hour intervals 
and stained with hematoxylin and eosin. Akirin1 knock-out primary culture 
showed increased myoblast fusion and formed highly branched and elongated 
myotubes especially at 48 and 72 hours of differentiation compared to the 
wild-type primary culture (Figure 3.5A).  
To further investigate if Akirin1 knock-out primary myoblasts showed earlier 
fusion, we estimated the fusion index in differentiating Akirin1 knock-out and 
wild-type primary culture. Fusion index reflects the extent of fusion of 
myoblasts with each other to form myotubes. This index is estimated by the 
ratio of number of nuclei inside the myotubes to total number of myonuclei. 
Akirin1 knock-out primary cultures showed significantly increased fusion 
index at 24, 48 and 72 hours of differentiation compared to the wild-type 
primary cultures (Figure 3.5B).  We also investigated the number of myotubes 
formed during differentiation in Akirin1 knock-out and wild-type primary 
cultures. Akirin1 knock-out primary culture formed significantly reduced 
number of myotubes at 48 and 72 hours of differentiation compared to the 
wild-type primary culture (Figure 3.5C). The area of the myotubes formed at 
each time point were calculated using ImagePro software and the frequency 
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distribution of the myotubes formed showed that Akirin1 knock-out primary 
cultures formed bigger myotubes compared to the wild-type at 24 hours of 
differentiation (Figure 3.5D). However at 72 hours of differentiation, no 
significant difference in myotubes area between Akirin1 knock-out and wild-
type primary cultures was observed (Figure 3.5E).    
These results together suggest that Akirin1 knock-out primary myoblasts have 
the tendency to fuse early compared to the wild-type primary myoblasts to 




































Figure 3.5 Akirin1 knock-out primary myoblasts show increased 
myoblast fusion. Akirin1 knock-out and wild-type primary myoblasts were 
allowed to differentiate in low serum media. (A) The cells were fixed and 
stained with hematoxylin and eosin and images were taken using Leica upright 
bright field microscope under 10X magnification. Scale bar of the 
representative images represents 500 μm. (B) and (C) Graphs showing fusion 
index and myotube number respectively (*p<0.05 and **p<0.01) (n=3, where 
n is the number of times the differentiation assay was performed and for each 
differentiation assay four mice per genotype were used). (D) and (E) 
Frequency distribution graphs of area of myotubes formed by Akirin1 knock-










































Figure 3.6 Akirin1 knock-out primary myotubes show increased p21 
levels while the levels of other myogenic regulators were unchanged. 
Western blotting analysis was performed on Akirin1 knock-out and wild-type 
primary myotube protein lysates. A(i) A representative immunoblot showing 
protein levels of myogenic regulators like MyoD, p21, myogenin and MyHC. 
α-tubulin was used as the internal loading control. A(ii), A(iii), A(iv) and A(v) 
Corresponding densitometry graphs of MyoD, p21, myogenin and MyHC 
respectively. Level of significance was calculated by non-parametric Mann-
Whitney U test (*p<0.05, **p<0.01 and p<0.001) (n=2, where n is the number 
of primary myoblast culture isolations done and for each primary myoblast 











3.6 Akirin1 knock-out primary myotubes show increased p21 levels while 
the levels of other myogenic regulators were unchanged.  
The process of myogenic differentiation is profoundly affected by important 
myogenic regulators like MyoD, p21 (WAF1/CDK inhibitor-1), Myogenin 
and MyHC. First of all, induction of MyoD expression leads the myoblasts 
into differentiation program. Later, p21 expression inhibits the cell cycle 
progression leading to withdrawal of myoblasts from cell cycle. Followed by 
p21 is myogenin, an important protein responsible for the fusion of myoblasts 
with each other to form myotubes is expressed. Lastly, MyHC is expressed 
leading to the maturation of myotubes.  
Protein lysates of differentiating primary myotubes were subjected to 
immunoblotting with anti-p21 antibody. Akirin1 knock-out primary myotubes 
showed significantly increased levels of p21 protein at 24, 48,72 and 96 hours 
of differentiation compared to the wild-type primary myotubes [Figure 3.6A(i) 
and A(iii)]. 
The western blotting for MyoD, myogenin and MyHC in Akirin1 knock-out 
and wild-type primary myotubes were performed with anti-MyoD, anti-
myogenin and anti-MyHC antibodies. The results showed no significant 
difference in the protein levels of MyoD, myogenin and MyHC between 
Akirin1 knock-out and wild-type primary myotubes during 24, 48,72 and 96 
hours of differentiation [Figure 3.6A(i), A(ii), A(iv) and A(v)]. These results 
together suggest that the earlier fusion of myoblasts may be due to increased 




3.7 Lack of Akirin1 leads to increased levels of Serum Response Factor 
(SRF) protein during differentiation.  
As our previous results showed that Akirin1 knock-out primary myoblasts 
showed increased myoblast fusion, we investigated the level of SRF during 
myogenic differentiation. It has been shown that SRF is necessary for 
myoblast fusion and differentiation into myotubes in C2C12 myoblasts (Soulez 
et al., 1996).  
Akirin1 knock-out and wild-type differentiating primary myotubes protein 
lysates were subjected to western blotting with anti-SRF antibody. Similar to 
the quadriceps muscle results, protein levels of SRF were elevated in cell 
lysates of differentiating primary myotubes derived from Akirin1 knock-out 
mice compared to the wild-type [Figure 3.7A(i) and A(ii)].    
Further, SRF mRNA levels were quantified by real time-qPCR in wild-type 
and Akirin1 knock-out differentiating primary myotubes and normalised to 
cyclophilin Ct values. The results obtained showed no significant change in 
the mRNA level of SRF gene in Akirin1 knock-out primary myotubes 
compared to the wild-type primary myotubes during 24, 48, 72 and 96 hours 
of differentiation (Figure 3.7B). These results together suggest a post-












Figure 3.7 Lack of Akirin1 leads to increased levels of Serum Response 
Factor (SRF) protein during differentiation. Western blotting analysis was 
performed on protein lysates of Akirin1 knock-out and wild-type primary 
myotubes at 24, 48, 72 and 96 hours of differentiation. A(i) A representative 
immunoblot showing the protein level of SRF. GAPDH was used as the 
internal control for equal protein loading on the gel. A(ii) A graph showing 
corresponding densitometry analysis of SRF protein levels. Level of 
significance was calculated by non-parametric Mann-Whitney U test 
(*p<0.05, p<0.001) (n=2, where n is the number of primary myoblast culture 
isolations done and for each primary myoblast culture isolation four mice per 
genotype were used). (B) A graph showing the fold change mRNA expression 
of SRF in differentiating Akirin1 knock-out and wild-type primary myotubes 
(n=2, where n is the number of primary myoblast culture isolations done and 






3.8 Lack of Akirin1 leads to lower MuRF1 levels in differentiating 
primary myotubes.     
Another important protein that is shown to be important for the process of 
myogenic differentiation is MuRF1 (Spencer et al., 2000). Also, our results in 
section 4.6 showed that absence of Akirin1 in fully differentiated skeletal 
muscle like quadriceps lead to reduced MuRF1 levels. Therefore, we wanted 
to check the levels of MuRF1 during differentiation. For this, protein lysates 
from Akirin1 knock-out and wild-type differentiating primary myotubes were 
subjected to western blotting with anti-MuRF1 antibody. Consistent with the 
quadriceps muscle results, Akirin1 knock-out myotubes also showed lower 
protein levels of MuRF1 compared to the wild-type myotubes during 24, 48, 
72 and 96 hours of differentiation [Figure 3.8A(i) and A(ii)]. However, 
Akirin1 knock-out myotubes did not indicate any significant difference in 
other ubiquitin ligases like atrogin-1 when compared to the wild-type 
myotubes during 24, 48, 72 and 96 hours of differentiation [Figure 3.8A(i) and 
A(iii)].  
As MuRF1 mRNA level was down-regulated in Akirin1 knock-out quadriceps 
muscle, we investigated if MuRF1 mRNA level was also down-regulated in 
Akirin1 knock-out primary myotubes using real time-qPCR. Consistent with 
the reduced MuRF1 protein levels, Akirin1 knock-out primary myotubes 
showed significantly lower levels of MuRF1 mRNA levels compared to the 
wild-type primary myotubes at 48, 72 and 96 hours of differentiation (Figure 
3.8B).  These results together indicate that Akirin1 regulates transcription of 






Figure 3.8 Lack of Akirin1 leads to lower MuRF1 levels in differentiating 
primary myotubes. Western blotting analysis for MuRF1 and atrogin-1 was 
performed on protein lysates of Akirin1 knock-out and wild-type primary 
myotubes during differentiation. A(i) A representative immunoblot showing 
the protein levels of MuRF1 and atrogin1. GAPDH was used as the internal 
control for equal protein loading on the gel. A(ii) and A(iii) Graphs showing 
corresponding densitometry analysis of MuRF1 and atrogin1 respectively 
(*p<0.05) (n=3, where n is the number of primary myoblast culture isolations 
done and for each primary myoblast culture isolation four mice per genotype 
were used). (B) Graph showing the fold change MuRF1 mRNA expression in 
Akirin1 knock-out primary myotubes compared to the wild-type primary 
myotubes during 0, 24, 48, 72 and 96 hours of differentiation (n=3, where n is 
the number of primary myoblast culture isolations done and for each primary 
myoblast culture isolation four mice per genotype were used). Level of 
significance was compared to wild-type primary myotubes (*p<0.05). 
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3.9 Akirin1 regulates the phosphorylation of FoxO3 protein in 
differentiating primary myotubes.  
An important upstream transcription factors that binds to and activates 
transcription of MuRF1 promoter is FoxO3 protein. As differentiating Akirin1 
knock-out myotubes showed reduced levels of MuRF1 compared to the wild-
type, the proteins levels of phospho-FoxO3 as well as total FoxO3 were 
estimated in Akirin1 knock-out and wild-type differentiating primary 
myotubes using anti-phospho FoxO3 (ser253) and anti-FoxO3 antibodies. The 
results showed that Akirin1 knock-out primary myotubes have increased 
phospho-FoxO3 protein and reduced total FoxO3 protein compared to the 
wild-type primary myotubes during 24, 48, 72 and 96 hours of differentiation 
[Figure 3.9A(i), A(ii) and A(iii)]. Densitometry analysis confirmed that the 
ratio of phospho-FoxO3 (inactive form) to total FoxO3 is significantly more in 
differentiating Akirin1 knock-out primary myotubes compared to the wild-
type [Figure 3.9A(iv)]. These results suggested that lack of Akirin1 leads to 
phosphorylation of FoxO3 protein there by leading to reduced MuRF1 levels 










Figure 3.9 Akirin1 regulates the phosphorylation of FoxO3 protein in 
differentiating primary myotubes. Western blotting analysis for phospho-
FoxO3 (ser 253) and total FoxO3 was performed on protein lysates of Akirin1 
knock-out and wild-type primary myotubes at 24, 24, 72 and 96 hours of 
differentiation. A(i) A representative immunoblot showing the protein levels 
of phospho-FoxO3 (ser 253) and total FoxO3. GAPDH was used as the 
internal control for equal protein loading on the gel. A(ii) and A(iii) Graphs 
showing corresponding densitometry analysis of phospho-FoxO3 (ser 253) 
and total FoxO3 respectively. A(iv) A graph representing the ratio of phospho-
FoxO3 (ser 253) to total FoxO3 levels. (*p<0.05 and **p<0.01) (n=3, where n 
is the number of primary myoblast culture isolations done and for each 
primary myoblast culture isolation four mice per genotype were used). 
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3.10 Akirin1 regulates CREB-1 protein levels during differentiation.  
Another transcription factor that is known to bind to MuRF1 promoter and 
regulate MuRF1 transcription is CREB-1 (Tobimatsu et al., 2009). CREB-1 is 
known to regulate cellular energy metabolism in skeletal muscle (Thomson et 
al., 2007; St-Pierre et al., 2003). To investigate if Akirin1 regulates CREB-1 
levels in differentiating primary myotubes, Akirin1 knock-out and wild-type 
differentiating myotubes protein lysates were subjected to western blotting 
using phospho-CREB-1 (ser 133) and total CREB-1 antibodies. The results 
showed that Akirin1 knock-out primary myotubes have reduced phospho-
CREB-1 (active form) and total CREB-1 levels and compared to the wild-type 
primary myotubes during 24, 48, 72 and 96 hours of differentiation [Figure 
3.10A(i); A(ii) and A(iii)]. Densitometry analysis also confirmed that the ratio 
of phospho-CREB-1 (ser 133) (active) and total CREB-1 is significantly 
reduced in differentiating Akirin1 knock-out primary myotubes compared to 
the wild-type [Figure 3.10A(iv)]. These results suggest that lack of Akirin1 
leads to reduced CREB-1 levels as a result of which MuRF1 is down-regulated 




















Figure 3.10 Akirin1 regulates CREB-1 protein levels during 
differentiation.  Western blotting analysis for phospho-CREB-1 (ser 133) and 
total CREB-1 was performed on protein lysates of Akirin1 knock-out and 
wild-type primary myotubes at 24, 24, 72 and 96 hours of differentiation. A(i) 
A representative immunoblot showing the protein levels of phospho-CREB-1 
(ser 133) and total CREB-1. GAPDH was used as the internal control for equal 
protein loading on the gel. A(ii) and A(iii) Graphs showing corresponding 
densitometry analysis of phospho-CREB-1 (ser 133) and total CREB-1 
respectively. A(iv) A graph representing the ratio of phospho-CREB-1 (ser 
133) to total CREB-1 levels (*p<0.05 and **p<0.01) (n=3, where n is the 
number of primary myoblast culture isolations done and for each primary 
myoblast culture isolation four mice per genotype were used). 
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3.11 Absence of Akirin1 leads to reduced mitochondrial DNA copy 
number in differentiating primary myotubes. 
Reduced level of CREB-1 has been shown to down-regulate the expression of 
its other downstream target genes like PPARα and PGC1α. Reduced levels of 
these proteins are shown to reduce the oxidative potential of the skeletal 
muscle thus affecting the metabolic activity of the muscle (Thomson et al., 
2007; St-Pierre et al., 2003). We know that amount of ATP generation through 
oxidative  phosphorylation occurs in the mitochondria, which is strictly 
dependent on the mitochondrial DNA copy number (Chen et al., 2010; 
Dickinson et al., 2013). So, we estimated the copy number of mitochondrial 
DNA (mtDNA) per nuclear DNA (nuDNA) ratio by performing real time-
qPCR with specific set of primers for mtDNA and nuDNA. Akirin1 knock-out 
differentiating primary myotubes contained significantly lower mtDNA per 
nuDNA ratio compared to the wild-type (Figure 3.11A). Thus showing that 
lack of Akirin1 reduces the mitochondrial DNA copy number during 



































Figure 3.11 Absence of Akirin1 leads to reduced mitochondrial DNA copy 
number in differentiating primary myotubes. (A) Graph showing the ratio 
of mitochondrial DNA (mtDNA) copy number per nuclear DNA (nuDNA) in 
differentiating Akirin1 knock-out and wild-type primary myotubes. Level of 
significance was calculated by non-parametric Mann-Whitney U test (*p<0.05 
and ***p<0.001) (n=2, where n is the number of primary myoblast culture 
isolations done and for each primary myoblast culture isolation four mice per 























Figure 3.12 A schematic diagram summarizing the various results 


































































4. ROLE OF AKIRIN1 IN SKELETAL MUSCLE 
 
 
This chapter explains the results, which help us in understanding the role of 
Akirin1 in skeletal muscle. The materials and methods used in this chapter are 
discussed in chapter 2 of this thesis.    
RESULTS 
4.1 Analysis of Akirin1 knock-out skeletal muscle.  
To understand if lack of Akirin1 alters skeletal muscle characteristics, firstly 
we investigated the body size of Akirin1 knock-out and wild-type mice.  The 
body size of all the Akirin1 knock-out mice that were investigated in this 
thesis was comparable to that of the wild-type mice (Figure 4.1A). Also, we 
looked at the limb skeletal muscle mass in Akirin1 knock-out and wild-type 
mice. Akirin1 knock-out mice muscle mass was comparable to that of the 
wild-type (Figure 4.1B).  Furthermore, to investigate the effect of Akirin1 on 
muscle fiber histology, tibialis anterior muscles were sectioned and stained 
with hematoxylin and eosin (Figure 4.1C). No significant difference in 
myofiber number was seen between Akirin1 knock-out and wild-type mice 
(Figure 4.1D). We also looked at the weights of quadriceps muscle of Akirin1 
knock-out and compared to the wild-type quadriceps muscle (Figure 4.1E).  
These results showed that absence of Akirin1 did not affect the body size, 






Figure 4.1 Analysis of Akirin1 knock-out skeletal muscle. (A) 
Representative images of body size of Akirin1 knock-out and wild-type mice. 
(B) Representative images of limb skeletal muscle mass of Akirin1 knock-out 
and wild-type mice. (C) Representative images of hematoxylin and eosin 
stained Akirin1 knock-out and wild-type tibialis anterior muscle. Scale bar 
represents 100 μm. (D) Total muscle fiber number in TA muscles from 
Akirin1 knock-out and wild-type mice. The values are mean ± S.E. of three 
animals. (E) Quadriceps muscle weights of Akirin1 knock-out and wild-type 
mice expressed as a percentage of total body weight. The values are mean ± 
S.E. of six animals.  
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4.2 Lack of Akirin1 affects the levels of myogenic genes in quadriceps 
muscle. 
The process of muscle development is predominantly affected by myogenic 
regulatory factors (MRFs). It was previously shown by Marshall et al. that 
Akirin1 is a pro-myogenic protein that is downstream of myostatin, and is 
negatively regulated by myostatin (Marshall et al., 2008). So, to investigate if 
lack of Akirin1 affects the process of myogenesis through modifying the 
expression of important MRFs, protein lysates made from wild-type and 
Akirin1 knock-out quadriceps muscle were subjected to western blotting using 
anti-MyHC, anti-MyoD and anti-Myogenin antibodies (Figure 4.2A). 
Densitometry analysis clearly indicated that Akirin1 knock-out muscle showed 
significantly reduced protein levels of myogenin compared to the wild-type 
muscle, while the amounts of other MRFs like MyHC and MyoD were 
comparable to that of the wild-type muscle [Figure 4.2B(i), B(ii) and B(iii)]. 
In order to see if myogenin was down-regulated transcriptionally as well, 
myogenin mRNA level was quantified in wild-type and Akirin1 knock-out 
muscle. Consistent with the reduced protein level, myogenin mRNA levels 
were also significantly reduced in Akirin1 knock-out muscle compared to the 
wild-type [Figure 4.2C(iii)], while the mRNA levels of other MRFs did not 
change which were consistent with their protein levels [Figure 4.2C(i) and 














































Figure 4.2 Lack of Akirin1 affects the level of myogenic genes in 
quadriceps muscle. Myogenic regulatory factors (MRFs) profile in Akirin1 
knock-out and wild-type skeletal muscle. Western blotting analysis was 
performed on Akirin1 knock-out and wild-type quadriceps muscle protein 
lysates. A(i) A representative immunoblot showing protein levels of important 
myogenic genes i.e., MyHC, MyoD and myogenin. GAPDH was used as the 
internal control for equal protein loading on the gel.  B(i), B(ii), B(iii) and 
B(iv) Corresponding densitometry graphs of MyHC, MyoD and myogenin 
respectively showing significant decrease or no change in the protein content 
in skeletal muscle (*p<0.05) (n=4). (C) mRNA expression for MyHC, MyoD 
and myogenin was determined in Akirin1 knock-out and wild-type quadriceps 
muscle. The values are mean ± S.E. of four different animals. **p<0.01 
denotes significant fold change difference in Akirin1 mRNA expression 







4.3 Akirin1 does not regulate the levels of MEF2C class of myogenic 
regulators. 
Apart from Myogenic Regulatory Factors (MRFs), another family of 
transcription proteins called the MEF2s is known to influence the process of 
muscle development. And among the MEF2 family of transcription factors, it 
has been shown that MEF2C plays an important role in muscle development 
(Edmondson et al., 1994). So, we investigated if lack of Akirin1 affected the 
MEF2C levels by subjecting the wild-type and Akirin1 knock-out quadriceps 
muscle protein lysates to immunoblotting with anti-phospho-MEF2C (thr300) 
(active) and anti-MEF2C antibodies. Densitometry analysis showed slightly 
reduced but non-significant levels of both total and phospho-MEF2C [Figure 
4.3A, B(i) and B(ii)]. Consistent with the protein levels, the mRNA expression 
levels of Mef2c in Akirin1 knock-out was comparable to that of the wild-type 
(Figure 4.3C).  Thus suggesting that, Akirin1 does not affect MEFC2 class of 























Figure 4.3 Akirin1 does not regulate the levels of MEF2C class of 
myogenic regulators. Analysis of another class of myogenic regulators, 
MEF2C in Akirin1 knock-out and wild-type quadriceps muscle. Western 
blotting analysis was performed on protein lysates of Akirin1 knock-out and 
wild-type quadriceps muscle. (A) A representative immunoblot showing the 
protein levels of both phospho-MEF2C (thr300) and total MEF2C. GAPDH 
was used as the internal control for equal protein loading on the gel. B(i) and 
B(ii) graphs showing corresponding densitometry analysis of phospho-
MEF2C (thr300) and total MEF2C respectively (n=4). mRNA expression of 
Mef2c was determined in Akirin1 knock-out and wild-type quadriceps muscle. 
(C) A graph showing the fold change mRNA expression of Mef2c in Akirin1 
knock-out quadriceps muscle compared to the wild-type. The values are mean 
± S.E. of four different animals. 
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4.4 Akirin1 regulates the protein levels of important sarcomeric proteins 
in the skeletal muscle.  
As explained in section 1.1.1.1, sarcomeres are the contractile units of a 
muscle. A sarcomere consists of three categories of proteins which function 
jointly leading to the contraction of the muscle.  1) Structural proteins, such as 
desmin, which give the frame work and elasticity to the muscle 2) Contractile 
proteins like actin and myosin, which provide force during contraction of the 
muscle 3) Regulatory proteins like troponins, which regulate the process of 
contraction and relaxation of the muscle. Troponin T binds to tropomyosin and 
facilitates sarcomere contraction, troponin I regulates the contraction of the 
sarcomere by either turning on or off the interaction between the actin and 
myosin filaments and troponin C binds to Ca
2+
 ions released from the 
sarcoplasmic reticulum to initiate contraction (Martini, 2006).  To investigate 
if Akirin1 has a novel role in maintaining the levels of the regulatory proteins, 
immunoblotting was performed on protein lysates of wild-type and Akirin1 
knock-out quadriceps muscle using anti-troponin T, anti-troponin I and anti-
troponin C antibodies. Densitometry analysis showed that troponin T was 
significantly lower in Akirin1 knock-out muscle compared to the wild-type 
muscle. Another regulatory protein, Troponin I, was also significantly down-
regulated in the Akirin1 knock-out muscle compared to the wild-type muscle. 
However the level of troponin C was unchanged [Figure 4.4A, B(i), B(ii) and 
B(iii)]. 
Further, the protein levels of α-actin, desmin and MyHC, movement of which 
leads to the contraction of the sarcomere, were also estimated. Akirin1 knock-
out and wild-type quadriceps muscle protein was probed with anti-α-actin and 
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anti-desmin antibody. Densitometry analysis showed that Akirin1 knock-out 
muscle showed significantly lower levels of α-actin, MyHC and desmin when 
compared to the wild-type muscle [Figure 4.4C, D(i) and D(ii)]. These results 
together suggest that absence of Akirin1 leads to reduced levels of important 
sarcomeric proteins, thus implying a novel role of Akirin1 in maitaining the 

























































Figure 4.4 Akirin1 regulates the protein levels of important sarcomeric 
proteins in the skeletal muscle. Analysis of the different sarcomeric 
contractile and regulatory proteins in Akirin1 knock-out and wild-type 
quadriceps muscle. Western blotting analysis was performed on Akirin1 
knock-out and wild-type quadriceps muscle protein lysates. (A) A 
representative immunoblot showing the protein levels of sarcomeric 
contractile proteins like α-actin and desmin in Akirin1 knock-out and wild-
type quadriceps muscle. GAPDH was used as an internal control for equal 
protein loading on the gel. B(i) and B(ii) Corresponding densitometry graphs 
of α-actin and desmin respectively (**p<0.01 and ***p<0.001) (n=4). (C) A 
representative immunoblot showing the sarcomeric regulatory protein levels 
i.e., troponin T, troponin I and troponin C in Akirin1 knock-out and wild-type 
quadriceps muscle. D(i), D(ii) and D(iii) Graphs showing the densitometry 
analysis of troponin T, troponin I and troponin C respectively (**p<0.01) 







4.5 Akirin1 regulates α-actin and desmin proteins in the sarcomere post-
transcriptionally.   
Although Akirin1 regulates the protein levels of the sarcomeric proteins like 
α-actin and desmin, the mRNA levels of both α-actin and desmin in the 
Akirin1 knock-out muscle were not significantly different from wild-type 
muscle (Figure 4.5A and B). This shows that Akirin1 regulates α-actin and 










































Figure 4.5 Akirin1 regulates α-actin and desmin proteins in the sarcomere 
post-trancriptionally. Gene expression analysis of sarcomeric proteins like α-
actin and desmin, in Akirin1 knock-out and wild-type quadriceps muscle. (A) 
and (B) Graphs showing the fold change mRNA expression of α-actin and 
desmin in Akirin1 knock-out quadriceps muscle compared to that of the wild-

















































Figure 4.6 Absence of Akirin1 regulates MuRF1, but not atrogin1 in 
skeletal muscle. Analysis of skeletal muscle specific E3 ubiquitin ligases, 
MuRF1 and atrogin1 in Akirin1 knock-out and wild-type quadriceps muscle. 
Western blotting analysis for MuRF1 and atrogin1 was performed on protein 
lysates of Akirin1 knock-out and wild-type quadriceps muscle. A(i) A 
representative immunoblot showing the protein levels of MuRF1 and atrogin1. 
GAPDH was used as the internal control for equal protein loading on the gel. 
A(ii) and A(iii) Graphs showing corresponding densitometry analysis of 
MuRF1 and atrogin1 respectively (***p<0.001) (n=4). Expression analysis of 
MuRF1 in Akirin1 over-expressing myoblasts. Western blotting was 
performed on protein lysates from differentiating Akirin1 over-expressor 
myoblasts and control C2C12 myoblasts. B(i) A representative immunoblot 
showing the protein levels of MuRF1. B(ii) A graph showing the 
corresponding densitometry analysis of MuRF1 protein levels in Akirin1 over-
expressor myoblasts and control C2C12 myoblasts. The graph is representative 
of at least two independent experiments. Level of significance was compared 


















4.6 Absence of Akirin1 regulates MuRF1, but not atrogin1 in skeletal 
muscle.  
Loss of skeletal muscle mass is attributed to two important muscle atrogenes 
called MuRF1 and atrogin1. Marshall et al. showed that over-expression of 
Akirin1 in C2C12 myoblasts lead to increased fusion of myoblasts resulting in 
hypertrophy of myotubes (Marshall et al., 2008). As the results in section 4.5 
showed reduced levels of sarcomeric proteins, we wanted to quantify the 
protein levels of atrogenes- MuRF1 and atrogin1. For this, western blotting 
was performed on wild-type and Akirin1 knock-out quadriceps muscle protein 
lysates and probed with anti-MuRF1 and anti-atrogin1 antibody.  Although the 
protein levels of atrogin1 remained unchanged between wild-type and Akirin1 
knock-out muscle (Figure 4.6A(i) and C), the levels of MuRF1 protein was 
significantly down-regulated in Akirin1 knock-out compared to the wild-type 
muscle [Figure 4.6A(i) and A(ii)].  
A C2C12 cell line that stably over-expresses Akirin1 was generated by 
Marshall et al., 2008. Using this Akirin1 over-expression model, we further 
studied the results obtained above. MuRF1 protein level was estimated in 
Akirin1 over-expressor cells with C2C12 cells as control. Contrary to the 
results obtained in Akirin1 knock-out model, MuRF1 protein level was indeed 
up-regulated in Akirin1 over-expressor cells compared to the control cells at 
48 and 72 hours of differentiation [Figure 4.6B(i) lanes 2 and 4]. Densitometry 
analysis confirmed that MuRF1 levels were significantly up-regulated in 
Akirin1 over-expressor cells compared to the control C2C12 cells during 
differentiation [Figure 4.6B(ii)].  
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4.7 Akirin1 transcriptionally regulates the levels of MuRF1 in both C2C12 
myoblasts and skeletal muscle. 
As we observed reduced MuRF1 protein levels in the absence of Akirin1, we 
wanted to further investigate if MuRF1 was down-regulated at the 
transcriptional level. For this, MuRF1 mRNA levels were quantified by real 
time-qPCR in wild-type and Akirin1 knock-out quadriceps muscle and 
normalised to cyclophilin Ct values. Consistent with the reduced MuRF1 
protein levels, Akirin1 knock-out muscle showed significantly lower levels of 
MuRF1 mRNA levels compared to the wild-type muscle (Figure 4.7A).  On 
the contrary, MuRF1 mRNA levels were up-regulated upon Akirin1 over-
expression during differentiation when compared to control C2C12 cells. 
Consistent with the increased MuRF1 protein levels, Akirin1 over-expressor 
cells clearly showed significantly increased MuRF1 mRNA levels compared 
to the control C2C12 cells during differentiation (Figure 4.7B).  
Knowing that Akirin1 regulates the level of MuRF1 mRNA, it was necessary 
to investigate if Akirin1 regulates MuRF1 transcriptionally. To achieve this, 
MuRF1 promoter-luciferase plasmid was co-transfected with Akirin1 
expression plasmid into C2C12 myoblasts and the luciferase activity was 
quantified. C2C12 myoblasts transfected with both MuRF1 promoter-luciferase 
plasmid and Akirin1 expression plasmid showed nearly two fold significant 
increase in luciferase activity when compared to luciferase activity of C2C12 
myoblasts transfected with MuRF1 promoter alone (Figure 4.7C). These 
findings together demonstrate a novel function of Akirin1 in regulating 







Figure 4.7 Akirin1 transcriptionally regulates the levels of MuRF1 in both 
C2C12 myoblasts and skeletal muscle. (A) A graph showing the fold change 
MuRF1 mRNA expression in Akirin1 knock-out quadriceps muscle compared 
to the wild-type. The values are mean ± S.E. of four different animals. Level 
of significance was compared to wild-type (*p<0.05). (B) A graph showing 
fold change MuRF1 mRNA expression in Akirin1 over-expressor myoblasts 
and control C2C12 myoblasts during differentiation. The graph is representative 
of at least two independent experiments. Level of significance was compared 
to control C2C12 myoblasts (*p<0.05 and **p<0.01). (C) A graph showing 
promoter-luciferase reporter activity in C2C12 myoblasts transfected with 
either pGL4.1 or pcDNA3.1 empty vectors or MuRF1 promoter (MuRF1-
pGL4.1) and Akirin1 expression vector (Akirin1-pcDNA3.1), together with 
control Renilla luciferase vector pRL-TK. The graph is representative of four 
independent experiments. (
####
p<0.0001, ****p<0.0001 and ^^^^p<0.0001).  
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4.8  Akirin1 regulates MuRF1 expression via modulating the 
phosphorylation of FoxO3 protein in skeletal muscle. 
One of the important upstream transcription factors that bind to and activate 
transcription of MuRF1 promoter is FoxO3 protein. FoxO3 protein belongs to 
the family of fork-head transcription factors that bind to DNA with their fork-
head DNA-binding domain. FoxO3 protein possesses the ability to be 
phosphorylated leading to its translocation out of the nucleus thus down-
regulating the down-stream target genes. To investigate if MuRF1 expression 
is down-regulated through FoxO3 protein, Akirin1 knock-out and wild-type 
quadriceps muscle protein lysates were subjected to immunoblotting using 
anti-phospho FoxO3 (ser253) and anti-FoxO3 antibodies. The results revealed 
that Akirin1 knock-out mice have increased phospho-FoxO3 protein (inactive 
form) and reduced total FoxO3 protein compared to the wild-type [Figure 
4.8.1A(i), A(ii) and A(iii)]. Densitometric analysis also confirmed that the 
ratio of phospho-FoxO3 (inactive form) to total FoxO3 is significantly more in 
Akirin1 knock-out muscle compared to the wild-type [Figure 4.8.2A(iv)]. This 
shows that lack of Akirin1 leads to phosphorylation of FoxO3 leading to 
reduced active FoxO3 protein in skeletal muscle.  
 To see if the expression profile of phospho-FoxO3 and total FoxO3 proteins 
changes when Akirin1 was over-expressed, control C2C12 and Akirin1 over-
expressor cell protein lysates were subjected to western blotting and probed 
with anti-phospho FoxO3 (ser253) and anti-FoxO3 antibodies. The results 
clearly show that Akirin1 over-expressor cells showed reduced phospho-
FoxO3 protein and increased total FoxO3 protein compared to the control 
C2C12 cells [Figure 4.8.1B(i) lanes 2 and 4, B(ii) and B(iii)]. Densitometry 
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analysis also shows that the ratio of phospho-FoxO3 to total FoxO3 is 
significantly reduced in Akirin1 over-expressor compared to the control C2C12 
cells [Figure 4.8.2B(iv)]. This shows that over-expression of Akirin1 leads to 
reduced FoxO3 phosphorylation that would allow its translocation to the 
nucleus and binding to the MuRF1 promoter thereby activating MuRF1 
transcription.   
FoxO3 mRNA levels were quantified by real time-qPCR in wild-type and 
Akirin1 knock-out quadriceps muscle and normalised to cyclophilin Ct values. 
The FoxO3 mRNA level in Akirin1 knock-out skeletal muscle was similar to 
that of the wild-type. (Figure 4.8.2C). These findings together suggest that 
Akirin1 may regulate the expression of MuRF1 by modulating FoxO3 






Figure 4.8.1 Akirin1 regulates MuRF1 expression via modulating the 
phosphorylation of FoxO3 protein in skeletal muscle. Western blotting 
analysis for phospho-FoxO3 (ser 253) and total FoxO3 was performed on 
protein lysates of Akirin1 knock-out and wild-type quadriceps muscle. A(i) A 
representative immunoblot showing the protein levels of phospho-FoxO3 (ser 
253) and total FoxO3. GAPDH was used as the internal loading control. A(ii) 
and A(iii) Graphs showing corresponding densitometry analysis of phospho-
FoxO3 (ser 253) and total FoxO3 respectively. (*p<0.05) (n=4). Expression 
analysis of FoxO3 in Akirin1 over-expressor myoblasts. Western blotting was 
performed on protein lysates from differentiating Akirin1 over-expressor 
myoblasts and control C2C12 myoblasts. B(i) A representative immunoblot 
showing the protein levels of phospho-FoxO3 (ser 253) and total FoxO3. B(ii) 
and B(iii) Graphs showing the corresponding densitometry analysis of 
phospho-FoxO3 (ser 253) and total FoxO3 protein levels in Akirin1 over-
expressor myoblasts and control C2C12 myoblasts. All the graphs are 
representative of at least two independent experiments. Level of significance 

























Figure 4.8.2 Akirin1 regulates the levels of active form of FoxO3 protein 
post-trancriptionally. A(iv) A graph representing the ratio of phospho-
FoxO3 (ser 253) to total FoxO3 levels. (*p<0.05) (n=4). B(iv) A graph 
representing the ratio of phospho-FoxO3 (ser 253) to total FoxO3 levels. All 
the graphs are representative of at least two independent experiments. Level of 
significance was compared to control C2C12 myoblasts (*p<0.05 and 
**p<0.01). (C) A graph showing the fold change mRNA expression of FoxO3 
in Akirin1 knock-out quadriceps muscle compared to that of the wild-type. 






4.9  Lack of Akirin1 affects the extent of glutamylation of tubulin 
molecules due to reduced MuRF1 levels.       
MuRF1 is also known to be an important sarcomeric protein that binds to 
microtubules and stabilize them. Binding of MuRF1 molecules to the 
microtubules lead to the addition of glutamic acid to the tubulin molecules 
there by making them resistant to depolymerisation and facilitating myoblast 
fusion (Spencer et al., 2000). As our previous data from section 4.7 revealed 
that Akirin1 knock-out quadriceps muscle have reduced MuRF1 expression, 
we wanted to investigate the level of glutamylation of tubulin proteins. For 
this, Akirin1 knock-out and wild-type quadriceps muscle protein lysates were 
probed with anti-poly-glutamylated tubulin and α-tubulin antibody. The results 
obtained showed that Akirin1 knock-out muscle have significantly lower 
levels of poly-glutamylated tubulin proteins compared to the wild-type muscle  
while the α-tubulin levels were unchanged (Figure 4.9A and B). Thus, 
suggesting that reduced MuRF1 protein level indeed leads to reduced 


































Figure 4.9 Lack of Akirin1 affects the extent of glutamylation of tubulin 
molecules due to reduced MuRF1 levels. Analysis of poly-glutamylated 
tubulin in Akirin1 knock-out and wild-type quadriceps muscle. Western 
blotting analysis was performed on protein lysates of Akirin1 knock-out and 
wild-type quadriceps muscle. (A) A representative immunoblot showing the 
protein levels of poly-glutamylated tubulin and α-tubulin. GAPDH was used 
as the internal control for equal protein loading on the gel. (B) A graph 
showing corresponding densitometry analysis of poly-glutamylated tubulin. 















4.10 Lack of Akirin1 leads to reduced ubiquitination of various cellular 
proteins due to reduced MuRF1 activity. 
Another known function of MuRF1 is to mark the target proteins that are 
destined to be degraded, by adding ubiquitin molecules, which later, are 
degraded by the proteasomes. As our results showed lower MuRF1 levels in 
the absence of Akirin1, we wanted to study the ubiquitination profile of 
various cellular proteins in the Akirin1 knock-out muscle. Protein lysates from 
Akirin1 knock-out and wild-type quadriceps muscle were probed with anti-
ubiquitin antibody. Results showed that Akirin1 knock-out muscle have 
significantly lower extent of ubiquitination of the cellular proteins when 
compared to the wild-type muscle (Figure 4.10A and B). This suggests that 
due to reduced MuRF1 levels, the normal turn-over of the various cellular 






































Figure 4.10 Lack of Akirin1 leads to reduced ubiquitination of various 
cellular proteins due to reduced MuRF1 activity. Analysis of ubiquitination 
of cellular proteins in Akirin1 knock-out and wild-type quadriceps muscle. 
Western blotting analysis was performed on protein lysates of Akirin1 knock-
out and wild-type quadriceps muscle. (A) A representative immunoblot 
showing the extent of ubiquitination of cellular proteins in Akirin1 knock-out 
and wild-type quadriceps muscle. GAPDH was used as the internal control for 
equal protein loading on the gel. (B) A graph showing corresponding 
densitometry analysis of ubiquitination in Akirin1 knock-out and wild-type 








4.11 Absence of Akirin1 leads to reduced levels of CREB-1 protein in 
skeletal muscle. 
One of the important transcription factors that are known to bind to MuRF1 
promoter and regulate MuRF1 transcription is CREB-1 (Tobimatsu et al., 
2009). But, apart from regulating the expression of MuRF1, CREB-1 is also 
known to regulate important genes like PPARα and PGC1α, which are 
involved in cellular energy metabolism homeostasis in skeletal muscle 
(Thomson et al., 2007; St-Pierre et al., 2003). So, to investigate the regulation 
of CREB-1 by Akirin1 in fully-differentiated muscle, protein lysates from 
Akirin1 knock-out and wild-type quadriceps muscle were probed with 
phospho-CREB1 (ser133) and CREB-1 antibodies. The results showed that the 
protein levels of both phospho-CREB-1 (active form) and total CREB-1 was 
significantly reduced compared to the wild-type muscle [Figure 4.11.1A(i)]. 
Densitometry analysis confirmed that both phospho-CREB1 (ser133) (active 
form) and total CREB-1 protein levels were significantly lower in Akirin1 
knock-out quadriceps muscle compared to the wild-type [Figure 4.11.1A(ii) 
and A(iii)]. Further, no significant difference was observed in the ratio of 
phospho-CREB-1 (active form) to total CREB-1 levels between the Akirin1 
knock-out and wild-type muscle [Figure 4.11.2A(iv)]. These results indicate 
that lack of Akirin1 affects the total CREB-1 protein levels in skeletal muscle. 
Due to reduced CREB-1 protein levels, the regulation of metabolically 
important genes like PPARα and PGC1α may further be affected.  
On the contrary, when control C2C12 and Akirin1 over-expressors cell protein 
lysates were subjected to western blotting with anti-phospho-CREB1 (ser133) 
and anti-CREB-1 antibodies, the results showed reduced levels of phospho-
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CREB-1 (active form), while the total CREB-1 protein levels were 
significantly increased in Akirin1 over-expresssor myoblasts compared to the 
control C2C12 myoblasts [Figure 4.11.1B(i) lanes 2 and 4, B(ii) and B(iii)].  
Futhermore, the ratio of phospho-CREB-1 (active form) to total CREB-1 
levels, which is indicative of the inactive CREB-1 levels was significantly 
reduced in Akirin1 over-expressor myoblasts compared to the control C2C12 
myoblasts [Figure 4.11.2A(iv)].  
As the CREB-1 protein level was reduced in the absence of Akirin1, we 
wanted to further investigate the Creb-1 mRNA expression level. The Creb-1 
mRNA levels were quantified by real time-qPCR and the Creb-1 Ct values 
were normalised to cyclophilin Ct values. The results showed that there was 
no significant difference in the amount of Creb-1 mRNA between Akirin1 
knock-out and wild-type quadriceps muscles (Figure 4.11.2C). These above 
findings clearly suggest that Akirin1 regulates CREB-1 protein at the post-
transcriptional level in skeletal muscle.    
 
Figure 4.11.1 Absence of Akirin1 leads to reduced levels of CREB-1 
protein in skeletal muscle. Western blotting analysis for phospho-CREB-1 
(ser 133) and total CREB-1 was performed on protein lysates of Akirin1 
knock-out and wild-type quadriceps muscle. A(i) A representative 
immunoblot showing the protein levels of phospho-CREB-1 (ser 133) and 
total CREB-1. GAPDH was used as the internal loading control. A(ii) and 
A(iii) Graphs showing corresponding densitometry analysis of phospho-
CREB-1 (ser 133) and total CREB-1 levels respectively. (*p<0.05 and 
**p<0.01) (n=4). Western blotting was performed on protein lysates from 
differentiating Akirin1 over-expressor myoblasts and control C2C12 myoblasts. 
B(i) A representative immunoblot showing the protein levels of phospho-
CREB-1 (ser 133) and total CREB-1. B(ii) and B(iii) Graphs showing the 
corresponding densitometry analysis of phospho-CREB-1 (ser 133) and total 
CREB-1 protein levels in differentiating Akirin1 over-expressor myoblasts 
and control C2C12 myoblasts. The graphs are representative of at least two 
independent experiments. Level of significance was compared to control 


























Figure 4.11.2 Akirin1 regulates the levels of active form of CREB-1 
protein post-trancriptionally. A(iv) A graph representing the ratio of 
phospho-CREB-1 (ser 133) to total CREB-1 levels in skeletal muscle (n=4). 
B(iv) A graph representing the ratio of phospho-CREB-1 (ser 133) to total 
CREB-1 levels in Akirin1 over-expressor cells. This graph is representative of 
at least two independent experiments. Level of significance was compared to 
control C2C12 myoblasts (**p<0.01). (C) A graph showing the fold change 
mRNA expression of Creb-1 in Akirin1 knock-out quadriceps muscle 
compared to the wild-type. The values are mean ± S.E. of four different 





4.12 Lack of Akirin1 leads to reduced binding of CREB-1 protein on 
MuRF1 promoter.  
CREB-1 is a leucine zipper protein that binds to cAMP responsive element 
and initiate transcription of its down-stream target genes like MuRF1. Results 
in section 4.11 showed that Akirin1 knock-out muscle have lower levels of 
both total and phospho-CREB-1 protein compared to the wild-type muscle.  
To further investigate if reduced levels of CREB-1 protein binding to MuRF1 
promoter leads to reduced MURF1 levels, Electrophoretic Mobility Shift 
Assay (EMSA) was performed. Oligonucleotides containing the CREB-1 
consensus-binding region on MuRF1 promoter were designed. Nuclear 
extracts from wild-type and Akirin1 knock-out quadriceps muscles were 
isolated and EMSA was performed using CREB-1 antibody. The results 
showed significantly lower amounts of CREB-1 protein binding activity in 
Akirin1 knock-out muscle nuclear extracts compared to the wild-type muscle 
nuclear extracts (Figure 4.12A lane 2 and 4).  The specificity of the band 
obtained was confirmed by addition of increasing concentration of CREB-1 
antibody i.e. 2µg CREB-1 antibody in lane 4 and 5; 4µg CREB-1 antibody in 
lane 6 and 7. The amount of DNA-CREB-1 complex reduces proportional 
with increasing concentration of CREB-1 antibody (Figure 4.12A lane 4, 5, 6 
and 7). This shows that in the absence of Akirin1, CREB-1 transcription factor 




















Figure 4.12 Lack of Akirin1 leads to reduced binding of CREB-1 protein 
on MuRF1 promoter. EMSA was performed using nuclear lysates from 
Akirin1 knock-out and wild-type quadriceps muscle with or without CREB-1 
antibody. (A) A representative gel showing reduced CREB-1 binding in 
Akirin1 knock-out muscle compared to the wild-type as indicated by the 
shifted band in lane 3 (lane 1-oligo only, lane 2-wild type and lane 3-Akirin1 
knock-out). The diminishing band intensity of CREB-1 specific band with 











4.13 Lack of Akirin1 does not significantly affect the Serum Response 
Factor (SRF) expression in the skeletal muscle.  
SRF, a transcription factor belonging to MADS box family of transcription 
factors, binds to serum response element (SRE) on the promoters of target 
genes and stimulates its transcription. Also, SRF has been known to be 
targeted for degradation by MuRF1 (Patterson et al., 2011). As we observed 
reduced MuRF1 levels in the absence of Akirin1, we investigated the SRF 
levels in Akirin1 knock-out and wild-type quadriceps muscle. Although 
Akirin1 knock-out muscle showed slightly elevated SRF protein levels 
compared to wild-type muscle, this increase was not statistically significant 
[Figure 4.13A(i) and (ii)].   
Also, when Akirin1 was over-expressed, no significant difference in SRF 
protein levels in Akirin1 over-expressor myoblasts was observed compared to 
control C2C12 myoblasts at 48 and 72 hours of differentiation [Figure 4.13B(i) 
lane 2 and 4; B(ii)]. 
SRF mRNA levels were quantified by real time-qPCR in wild-type and 
Akirin1 knock-out quadriceps muscle and normalised to cyclophilin Ct values. 
The results showed that Akirin1 knock-out muscle showed no significant 
difference in the mRNA level of SRF gene when compared to the wild-type 







































Figure 4.13 Lack of Akirin1 does not significantly affect the Serum 
Response Factor (SRF) expression in the skeletal muscle. Analysis of SRF 
in Akirin1 knock-out and wild-type quadriceps muscle. Western blotting 
analysis was performed on protein lysates of Akirin1 knock-out and wild-type 
quadriceps muscle. A(i) A representative immunoblot showing the protein 
level of SRF. GAPDH was used as the internal loading control. A(ii) A graph 
showing corresponding densitometry analysis of SRF protein levels (n=3). 
Expression analysis of SRF in Akirin1 over-expressor myoblasts. Western 
blotting was performed on protein lysates from differentiating Akirin1 over-
expressor myoblasts and control C2C12 myoblasts. B(i) A representative 
immunoblot showing the protein level of SRF. B(ii) A graph showing the 
corresponding densitometry analysis of SRF protein level in Akirin1 over-
expressor myoblasts and control C2C12 myoblasts. All the graphs are 
representative of at least two independent experiments. Level of significance 
was compared to control C2C12 myoblasts. mRNA expression of SRF was 
determined in Akirin1 knock-out and wild-type quadriceps muscle. (C) A 
graph showing the fold change mRNA expression of SRF in Akirin1 knock-
out quadriceps muscle compared to the wild-type (n=4).  Level of significance 

















4.14 Lack of Akirin1 results in a fiber type switch, from oxidative to fast 
oxidative fibers in tibialis anterior muscle.   
Our previous results in quadriceps muscle showed that absence of Akirin1 
affected the levels of certain important metabolic proteins like CREB-1, 
MuRF1 and SRF. So, we wanted to investigate the metabolic profile in a 
muscle made up of mixed types of fibers such as tibialis anterior. As 
explained in section 1.1.2, a muscle is made up of four types of muscle fibers 
in mice, which use different metabolic pathways to derive energy for muscle 
contraction (Talmadge et al., 1993; Lompre et al., 1984). One of the ways to 
study the metabolic pattern in the skeletal muscle is by identifying the type of 
MyHC expressed in different muscle fiber types through fiber-typing studies. 
To investigate this, immunohistochemistry was performed on tibialis anterior 
muscle sections with anti-MyHC type I, anti-MyHC type IIa and anti-MyHC 
type IIb antibodies which recognize myofibers containing specific type of 
MyHC protein. Fiber typing images revealed that Akirin1 knock-out tibialis 
anterior muscle sections have significantly lower number of MyHC type I 
fibers compared to the wild-type tibialis anterior muscle sections. Also, 
Akirin1 knock-out muscle sections showed significantly higher number of 
MyHC type IIa fibers compared to the wild-type muscle sections. However the 
number of MyHC type IIb fibers remain the same in Akirin1 knock-out 
compared to wild-type muscle sections (Figure 4.14.1A and B).   
To investigate whether the fiber type switch was due to differential gene 
expression of MyHC type in the muscle fibers, real time-qPCR was performed 
on Akirin1 knock-out and wild-type quadriceps muscle which is also a mixed 
fiber type muscle. Consistent with the immunohistochemistry results, Akirin1 
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knock muscle showed significantly lower Myh7 (MyHC type I) mRNA 
expression compared to the wild-type muscle (Figure 4.14.2A). Furthermore, 
the mRNA level of Myh2 (MyHC type IIa) was also significantly higher in 
Akirin1 knock-out muscle when compared to the wild-type muscle (Figure 
4.14.2B). However, the mRNA levels of Myh4 (MyHC type IIb) was 
unchanged Figure 4.14.2C). All these results suggest that lack of Akirin1 
results in a fiber type switch, from oxidative (type I) to fast oxidative (type 













































































Figure 4.14.1 Lack of Akirin1 results in a fiber type switch, from 
oxidative to fast oxidative fibers in tibialis anterior muscle. (A) Panel 
showing the different types of MyHC (type I, type IIa and type IIb) staining on 
Akirin1 knock-out and wild-type tibialis anterior muscle sections. (B) 
Quantification of number of myofibers stained positive for different MyHC 
types (type I, type IIa and type IIb) in Akirin1 knock-out and wild-type 
quadriceps muscle sections. The values are mean ± S.E. of two animals. Level 


















Figure 4.14.2 Gene expression profile of different types of Myh genes in 
Akirin1 knock-out quadriceps muscle. mRNA expression of Myh7, Myh2 
and Myh4 was determined in Akirin1 knock-out and wild-type quadriceps 
muscle. (A), (B) and (C) Graphs showing the fold change mRNA expression 
of Myh7, Myh2 and Myh4 in Akirin1 knock-out quadriceps muscle 
respectively. The values are mean ± S.E. of four different animals. Level of 








4.15 Lack of Akirin1 makes the muscle fibers less oxidative. 
To further confirm that lack of Akirin1 affects the oxidative potential of the 
skeletal muscle, Akirin1 knock-out and wild-type muscle tibialis anterior 
sections were stained for succinate dehydrogenase (SDH), an important 
enzyme in citric acid cycle and α-glycerophosphate dehydrogenase (α-GPD), 
an important enzyme in glycolysis pathway. Histochemistry results revealed 
that Akirin1 knock-out muscle sections have significantly lower SDH staining 
compared to the wild-type sections (Figure 4.15A). The normalised optical 
density also showed significant reduction of SDH staining in Akirin1 knock-
out muscle sections compared to the wild-type (Figure 4.15B). However, there 
was no significant difference in α-GPD staining between Akirin1 knock-out 

































































Figure 4.15 Lack of Akirin1 makes the muscle fibers less oxidative. (A) 
Panel showing representative succinate dehydrogenase (SDH) staining in 
Akirin1 knock-out and wild-type tibialis anterior muscle sections. Scale bar 
represents 100 μm. (B) Quantification of optical density of SDH staining in 
Akirin1 knock-out and wild-type tibialis anterior muscle sections. The values 
are mean ± S.E. of three animals. Level of significance was compared to wild-
type (***p<0.001). (C) Panel showing representative α-glycerophosphate 
dehydrogenase (α-GPD) staining in Akirin1 knock-out and wild-type tibialis 
anterior muscle sections. Scale bar represents 100 μm. (D) Quantification of 
optical density of α-GPD staining in Akirin1 knock-out and wild-type tibialis 

















4.16 Absence of Akirin1 leads to reduced mitochondrial DNA copy 
number in skeletal muscle. 
Reduced CREB-1 levels have been shown to down-regulate its target genes 
like PPARα and PGC1α. Thus, leading to reduced oxidative potential of the 
skeletal muscle and affecting the energy homeostasis (Thomson et al., 2007; 
St-Pierre et al., 2003). Other research groups have also shown that the amount 
of ATP generated through oxidative phosphorylation in the mitochondria is 
proportional to the mitochondrial DNA copy number (Chen et al., 2010; 
Dickinson et al., 2013). So, copy number of mitochondrial DNA (mtDNA) per 
nuclear DNA (nuDNA) ratio was estimated by performing real time-qPCR 
with specific set of primers for mtDNA and nuDNA. The results showed that 
Akirin1 knock-out quadriceps muscle contained significantly lower mtDNA 
per nuDNA ratio compared to the wild-type muscle (Figure 4.16A). Thus 
showing that lack of Akirin1 reduces the mitochondrial DNA copy number in 
skeletal muscle, there by affecting the oxidative potential of the skeletal 


































Figure 4.16 Absence of Akirin1 leads to reduced mitochondrial DNA copy 
number in skeletal muscle. (A) Graph showing the copy number of 
mitochondrial DNA (mtDNA) per nuclear DNA (nuDNA) ratio in Akirin1 














































Figure 4.17 Lack of Akirin1 regulates the protein levels of AMPK in 
skeletal muscle. Western blotting analysis for AMPKα was performed on 
protein lysates of Akirin1 knock-out and wild-type quadriceps muscle. A(i) A 
representative immunoblot showing the protein level of AMPKα. GAPDH 
was used as the internal control for equal protein loading on the gel. A(ii) A 
graph showing corresponding densitometry analysis of AMPKα level. 
(*p<0.05) (n=4). Expression analysis of AMPKα in Akirin1 over-expressor 
myoblasts during differentiation. Western blotting was performed on protein 
lysates from differentiating Akirin1 over-expressor myoblasts and control 
C2C12 myoblasts. B(i) A representative immunoblot showing the protein level 
of AMPKα. B(ii) A graph showing the corresponding densitometry analysis of 
AMPKα protein level in differentiating Akirin1 over-expressor myoblasts and 
control C2C12 myoblasts. All the graphs are representative of at least two 
independent experiments. Level of significance was compared to control 
C2C12 myoblasts (*p<0.05). mRNA expression of AMPKα2 was determined in 
Akirin1 knock-out and wild-type quadriceps muscle. (C) A graph showing the 
fold change mRNA expression of AMPKα2 in Akirin1 knock-out quadriceps 















4.17 Lack of Akirin1 regulates the protein levels of AMPK in skeletal 
muscle. 
Skeletal muscle is a highly metabolic tissue that quickly responds and adapts 
to the various energy fluctuations in the body. One of the most important 
proteins that help in maintaining the energy metabolism in skeletal muscle is 
AMPK. Being known as a “metabolic master switch”, AMPK senses the ATP 
levels and mediates the cellular adaptation to nutritional and environmental 
variations. As results from section 4.15 and 4.16 showed that Akirin1 knock-
out muscle is less oxidative compared to the wild-type muscle, we wanted to 
investigate the AMPKα protein level in Akirin1 knock-out muscle. Protein 
levels of AMPKα were reduced in Akirin1 knock-out quadriceps muscle 
compared to the wild-type [Figure 4.17A(i) and A(ii)].      
To validate if AMPK protein levels are indeed regulated by Akirin1, we 
analyzed AMPK levels in Akirin1 over-expressor cells and control C2C12 
cells. Akirin1 over-expressor cells showed significantly higher levels of 
AMPKα protein levels at 48 and 72 hours of differentiation [Figure 4.17B(i) 
lanes 2 and 4; B(ii)] .  
As AMPKα protein level was reduced in Akirin1 knock-out muscle, we 
wanted to investigate if the AMPKα2 expression was down-regulated at 
mRNA level in the absence of Akirin1. For this, AMPKα2 mRNA levels were 
quantified by real time-qPCR and the AMPKα2 Ct values were normalised to 
cyclophilin Ct values. Results showed that there was no significant difference 
in the amount of AMPKα2 mRNA between Akirin1 knock-out and wild-type 
muscles (Figure 4.17C). These results together indicate that Akirin1 regulates 
the expression of AMPKα post-transcriptionally in skeletal muscle. 
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4.18 Protein levels of PPARα and PGC1α are affected in the absence of 
Akirin1 in skeletal muscle.   
Activation of AMPK triggers a number of downstream effectors, which 
together maintain the energy homeostasis. The important downstream 
molecules of AMPK that play an important role in ATP synthesis through 
oxidative phosphorylation are Peroxisome Proliferator Activated Receptor-α 
(PPARα) and its coactivator Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α). These two proteins interact and induce 
transcription of various genes, making the skeletal muscle oxidative in nature. 
Other studies have shown that over-expression of PPARα result in fiber-type 
switch, from glycolytic (type II) to oxidative (type I) (Holst et al., 2003).  
As Akirin1 knock-out muscle is less oxidative, we wanted to ascertain if 
downstream signaling of AMPK is affected via PPARα and PGC1α. For this, 
Akirin1 knock-out and wild-type quadriceps muscle protein lysates were 
subjected to western blotting with anti-PPARα and anti-PGC1α antibodies. 
The results showed that Akirin1 knock-out muscle showed significantly lower 
levels of both the proteins compared to the wild-type muscle [Figure 
4.18.1A(i), A(ii) and A(iii)].  
On the contrary, PGC1α protein level was significantly up-regulated when 
Akirin1 was over-expressed compared to control C2C12 myoblasts at 48 and 72 
hours of differentiation.  However, PPARα protein level was unchanged. 
[Figure 4.18.1B(i) lane 2 and 4; B(ii) and B(iii)]. 
As the absence of Akirin1 down-regulated the protein levels of PPARα and 
PGC1α in quadriceps muscle, we analyzed the expression of these two genes 
by real time-qPCR in wild-type and Akirin1 knock-out quadriceps muscle and 
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normalised to cyclophilin Ct values. The results showed that Akirin1 knock-
out muscle showed no significant difference in the mRNA levels of both 
PPARα and PGC1α genes when compared to the wild-type muscle (Figure 
4.18.2 A and B). These results together suggest that Akirin1 regulates PPARα 


















Figure 4.18.1 Akirin1 regulates the downstream target of AMPK, PPARα 
and PGC1α, thus affecting the transcription of energy homeostasis genes 
in skeletal muscle. Analysis of PPARα and PGC1α levels in Akirin1 knock-
out quadriceps muscle and Akirin1 over-expressor myoblasts. Western 
blotting analysis for PPARα and PGC1α was performed on protein lysates of 
Akirin1 knock-out and wild-type quadriceps muscle. A(i) A representative 
immunoblot showing the protein levels of PPARα and PGC1α. GAPDH was 
used as the internal control for equal protein loading on the gel. A(ii) and 
A(iii) Graphs showing corresponding densitometry analysis of PPARα and 
PGC1α levels respectively. (**p<0.01) (n=4). Expression analysis of PPARα 
and PGC1α in Akirin1 over-expressing myoblasts. Western blotting was 
performed on protein lysates from differentiating Akirin1 over-expressor 
myoblasts and control C2C12 myoblasts. B(i) A representative immunoblot 
showing the protein levels of PPARα and PGC1α. B(ii) and B(iii) Graphs 
showing the corresponding densitometry analysis of PPARα and PGC1α 
protein levels in Akirin1 over-expressor myoblasts and control C2C12 
myoblasts. All the graphs are representative of at least two independent 































Figure 4.18.2 Akirin1 post-trancriptionally regulates PPARα and PGC1 α 
in skeletal muscle. mRNA expression of PPARα and PGC1α was determined 
in Akirin1 knock-out and wild-type quadriceps muscle. (A) and (B) Graphs 
showing the fold change mRNA expression of PPARα and PGC1α in Akirin1 









4.19 Akirin1 negatively regulates HDAC4 in skeletal muscle. 
Histones play an important function in epigenetic regulation of transcription thus 
affecting various processes like developmental events and cell cycle progression 
etc. Histones can be acetylated or deacetylated leading to conformational changes 
in chromosome structure and restricting the access of transcription factors to the 
DNA. One of the most important histone modifying enzymes is HDAC4, which 
belong to class II histone deacetylase family. HDAC4 possess the ability to 
deacetylated the histone proteins and thus repressing the transcription of various 
promoters. One of the upstream regulators of HDAC4 is AMPK. As we observed 
reduced levels of AMPK in Akirin1 knock-out mice (Figure 4.17), we wanted to 
investigate the levels of HDAC4. For this, western blotting was performed on 
Akirin1 knock-out and wild-type quadriceps muscle protein lysates with anti-
HDAC4 antibody. The results showed significantly increased levels of HDAC4 
protein in Akirin1 knock-out muscle when compared to wild-type muscle [Figure 
4.19A(i) and (ii)].    
On the contrary, when Akirin1 was over-expressed, HDAC4 protein levels 
were significantly down-regulated in Akirin1 over-expressor myoblasts 
compared to control C2C12 myoblasts at 48 and 72 hours of differentiation 
[Figure 4.19B(i) lane 2 and 4; B(ii)]. 
HDAC4 mRNA levels were quantified by real time-qPCR in wild-type and 
Akirin1 knock-out quadriceps muscle and normalised to cyclophilin Ct values. 
The results showed no significant difference in the mRNA level of HDAC4 
gene between Akirin1 knock-out and wild-type muscle (Figure 4.19C). These 
results suggest that Akirin post-transcriptionally regulates HDAC4 expression 
































Figure 4.19 Akirin1 negatively regulates HDAC4 in skeletal muscle. 
Analysis of HDAC4 levels in Akirin1 knock-out quadriceps muscle and 
Akirin1 over-expressor myoblasts. Western blotting analysis for HDAC4 was 
performed on protein lysates of Akirin1 knock-out and wild-type quadriceps 
muscle. A(i) A representative immunoblot showing the protein level of 
HDAC4. GAPDH was used as the internal control for equal protein loading on 
the gel. A(ii) A graph showing corresponding densitometry analysis of 
HDAC4 protein level. (***p<0.001) (n=4). Expression analysis of HDAC4 in 
Akirin1 over-expressor myoblasts. Western blotting was performed on protein 
lysates from differentiating Akirin1 over-expressor myoblasts and control 
C2C12 myoblasts. B(i) A representative immunoblot showing the protein level 
of HDAC4. B(ii) A graph showing the corresponding densitometry analysis of 
HDAC4 protein level in Akirin1 over-expressor myoblasts and control C2C12 
myoblasts. All the graphs are representative of at least two independent 
experiments. Level of significance was compared to control C2C12 myoblasts 
(*p<0.05). mRNA expression of Hdac4 was determined in Akirin1 knock-out 
and wild-type quadriceps muscle. (C) A graph showing the fold change 
mRNA expression of Hdac4 in Akirin1 knock-out quadriceps muscle 






























Figure 4.20 A schematic diagram summarizing the various results 
obtained in understanding the possible role of Akirin1 in fully 

























































5. ROLE OF AKIRIN1 IN CARDIAC MUSCLE 
 
This chapter explains the results, which help us in understanding the role of 
Akirin1 in cardiac muscle. The materials and methods used in this chapter are 
discussed in chapter 2 of this thesis.    
RESULTS 
5.1 Lack of Akirin1 leads to cardiac hypertrophy. 
To understand the effect of Akirin1 in cardiac muscle, we primarily 
investigated the size of Akirin1 knock-out and wild-type hearts. Ex-vivo 
Akirin1 knock-out heart showed no significant difference in heart size 
compared to the wild-type (Figure 5.1A). We examined the weights of the 
heart and calculated as percentage body weight. The results showed no 
significant difference in the heart weights between Akirin1 knock-out and 
wild-type mice (Figure 5.1B). Further, to investigate the effect of Akirin1 on 
cardiac muscle histology, whole hearts were transversely and longitudinally 
sectioned and stained with hematoxylin and eosin. The histology images 
revealed that the ventricular cavities were larger in Akirin1 knock-out heart 






















Figure 5.1 Lack of Akirin1 leads to cardiac hypertrophy. (A) A 
representative image of ex-vivo Akirin1 knock-out and wild-type heart. (B) 
Graph showing the heart weights of Akirin1 knock-out and wild-type mice 
calculated as percentage of total body weight. The values are mean ± S.E. of 
ten animals. (C) Longitudinal and transverse images of Akirin1 knock-out and 
wild-type hearts stained with hematoxylin and eosin showing larger 
ventricular cavities in Akirin1 knock-out heart compared to the wild-type 




























Figure 5.2.1 Lack of Akirin1 up-regulates the sarcomeric proteins in the 
cardiac muscle. Western blotting analysis was performed on Akirin1 knock-
out and wild-type cardiac muscle protein lysates. A(i) A representative 
immunoblot showing the protein levels of various sarcomeric contractile 
proteins (α-actin, α-MyHC, β-MyHC and desmin). GAPDH was used as an 
internal control for equal protein loading on the gel. A(ii), A(iii), A(iv) and 
A(v) are corresponding densitometry graphs of α-actin, α-MyHC, β-MyHC 
and desmin showing significant increase in protein content in Akirin1 cardiac 








5.2 Lack of Akirin1 up-regulates the sarcomeric protein levels in the 
cardiac muscle.   
Our results in section 4.4 suggested that lack of Akirin1 in skeletal muscle 
lead to reduced levels of sarcomeric proteins. So, we wanted to investigate if 
the expression of the important cardiac contractile proteins were also affected 
in the absence of Akirin1. For this, Akirin1 knock-out and wild-type cardiac 
muscle protein lysates were subjected to immunoblotting with anti-α-actin, 
anti-β-MyHC, anti-α-MyHC and anti-desmin antibodies. Protein analysis 
results revealed that Akirin1 knock-out cardiac muscle indeed show 
significantly increased levels of major sarcomeric proteins like α-actin, β-
MyHC, α-MyHC and desmin compared to the wild-type cardiac muscle 
[Figure 5.2.1A(i), A(ii), A(iii), A(iv) and A(v)].  
Next, we wanted to determine if the increase in sarcomeric protein levels 
corresponded to increased gene expression. For this, we quantified the α-actin, 
Myh7/β-MyHC and desmin mRNA expression in Akirin1 knock-out and wild-
type cardiac muscle by real-time qPCR. The gene expression analysis revealed 
that α-actin and Myh7/β-MyHC mRNA levels were significantly up-regulated 
in the Akirin1 knock-out cardiac muscle compared to the wild-type cardiac 
muscle [Figure 5.2.2A and B]. However the desmin mRNA levels were 
unchanged in Akirin1 knock-out and wild-type cardiac muscle [Figure 
5.2.2C]. These results suggest that Akirin1 knock-out mice show signs of 













Figure 5.2.2 Akirin1 regulates the cytoskeletal and contractile genes post-
transcriptionally in the cardiac muscle. mRNA expression of α-actin, β-
MyHC and desmin was determined in Akirin1 knock-out and wild-type cardiac 
muscle. (A), (B) and (C) graphs showing the fold change mRNA expression of 
α-actin, β-MyHC and desmin in cardiac muscle respectively. The values are 














































Figure 5.3 Lack of Akirin1 down-regulates the sarcomeric regulatory 
proteins in the cardiac muscle. Western blotting analysis was performed on 
Akirin1 knock-out and wild-type cardiac muscle protein lysates. A(i) A 
representative immunoblot showing the protein levels of various sarcomeric 
regulatory proteins (cardiac troponin T, cardiac troponin I and cardiac 
troponin C). GAPDH was used as an internal control for equal protein loading 
on the gel. A(ii), A(iii) and A(iv) Corresponding densitometry graphs of 
cardiac troponin T, cardiac troponin I and cardiac troponin C showing 
significant decrease or no change in protein content in Akirin1 cardiac muscle 
compared to the wild-type (*p<0.05 and **p<0.01). mRNA expression for 
cardiac troponin T, cardiac troponin I and cardiac troponin C was determined 
in Akirin1 knock-out and wild-type cardiac muscle. (B), (C) and (D) graphs 
showing the fold change mRNA expression of cardiac troponin T, cardiac 
troponin I and cardiac troponin C respectively. The values are mean ± S.E. of 












5.3 Lack of Akirin1 down-regulates the sarcomeric regulatory proteins in 
the cardiac muscle.  
The contraction of sarcomeres is mainly controlled by regulatory proteins like 
cardiac troponin T, cardiac troponin I and cardiac troponin C. It has been 
previously reported that the contractile ability of cardiac sarcomere reduced 
during pathological hypertrophy (James et al., 2000). So we determined the 
levels of these regulatory proteins by subjecting the protein lysates from 
Akirin1 knock-out and wild-type cardiac muscles to western blotting with 
anti-cardiac troponin T, anti-cardiac troponin I and anti-cardiac troponin C 
antibodies. The protein expression results showed that cardiac troponin T, 
known to bind to tropomyosin and facilitate sarcomere contraction, was 
significantly down-regulated in Akirin1 knock-out cardiac muscle compared 
to the wild-type cardiac muscle [Figure 5.3A(i) and A(ii)]. Another regulatory 
protein, cardiac troponin I, which regulates the contraction of the sarcomere 
by either turning on or off the interaction between the actin and myosin 
filaments, was also significantly down-regulated in the Akirin1 knock-out 
cardiac muscle compared to the wild-type cardiac muscle [Figure 5.3A(i) and 
A(iii)]. However the levels of cardiac troponin C which essentially binds to 
Ca
2+
 ions to initiate contraction was unchanged [Figure 5.3A(i) and A(iv)].  
The mRNA transcription of these genes was analyzed by real-time qPCR in 
Akirin1 knock-out and wild-type cardiac muscle using cyclophilin as the 
normalising internal control. Gene expression analysis showed that there was 
no significant difference in the mRNA levels of cardiac troponin T, cardiac 
troponin I and cardiac troponin C between Akirin1 knock-out and wild-type 
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cardiac muscles [Figure 5.3B, C and D]. This result shows that the cardiac 










































5.4  Lack of Akirin1 up-regulates Serum response factor (SRF) protein 
levels in cardiac muscle. 
Cardiac hypertrophy program is known to be induced by various transcription 
factors expressed in the cardiac muscle like SRF, GATA4 and MEF2C (Zhang 
et al., 2011; Hasegawa et al., 1997; Molkentin et al., 1993). Over-expression 
of SRF in cardiac muscle is specifically known to activate the cardiac 
hypertrophy genes like Atrial natriuretic protein (ANP) and β-MyHC via 
regulating miR-1 expression (Zhang et al., 2001). As we observed an increase 
in the levels of sarcomeric contractile proteins and decrease in sarcomeric 
regulatory proteins in the Akirin1 knock-out cardiac muscle, we wanted to 
investigate if cardiac hypertrophy was induced by SRF in Akirin1 knock-out 
mice.  
Firstly, we wanted to investigate the levels of SRF in both Akirin1 knock-out 
and wild-type cardiac muscle. Protein lysates of Akirin1 knock-out and wild-
type cardiac muscles were probed with anti-SRF antibody. The western 
blotting results showed significantly increased levels of SRF protein in 
Akirin1 knock-out cardiac muscle compared to that of the wild-type [Figure 
5.4A(i) and (ii)]. To see if the increase in cardiac SRF protein is due to 
increased cardiac SRF mRNA levels, we quantified the cardiac SRF mRNA 
levels using real-time qPCR with cyclophilin as the normalising internal 
control. No significant difference was observed in the SRF mRNA levels 
between Akirin1 knock-out and wild-type cardiac muscle (Figure 5.4B). These 
results suggest that Akirin1 regulates the expression of SRF post-












Figure 5.4 Lack of Akirin1 up-regulates Serum response factor (SRF) 
protein levels in cardiac muscle. Western blotting analysis was performed on 
Akirin1 knock-out and wild-type cardiac muscle protein lysates. A(i) A 
representative immunoblot showing the protein levels of SRF in Akirin1 
knock-out and wild-type cardiac muscle. Ponceau S staining was used as an 
internal control for equal protein loading on the gel. A(ii) Corresponding 
densitometry graph of SRF showing significant increase in protein content in 
Akirin1 cardiac muscle compared to the wild-type (**p<0.01) (n=4). mRNA 
expression of SRF was determined in Akirin1 knock-out and wild-type cardiac 
muscle. (B) A graph showing the fold change in mRNA expression of SRF in 
Akirin1 knock-out compared to the wild-type cardiac muscle. The values are 







5.5 Akirin1 regulates transcription of miR-1 in cardiac muscle. 
Zhang et al. showed that over-expression of SRF in cardiac muscle induced 
cardiac hypertrophy by down-regulating the miR-1 transcription, thereby up-
regulating the expression of miR-1 effector genes like ANP and β-MyHC 
(Zhang et al., 2011). The expression of primary miR-1 levels in both Akirin1 
knock-out and wild-type cardiac muscle was quantified using real time-qPCR. 
The miR-1 Ct values were normalised to that of U6. Gene expression analysis 
revealed that Akirin1 knock-out cardiac muscle showed significantly reduced 
primary miR-1level compared to the wild-type cardiac muscle (Figure 5.5A). 
As mature miR-1 is the active form of miRNA that binds to target genes and 
regulate their expression, the levels of mature miR-1 were analyzed in Akirin1 
knock-out and wild-type cardiac muscle. Similar to primary miR-1 levels, 
Akirin1 knock-out cardiac muscle showed significantly lower levels of mature 






































Figure 5.5 Akirin1 regulates transcription of miR-1 in cardiac muscle. 
Primary and mature miR-1 transcript levels in Akirin1 knock-out and wild-
type cardiac muscle. mRNA expression analysis was performed on Akirin1 
knock-out and wild-type cardiac muscle. (A) and (B) Representative graphs 
showing fold change expression of primary and mature miR-1 transcript levels 
in Akirin1 knock-out cardiac muscle respectively. The values are mean ± S.E. 




















































Figure 5.6 Absence of Akirin1 leads to increased expression of targets of 
miR-1: Atrial Natriuretic Peptide (ANP) and β-MyHC in cardiac muscle. 
Expression analysis of downstream targets of miR-1 namely ANP and β-
MyHC in Akirin1 knock-out and wild-type cardiac muscle. Western blotting 
analysis was performed on Akirin1 knock-out and wild-type cardiac muscle 
protein lysates. A(i) and B(i)  A representative immunoblot showing the 
protein levels of ANP and β-MyHC. GAPDH was used as an internal control 
for equal protein loading on the gel. A(ii) and B(ii) Corresponding 
densitometry graphs of ANP and β-MyHC showing significant increase in 
protein content in Akirin1 cardiac muscle compared to the wild-type 
(**p<0.01) (n=4). mRNA expression of ANP and β-MyHC was determined in 
Akirin1 knock-out and wild-type cardiac muscle. (C) and (D) Representative 
graphs showing the fold change mRNA expression of ANP and β-MyHC in 

















5.6 Absence of Akirin1 leads to increased expression of targets of miR-1: 
Atrial Natriuretic Peptide (ANP) and β-MyHC in cardiac muscle.   
 As miR-1 levels were down-regulated in Akirin1 knock-out cardiac muscle, 
we looked at the expression levels of some of the target genes regulated by 
miR-1 like Atrial natriuretic protein (ANP) and β-MyHC. Immunoblotting 
was performed on Akirin1 knock-out and wild-type cardiac muscle protein 
lysates with anti-ANP and anti-β-MyHC antibodies. The protein expression 
results showed that Akirin1 knock-out cardiac muscle expressed 
significantly increased levels of both ANP and β-MyHC protein compared to 
the wild-type cardiac muscle [Figure 5.6A(i), B(i), A(ii) and B(ii)]. To 
determine if the increase in ANP and β-MyHC protein levels is attributed to 
increased ANP and β-MyHC mRNA levels, gene expression analysis was 
performed to we quantify the ANP and b-MyHC mRNA level by real time-
qPCR with cyclophilin as normalising internal control. The results indicated 
that Akirin1 knock-out cardiac muscle showed significantly higher levels of 
both ANP and β-MyHC mRNA compared to the wild-type cardiac muscle 


















5.7 Cardiac hypertrophy induced due to lack of Akirin1 may not be 
through MEF2C.  
Another transcription factor, apart from SRF, that is known to induce cardiac 
hypertrophy is MEF2C (Molkentin et al., 1993). To see if MEF2C plays a role 
in inducing cardiac hypertrophy phenotype in the absence of Akirin1, western 
blotting was performed on protein lysates from Akirin1 knock-out and wild-
type cardiac muscles with anti-phospho-MEF2C (thr300) and anti-MEF2C 
antibodies. The results showed that there was no difference in the protein 
levels of both phospho-MEF2C (thr300) and total MEF2C levels between 
Akirin1 knock-out and wild-type cardiac muscle [Figure 5.7A(i)]. 
Densitometry analysis also showed no significant difference in both phospho-
MEF2C (thr300) and total MEF2C levels in Akirin1 knock-out and wild-type 
cardiac muscle [Figure 5.7A(ii) and A(iii)].    
To determine if there were any changes in Mef2c mRNA levels, gene 
expression analysis was performed to quantify the Mef2c mRNA level by real 
time-qPCR with cyclophilin as normalising internal control. The results 
indicated that there was no difference in Mef2c mRNA levels between Akirin1 

















Figure 5.7 Cardiac hypertrophy induced due to lack of Akirin1 may not 
be through MEF2C. Expression profile of MEF2C in Akirin1 knock-out and 
wild-type cardiac muscle. Western blotting analysis was performed on protein 
lysates of Akirin1 knock-out and wild-type cardiac muscle. A(i) A 
representative immunoblot showing protein levels of both phospho-MEF2C 
(thr 300) and total MEF2C in Akirin1 knock-out and wild-type cardiac 
muscle. GAPDH was used as an internal control for equal protein loading on 
the gel. A(ii) and A(iii) Corresponding densitometry analysis graphs of 
phospho-MEF2C (thr300) and total MEF2C (n=4). (B) Graph showing fold 
change in mRNA expression for MEF2C in Akirin1 knock-out and wild-type 
cardiac muscle. The values are mean ±S.E. of four different animals.   
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5.8 Absence of Akirin1 in the cardiac muscle leads to activation of IGF-
1/Akt/mTOR pathway leading to cardiac hypertrophy.   
To investigate the mechanism behind cardiac hypertrophy seen in Akirin1 
knock-out cardiac muscle, we investigated certain important cardiac 
hypertrophy inducing signaling pathways like IGF-1/Akt/mTOR pathway. 
This pathway involves cascade of intracellular components which together 
signal increased protein synthesis thus inducing cardiac hypertrophy (Haq et 
al., 2000; McMullen et al., 2003).  
Firstly, we investigated the protein level of the IGF-1 growth factor. Protein 
lysates from Akirin1 knock-out and wild-type cardiac muscle were subjected 
to western blotting with anti-IGF-1 antibody. Western blotting results showed 
that Akirin1 knock-out cardiac muscle have significantly increased levels of 
intracellular IGF-1 levels compared to the wild-type cardiac muscle [Figure 
5.8.1A(i)]. Densitometry analysis proved that the IGF-1 levels were 
significantly up-regulated in Akirin1 knock-out cardiac muscle compared to 
the wild-type [Figure 5.8.1A(ii)]. 
Binding of IGF-1 to its receptor activates its downstream target, phosphatidyl 
inositol-3-Kinase (PI3K). PI3K helps in phosphorylating membrane 
phospholipid phosphoinositide-4,5-biphosphate (PIP2) to phosphoinositide-
3,4,5-triphoshate (PIP3). So we looked at the levels of both active 
phosphorylated PI3K p85 subunit levels and total pI3K p85 subunit levels 
using western blotting. Akirin1 knock-out and wild-type cardiac muscle 
protein lysates were probed with anti-phospho-PI3K p85 (tyr458)/p55 (tyr199) 
and anti-PI3K p85 antibodies. Protein expression analysis showed 
significantly increased levels of phosho-PI3K p85 (tyr458)/p55 (tyr199) level  
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in Akirin1 knock-out compared to the wild-type cardiac muscle. However, the 
total PI3K p85 level did not change between Akirin1 knock-out and wild-type 
cardiac muscle [Figure 5.8.1B(i)]. Densitometry analysis showed that Akirin1 
knock-out cardiac muscle have significantly higher level of phospho-PI3K p85 
(tyr458)/p55 (tyr199) compared to the wild-type cardiac muscle while the total 
PI3K p85 level did not change [Figure 5.8.1B(ii) and B(iii)]. The ratio of 
phospho-PI3K p85 (tyr458)/p55 (tyr199) to total PI3K p85 also was higher in 














Figure 5.8.1 Absence of Akirin1 in the cardiac muscle leads to increased 
levels of IGF-1 and PI3K proteins. Western blotting analysis was performed 
on Akirin1 knock-out and wild-type cardiac muscle protein lysates. A(i) A 
representative immunoblot showing the protein levels of IGF-1 in Akirin1 
knock-out and wild-type cardiac muscle. GAPDH was used as an internal 
control for equal protein loading on the gel. A(ii) Densitometry graph of IGF-
1 protein levels  in Akirin1 knock-out and wild-type cardiac muscle. B(i) A 
representative immunoblot showing the protein levels of both phospho-PI3K 
p85 (tyr 458)/p55(tyr 199) and total PI3K p85 in Akirin1 knock-out and wild-
type cardiac muscle. GAPDH was used as an internal control for equal protein 
loading on the gel. B(ii) and B(iii) Densitometry graphs of phospho-PI3K p85 
(tyr 458)/p55(tyr 199) and total PI3K p85 protein levels  in Akirin1 knock-out 
and wild-type cardiac muscle respectively. B(iv) Densitometry graph 
representing the ratio of phospho-PI3K p85 (tyr 458)/p55(tyr 199) to total 
PI3K p85 levels. All the graph values are mean ±S.E. of four different 


















The signaling molecule that act downstream of PI3K is Akt. Akt also called 
protein kinase B is a serine/threonine protein kinase and is activated when 
phosphorylated at ser 473. We investigated the levels of both phospho-Akt 
(ser473) and total-Akt in Akirin1 knock-out and wild-type cardiac muscle. The 
immunoblotting results showed a significant increase in phosphorylation of Akt 
protein in Akirin1 knock-out cardiac muscle compared to the wild-type cardiac 
muscle, while the total Akt levels remained unchanged [Figure 5.8.2A(i)]. 
Densitometry analysis showed significant increase in Akt phosphorylation in 
Akirin1 knock-out cardiac muscle compared to the wild-type cardiac muscle 
with no changes in the total Akt levels [Figure 5.8.2A(ii) and A(iii)]. The ratio 
of phospho-Akt (ser473) to total Akt was higher in Akirin1 knock-out cardiac 





Figure 5.8.2 Absence of Akirin1 in the cardiac muscle leads to increased 
levels of Akt and mTOR proteins. Western blotting analysis was performed 
on Akirin1 knock-out and wild-type cardiac muscle protein lysates. A(i) A 
representative immunoblot showing the protein levels of both phospho-Akt 
(ser 473) and total Akt in Akirin1 knock-out and wild-type cardiac muscle. 
GAPDH was used as an internal control for equal protein loading on the gel. 
A(ii) and C(iii) Densitometry graphs of phospho-Akt (ser 473) and total Akt 
protein levels in Akirin1 knock-out and wild-type cardiac muscle respectively. 
A(iv) Densitometry graph representing the ratio of phospho-Akt (ser 473) to 
total Akt levels. B(i) A representative immunoblot showing the protein levels 
of both phospho-mTOR (ser 2448) and total mTOR in Akirin1 knock-out and 
wild-type cardiac muscle. GAPDH was used as an internal loading control. 
B(ii) and B(iii) Densitometry graphs of phospho-mTOR (ser 2448) and total 
mTOR protein levels in Akirin1 knock-out and wild-type cardiac muscle 
respectively. B(iv) Densitometry graph representing the ratio of phospho-
mTOR (ser 2448) to total mTOR levels. All the graph values are mean ±S.E. 
of four different animals. Level of significance was compared to wild-type 








Akt can further stimulate protein synthesis pathway via mammalian target of 
rapamycin (mTOR) and Glycogen synthase kinase-3-beta (GSK3β). Akt 
promotes protein synthesis by phosphorylating mTOR at ser2448 while 
inactivates GSK3b by phosphorylating at ser9 (Manning et al., 2007). Hence, 
we estimated the phosphorylated and total levels of both mTOR and GSK3β in 
Akirin1 knock-out and wild-type cardiac muscle. Firstly, western blotting was 
performed on Akirin1 knock-out and wild-type cardiac muscle with anti-
phospho-mTOR (ser2448) and anti-mTOR antibodies. Protein expression 
analysis showed that Akirin1 knock-out cardiac muscle have significantly 
increased levels of both phospho-mTOR (ser2448) and total mTOR compared 
to the wild-type cardiac muscle (Figure 5.8.2B(i), B(ii) and B(iii)]. The ratio 
of phospho-mTOR (ser2448) to total mTOR was also higher in Akirin1 




Figure 5.8.3 Absence of Akirin1 in the cardiac muscle leads to increased 
levels of GSK3β and 4eBP1 proteins. Western blotting analysis was 
performed on Akirin1 knock-out and wild-type cardiac muscle protein lysates. 
A(i) A representative immunoblot showing the protein levels of both phospho-
GSK3β (ser 9) and total GSK3β in Akirin1 knock-out and wild-type cardiac 
muscle. GAPDH was used as an internal loading control. A(ii) and A(iii) are 
densitometry graphs of phospho-GSK3β (ser 9) and total GSK3β protein 
levels in Akirin1 knock-out and wild-type cardiac muscle respectively. A(iv) 
Densitometry graph representing the ratio of phospho-GSK3β (ser 9) and total 
GSK3β levels. B(i) A representative immunoblot showing the protein levels of 
both phospho-4eBP1 (ser 65/thr 70) and total 4eBP1 in Akirin1 knock-out and 
wild-type cardiac muscle. GAPDH was used as an internal control for equal 
protein loading on the gel. B(ii) and B(iii) Densitometry graphs of phospho-
4eBP1 (ser 65/thr 70) and total 4eBP1 protein levels in Akirin1 knock-out and 
wild-type cardiac muscle respectively. B(iv)] Densitometry graph representing 
the ratio of phospho-4eBP1 (ser 65/thr 70) to total 4eBP1 levels. All the graph 
values are mean ±S.E. of four different animals. Level of significance was 








Further, western blotting was performed on Akirin1 knock-out and wild-type 
cardiac muscle protein lysates with anti-phospho-GSK3β (ser9) and anti-
GSK3β antibodies. Akirin1 knock-out cardiac muscle showed increased 
protein levels of both phospho-GSK3β (ser9) and total GSK3β compared to 
the wild-type cardiac muscle (Figure 5.8.3A(i), A(ii) and A(iii)]. The ratio of 
phospho-GSK3β (ser9) to total GSK3β was also significantly up-regulated in 
Akirin1 knock-out cardiac muscle compared to the wild-type cardiac muscle 
[Figure 5.8.3A(iv)].  
mTOR activates translation of various cellular proteins by activating 
eukaryotic translation initiation 4E (eIF4E) by phosphorylating the inhibitory 
eIF4E-binding proteins called 4eBPs. So we investigated the protein levels of 
a predominantly used 4eBP protein in mammals like 4eBP1. Western blotting 
was performed on protein lysates from Akirin1 knock-out and wild-type 
cardiac muscle with anti-phospho-4eBP1 (ser65/thr70) and anti-4eBP1 
antibodies. The levels of both phospho-4eBP1 (ser65/thr70) and total 
4eBP1was up-regulated in Akirin1 knock-out cardiac muscle compared to the 
wild-type [Figure 5.8.3B(i), B(ii) and B(iii)]. The ratio of phospho-4eBP1 
(ser65/thr70) to total 4eBP1 was also significantly increased in Akirin1 knock-
out cardiac muscle compared to the wild-type cardiac muscle [Figure 
5.8.3B(iv)]. All these results together suggest that in the absence of Akirin1, 
the signaling proteins involved in IGF-1/Akt/mTOR pathway are activated 






5.9 Lack of Akirin1 leads to activation of JNK signaling pathway in the 
cardiac muscle. 
Haq et al. showed that the three mitogen activated protein kinase (MAPK) 
pathways are activated during cardiac hypertrophy i.e., c-Jun N-terminal 
kinase (JNK), p38 and Extracellular signal-regulated kinase (ERK1/2) 
pathways (Haq et al., 2001). The protein levels of both phospho-JNK 
(T183/Y185) and total JNK in Akirin1 knock-out and wild-type cardiac 
muscles using anti-phospho-JNK (T183/Y185) and anti-JNK antibodies 
respectively were analyzed. Western blotting results showed that Akirin1 
knock-out cardiac muscle showed increased levels of phospho-JNK 
(T183/Y185) compared to the wild-type cardiac muscle while the total JNK 
levels were unchanged between Akirin1 knock-out and wild-type cardiac 
muscle [Figure 5.9A(i), A(ii) and A(iii)]. The ratio of phospho-JNK 
(T183/Y185) to total JNK was also significantly increased in Akirin1 knock-















Figure 5.9 Lack of Akirin1 leads to activation of JNK signaling pathway 
in the cardiac muscle. Western blotting analysis was performed on Akirin1 
knock-out and wild-type cardiac muscle protein lysates. A(i) A representative 
immunoblot showing the protein levels of both phospho-JNK(T183/Y185) and 
total-JNK in Akirin1 knock-out and wild-type cardiac muscle. GAPDH was 
used as an internal control for equal protein loading on the gel. A(ii) and A(iii) 
are corresponding densitometry graphs of phospho-JNK(T183/Y185) and 
total-JNK. A(iv) Densitometry graph representing the ratio of phospho-
JNK(T183/Y185) to total-JNK levels. All the graph values are mean ±S.E. of 




5.10 Lack of Akirin1 leads to activation of p38 signaling pathway in the 
cardiac muscle. 
Another important member of the MAPK pathways is p38 MAPK pathway. 
We wanted to investigate if p38 pathway was up-regulated in Akirin1 knock-
out cardiac muscle as it was shown by Haq et al., 2001 that p38 pathway is up-
regulated during cardiac hypertrophy. The protein lysates from Akirin1 knock-
out and wild-type cardiac muscle were subjected to western blotting with anti-
phospho-p38 MAPK (T180/Y182) and anti-p38 MAPK antibodies. Protein 
expression analysis showed that Akirin1 knock-out cardiac muscle showed 
increased levels of both phospho-p38 MAPK (T180/Y182) and p38 MAPK 
protein levels compared to the wild-type [Figure 5.10A(i)]. Densitometry 
analysis also showed that Akirin1 knock-out cardiac muscle showed increased 
levels of both phospho-p38 MAPK (T180/Y182) and p38 MAPK protein 
levels compared to the wild-type cardiac muscle [Figure 5.10A(ii) and A(iii)]. 
The ratio of phospho-p38 MAPK (T180/Y182) to p38 MAPK was also 
significantly up-regulated in Akirin1 knock-out cardiac muscle compared to 





















Figure 5.10 Lack of Akirin1 leads to activation of p38 MAPK signaling 
pathway in the cardiac muscle. Western blotting analysis was performed on 
Akirin1 knock-out and wild-type cardiac muscle protein lysates. A(i) A 
representative immunoblot showing the protein levels of both phospho-p38 
MAPK (T180/Y182) and total-p38 MAPK in Akirin1 knock-out and wild-type 
cardiac muscle. GAPDH was used as an internal control for equal protein 
loading on the gel. A(ii) and A(iii) Corresponding densitometry graphs of 
phospho-p38 MAPK (T180/Y182) and total-p38 MAPK. A(iv) Densitometry 
graph representing the ratio of phospho-p38 MAPK (T180/Y182) to total-p38 
MAPK levels. All the graph values are mean ±S.E. of four different animals 




5.11 Lack of Akirin1 leads to activation of ERK1/2 signaling pathway in 
the cardiac muscle. 
We investigated the levels of another member of MAPK pathway like 
ERK1/2, as it was shown by Haq et al., 2001 that ERK pathway is up-
regulated during cardiac hypertrophy. Akirin1 knock-out and wild-type 
cardiac muscle protein lysates were probed with anti-phospho-ERK1/2 
(thr202/tyr204) and ERK1/2 antibodies. Western blotting results showed that 
Akirin1 knock-out cardiac muscle showed increased levels of phospho-
ERK1/2 (thr202/tyr204) compared to the wild-type cardiac muscle while the 
total ERK1/2 levels were unchanged between Akirin1 knock-out and wild-
type cardiac muscle [Figure 5.11A(i), A(ii) and A(iii)]. The ratio of phospho-
ERK1/2 (thr202/tyr204) to total ERK1/2 was also significantly increased in 
Akirin1 knock-out cardiac muscle compared to the wild-type cardiac muscle 
[Figure 5.11A(iv)]. These results together suggest that all the three main 
MAPK signaling pathways are activated in the absence of Akirin1 in cardiac 




















Figure 5.11 Lack of Akirin1 leads to activation of ERK1/2 signaling 
pathway in the cardiac muscle. Western blotting analysis was performed on 
Akirin1 knock-out and wild-type cardiac muscle protein lysates. A(i) A 
representative immunoblot showing the protein levels of both phospho-
ERK1/2 (thr202/tyr204) and total-ERK1/2 in Akirin1 knock-out and wild-type 
cardiac muscle. GAPDH was used as an internal control for equal protein 
loading on the gel. A(ii) and A(iii) Corresponding densitometry graphs of 
phospho-ERK1/2 (thr202/tyr204) and total-ERK1/2. A(iv) Densitometry 
graph representing the ratio of phospho-ERK1/2 (thr202/tyr204) to total-
ERK1/2  levels. All the graph values are mean ±S.E. of four different animals 






5.12 Akirin1 does not regulate MuRF1 in cardiac muscle. 
It has been shown that MuRF1 is an important regulator of cardiac 
hypertrophy by affecting the sarcomeric protein turnover in the cardiocytes 
(Willis et al., 2007). The results in skeletal muscle in section 4.7 showed that 
Akirin1 regulates the expression of MuRF1. So we wanted to investigate if 
Akirin1 regulates MuRF1 expression in cardiac muscle as well causing cardiac 
hypertrophy. For this, protein lysates from Akirin1 knock-out and wild-type 
cardiac muscle were probed with anti-MuRF1 antibody. The results showed 
no significant difference in the MuRF1 protein levels between Akirin1 knock-
out and wild-type cardiac muscle [Figure 5.12A(i) and A(ii)]. The MuRF1 
mRNA levels were quantified by real time-qPCR and MuRF1 Ct values were 
normalised to Cyclophilin Ct values. Consistent with the protein levels, 
Akirin1 knock-out cardiac muscle showed no significant difference in the 
MuRF1 mRNA levels when compared to the wild-type cardiac muscle (Figure 
5.12B).  
As the expression of MuRF1 did not change in Akirin1 knock-out cardiac 
muscle, we wanted to investigate if the activity of MuRF1 as an E3 ubiquitin 
ligase changed. Western blotting was performed with anti-ubiquitin antibody. 
The results showed that the extent of ubiquitination of various cellular proteins 
were unchanged in Akirin1 knock-out cardiac muscle compared to the wild-
type cardiac muscle [Figure 5.12C(i)]. Densitometry analysis confirmed that 
the extent of protein ubiquitination in Akirin1 knock-out and wild-type cardiac 
muscles were the same [Figure 5.12C(ii)]. This proves that Akirin1 does not 


























Figure 5.12 Akirin1 does not regulate MuRF1 in cardiac muscle. Western 
blotting analysis was performed on protein lysates of Akirin1 knock-out and 
wild-type cardiac muscle. A(i) A representative immunoblot showing protein 
levels of MuRF1 in Akirin1 knock-out and wild-type cardiac muscle. α-
tubulin was used as an internal control for equal protein loading on the gel. 
A(ii) Corresponding densitometry analysis of MuRF1 showing no significant 
change in protein content between Akirin1 knock-out and wild-type cardiac 
muscle (n=4). (B) Graph showing fold change in mRNA expression of MuRF1 
in Akirin1 knock-out and wild-type cardiac muscle. The values are mean 
±S.E. of four different animals. C(i) A representative immunoblot showing the 
extent of ubiquitination of cellular proteins in Akirin1 knock-out and wild-
type cardiac muscle. GAPDH was used as an internal control for equal protein 
loading on the gel. C(ii) Corresponding densitometry graph of ubiquitination 



















Figure 5.13 A schematic diagram summarizing the various results 
obtained in understanding the possible role of Akirin1 in inducing cardiac 






















































Akirin1 is a recently known molecule that has not been extensively studied. 
Being a ubiquitously expressed nuclear protein, it can be speculated to have 
different functions in different tissues. Some of the important discoveries in the 
past revealed its role in myogenic differentiation (Marshall et al., 2008) and in 
satellite cell activation and skeletal muscle regeneration (Salerno et al., 2009).  
To further elucidate the function of Akirin1 in striated muscle (skeletal and 
cardiac muscle), Akirin1 knock-out mouse model was used in this study. 
The results obtained in this study show that Akirin1 knock-out mice did not 
show any obvious phenotypic change when compared to wild-type mice. The 
molecular analysis of important myogenic genes performed on Akirin1 knock-
out skeletal muscle revealed that levels of myogenic genes were unchanged 
except for myogenin. Myogenin is known to play an important role in early 
differentiation (Venuti et al., 1995; Cserjesi et al., 1991) and thus a decrease in 
myogenin levels would lead to impaired differentiation (Sassoon et al., 1989). 
Also, another research group has recently shown that reduced myogenin levels 
in primary myotubes can reverse the process of myogenic terminal 
differentiation (Nikolaos et al., 2012). Thus, it can be expected that Akirin1 
may be positively regulating myogenin levels and affecting myogenic 
differentiation. However, in Akirin1 knock-out primary cultures we did not 
observe reduced myogenic differentiation. In fact, the fusion index was higher 
in Akirin1 knock-out compared to the wild-type cultures. This phenotype 
could be an effect of increased SRF levels in the Akirin1 knock-out myoblasts 
(Figure 3.4 and 3.7). It also appears that SRF could be compensating for the 
reduced myogenin levels in differentiating primary myotubes. It has been 
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shown that SRF is known to be an important transcription factor essential for 
myogenic differentiation. So, it is likely that Akirin1 negatively regulates SRF 
during differentiation. Further, this regulation of SRF by Akirin1 was 
observed at post-transcriptional level as only the protein levels changed but 
not the mRNA levels. One of the mechanism by which Akirin1 may be post-
transcriptionally regulating SRF levels is through MuRF1. It has been 
previously reported that SRF is targeted by MuRF1, an ubiquitin ligase, 
leading to its degradation, there by affecting myoblast differentiation (Lange 
et al., 2005; Soulez et al., 1996). Consistent with these reports, our results 
showed that Akirin1 regulates MuRF1 transcription during myogenic 
differentiation and in the the absence of Akirin1, MuRF1 levels were down-
regulated (Figure 3.8 and 4.6). Thus, in the absence of Akirin1, it could be 
speculated that due to reduced MuRF1 levels, SRF is not being degraded to 
the wild-type levels leading to increased myoblast fusion. However, additional 
research is necessary to confirm this idea. Also, due to higher SRF and p21 
levels, the Akirin1 knock-out myoblasts would withdraw from the cell cycle 
and differentiate earlier when compared to the wild-type myoblasts. 
Consistently, the results show an increased fusion of the myoblasts in the early 
stages of differentiation and thus no obvious phenotypic change in Akirin1 
knock-out muscle was observed. 
Besides having a role in myogenic differentiation, MuRF1 has a role in 
maintaining the integrity of the sarcomeres. MuRF1 is localized to the Z and 
M lines of sarcomere where it interacts with an array of proteins in the 
sarcomere and cytoskeleton (McElhinny et al., 2004).  Our results have shown 
that lack of Akirin1 leads to reduced levels of MuRF1 in skeletal muscle 
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(Figure 4.6). Due to reduced MuRF1 protein level, important cytoskeletal 
proteins like desmin, actin and poly-glutamylated tubulin were also reduced 
when compared to the wild-type muscle (Figure 4.4 and 4.9). It has been 
previously reported that MuRF1 was involved in the glutamylation of tubulin 
(Spencer et al., 2000). Glutamylation renders stability to the microtubules, 
thus maintaining the sarcomeric integrity. Hence, it is quite possible that 
Akirin1 via MuRF1 regulates the stability of cytoskeletal proteins in muscle. 
Molecular analysis of sarcomeric genes like α-actin, Myosin heavy chain and 
troponins showed that Akirin1 knock-out skeletal muscle showed reduced 
levels of these proteins compared to the wild-type (Figure 4.2 and 4.4). 
Reduced levels of these sarcomeric and cytoskeletal proteins in Akirin1 
knock-out muscle may be compromising the sarcomeric stability and the 
effects of which can be extensively studied in a couple of ways. One is to 
study the detailed intra-cellular muscle fiber structure to directly assess the 
potential structural changes caused due to reduced levels of MuRF1 and other 
sarcomeric proteins using electron microscopy. Another way would be to 
study the extent of muscle regeneration after muscle injury by a myotoxin like 
notexin in Akirin1 knock-out mice compared to the wild-type mice. 
Apart from stabilizing sarcomeric structure, MuRF1 being an E3 Ubiquitin ligase 
is known to regulate protein turnover in the skeletal muscle (Sacheck et al., 
2004). A balance between synthesis and turnover of sarcomeric proteins is 
essential for maintenance of skeletal muscle structure and function. Our results 
showed that reduced MuRF1 levels lead to reduced ubiquitination of sarcomeric 
proteins (Figure 4.10). Reduced ubiquitination of sarcomeric proteins like MyHC 
has been previously reported to result in a myopathy characterized by 
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subsarcolemmal protein accumulation and reduced muscle contraction (Fielitz et 
al., 2007). So it may possible that lack of Akirin1 may be affecting the skeletal 
muscle function due to reduced MuRF1 levels. A detailed structure of Akirin1 
knock-out sarcomere by electron microscopy would help in further 
understanding the effect of reduced ubiquitination of sarcomeric proteins.     
Another important finding of this study is that the expression analysis showed 
that Akirin1 transcriptionally regulates the expression of different types of 
MyHC genes. Muscle fibers are made up of different types of MyHC like Myh7 
in type I fibers (oxidative fibers), Myh2 in type IIa fibers (fast oxidative fibers) 
and Myh4 in type IIb fibers (fast glycolytic fibers). These different MyHC 
proteins have been shown to have different extent of ATPase activity thereby 
regulating energy metabolism in skeletal muscle (Edstrom et al., 1982, Rajab et 
al., 2000; Conjard et al., 1998). The proportion of different muscle fiber types are 
already established during embryogenic myogenesis. However in adults, they 
adapt to the metabolic energy demands by switching from one fiber type to 
another (Berchtold et al., 2000; Fluck et al., 2003). For example, a sprinter would 
require bursts of energy for fast contraction of muscles. Hence a sprinter’s limb 
muscles would have higher proportion of fast twitch-glycolytic fibers. On the 
contrary, a marathon runner would require constant supply of energy to run long 
distances with slower muscle contraction compared to a sprinter. Hence a 
marathon runner’s limb muscles would have higher proportion of slow twitch-
oxidative fibers. Results obtained from our study showed that lack of Akirin1 
down-regulated Myh7 which encodes for MyHC in slow twitch and oxidative 
type I fibers and up-regulated Myh2 which encodes for MyHC in fast twitch and 
less oxidative type IIa fibers. As a result of which, ablation of Akirin1 makes the 
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muscle less oxidative by increasing Myh2 expression, leading to an increase in 
fast contracting type IIa muscle fibers and a decrease in Myh7 expression, 
causing a decrease in slow contracting type I muscle fibers (Figure 4.15.1 and 
4.15.2).  
Another way to estimate the oxidative capacity in skeletal muscle is by SDH 
histochemistry. Akirin1 knock-out muscle showed reduced SDH staining with no 
difference in the α-GPD staining (measure of glycolytic capacity) indicating that 
lack of Akirin1 makes the muscle less oxidative while the glycolytic potential is 
unaffected (Figure 4.15). This further confirms the results that ablation of 
Akirin1 leads to fiber type switch from slow twitch oxidative type I myofibers to 
fast twitch less oxidative type IIa myofibers. Based on these results it can be 
inferred that Akirin1 plays a novel role in the determination of fiber type in the 
muscle which in turn would have a profound impact on the metabolic activity of 
the muscle.  
In relevance to further comprehending the role of Akirin1 in energy metabolism, 
another aspect that would be worth exploring is the role of Akirin1 in regulating 
the mitochondrial DNA copy number and mitochondrial dynamics. We show 
herein that lack of Akirin1 leads to significant reduction in mitochondrial DNA 
copy number both during myogenic differentiation and in fully differentiated 
skeletal muscle (Figure 3.11 and 4.16). Reduced mitochondrial DNA copy 
number has been correlated to reduced ATP generation through oxidative 
phosphorylation thus serving as a read-out for mitochondrial function (Barazzoni 
et al., 2000). Furthermore, mitochondrial function and shape is dependent on two 
opposing processes called mitochondrial fission and fusion. An imbalance in 
these dynamic processes leads to impaired mitochondrial function eventually 
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leading to mitophagy (Bossy-Wetzel et al., 2003, Youle et al., 2012). Thus, it 
would be worth studying the role of Akirin1 in regulating the mitochondrial 
morphology by studying the expression profile of important marker genes 
involved in maintaining the balance between mitochondrial fission (e.g. Drp1, 
Fis1)  and mitochondrial fusion (e.g. Mfn1, OPA1) (Lee et al., 2004; Chen et al., 
2005). Also, mitochondrial number and morphology could be visualized by 
robust mitochondrial staining with Mito Tracker Red dye in Akirin1 knock-out 
and wild-type primary culture during differentiation and in skeletal muscle.  
Furthermore we investigated the levels of proteins involved in the oxidative 
metabolic activity of skeletal muscle. For example, AMPK, a master regulator of 
cellular energy metabolism that maintains energy homeostasis in skeletal muscle 
was down-regulated in Akirin1 knock-out muscle (Figure 4.17). Consistently, its 
downstream targets CREB-1, PPARα and PGC1α levels were also reduced in the 
absence of Akirin1 (Figure 4.11 and 4.18).  However, proteins like CREB-1 and 
PPARα were not up-regulated in differentiating Akirin1 over-expressing 
myoblasts (Figure 4.11.1 and 4.18.1). This could be due to differences in 
metabolic activity of fully differentiated skeletal muscle and differentiating 
myoblasts. Nonetheless, these results confirm a novel role of Akirin1 in 
regulating skeletal muscle metabolism. Research from other groups have 
established that reduced protein levels of CREB-1, PPARα and PGC1α leads to 
reduced mitochondrial function eventually leading to type 2 diabetes (Asmann et 
al., 2006).  
Previous reports have also implicated MuRF1 in energy metabolism. Koyama et 
al. showed that MuRF1 links protein synthesis and energy metabolism 
mechanisms in skeletal muscle (Koyama et al., 2008). MuRF1 is also shown to 
213 
 
regulate carbohydrate metabolism by regulating blood glucose levels in mice 
(Hirner et al., 2008). As we observed reduced MuRF1 levels in the absence of 
Akirin1, it could be possible that carbohydrate metabolism may be affected in 
Akirin1 knock-out mice. However, additional research is necessary to establish 
the function of Akirin1 in regulating carbohydrate metabolism in mice.  
This novel finding of effect of Akirin1 dysfunction on metabolic activity would 
be of significant clinical relevance as skeletal muscle is a highly metabolic tissue 
which plays an important role in maintaining energy metabolism homeostasis in 
the body. For example, Schuler et al. have shown that mice exhibiting fiber-type 
switch from slow contracting type I slow fibers to fast contracting type IIa fast 
fibers, developed metabolic disorders like obesity and Type 2 diabetes (Schuler 
et al., 2006). Thus, Akirin1 would have a significant role in maintaining a 
homeostatic balance in energy metabolism and would serve as a potential 
therapeutic target in the treatment of metabolic disorders like obesity and 
diabetes.  
 From the regulation point of view, we wanted to determine how Akirin1 
regulates MuRF1. Firstly we analyzed the promoter region of MuRF1. The 
promoter analysis showed FoxO3 and CREB-1 binding sites on MuRF1 
promoter. Previous reports have shown that FoxO3 transcription factor 
transcriptionally up-regulates MuRF1 in skeletal muscle (Zhao et al., 2007; Stitt 
et al., 2004). FoxO3 protein needs to be dephosphorylated to migrate to the 
nucleus to activate the transcription of MuRF1. The phosphorylated FoxO3 
remains cytoplasmic and is in an inactive form. In fact, our results show that 
there was an increase in phosphorylated form of FoxO3 in Akirin1 knock-out 
skeletal muscle and during myogenic differentiation. Consistently, the levels of 
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FoxO3 were up-regulated when Akirin1 was over-expressed in C2C12 myoblasts 
(Figure 3.9 and 4.8.1). Akirin1, a nuclear protein, is considered to act as co-
factor.  In-silico analysis of Akirin1 protein structure speculated that Akirin1 
contains putative Forkhead interacting motif. So it may be possible that Akirin1 
directly interacts with FoxO3 transcription factor, helping in the translocation of 
FoxO3 to the nucleus and leading to MuRF1 transcription. Transfection and 
band-shift assay results indicated that Akirin1 might be regulating the 
transcription of MuRF1 through CREB-1 also (Figure 4.7 and 4.12). The 
mechanism of CREB-1 mediated regulation of MuRF1 by Akirin1 is most likely 
an indirect one and hence is not clear yet.   
Our work showed that absence of Akirin1 results in de-regulation of several 
genes that participate in skeletal muscle metabolism. It is also clear that Akirin1 
regulates few genes like MuRF1 and Myh2 at transcriptional level while the 
others like AMPK, CREB-1, PPARα are regulated at post-transcriptional level. It 
is quite possible that some of the results we observe in this study due to lack of 
Akirin1 may be direct effects because of its interaction with transcription factors 
like FoxO3. This study clearly shows that Akirin1 regulates some molecules 
similarly both during differentiation and in fully differentiated muscle. However 
as the role of each of these molecules is different during myogenic differentiation 
and in fully differentiatiated muscle, we observe a different effect. Differential 
regulation of genes by Akirin1 can be further studied using a systems analysis 
approach to get more insights on understanding the exact mode of action of 
Akirin1 in regulating this array of genes. 
Recent studies in Drosophila have shown that DmAkirin physically interacts 
with muscle transcription factor twist, and regulates transcription of twist-related 
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genes (Nowak et al., 2012). DmAkirin protein is also known to co-localise with 
Brahma SWI/SNF complex subunits which is a chromatin remodelling complex. 
Hence DmAkirin is predicted to link twist and chromatin remodelling complex 
affecting the expression of twist-regulated genes (Nowak et al., 2012). Our 
results herein show that lack of Akirin1 post-transcriptionally up-regulated 
HDAC4 which is known to play an important role in epigenetic regulation of 
many skeletal muscle genes (Figure 4.19). So, it may be possible that Akirin1 
has a role directly or indirectly or both in epigenetically regulating the various 
genes that were observed in this study. 
Akirin1 was found to have an interesting and distinct function in cardiac muscle. 
Our results showed that Akirin1 knock-out heart had larger ventricular cavity as 
seen in left ventricular hypertrophy (LVH) (Figure 5.1). One of the important 
pathways involved in both pathological and physiological hypertrophy is 
PI3K/Akt/GSK3β pathway and activation of PI3K leads to cardiac hypertrophy 
(Naga Prasad et al., 2000). Consistent to this finding, increase in PI3K protein 
was seen in Akirin1 knock-out cardiac muscle leading to activation of PI3-
K/Akt/GSK3β pathway leading to increased protein synthesis (Figure 5.8). This 
increased protein synthesis was proven by increased protein levels of sarcomeric 
and cytosolic proteins like α-actin, MyHC and desmin in our study (Figure 
5.2.1). It has been proven in pathological hypertrophy that the contractility of 
cardiac sarcomeres is affected due to reduced troponin I and troponin T levels 
(Varnava et al., 2001; Takeishi et al., 1998). In Akirin1 knock-out cardiac 
muscle also the troponin I and troponin T levels were down-regulated suggesting 
that Akirin1 knock-out hearts are undergoing pathological hypertrophy (Figure 
5.3). Apart from PI3-K/Akt/GSK3β pathway, various other stress kinase 
216 
 
pathways are known to be activated during pathological cardiac hypertrophy like 
ERK pathway, p38 MAPK pathway and JNK pathway (Bueno et al., 2002; 
Bueno et al., 2000; Sugden et al., 1998; Wang et al., 1998; Wang et al., 1998; 
Zhang et al., 2003; Ramirez et al., 1997). The results from our study also showed 
that all the above pathways were activated in the absence of Akirin1 (Figure 5.9, 
5.10 and 5.11). Thus showing that lack of Akirin1 affects the cardiac muscle 
mass homeostasis.  
Zhang et al. showed that cardiac specific over-expression of SRF led to 
cardiomyopathy (Zhang et al., 2001). Later, the same research group in 2011 
showed that this cardiac-specific over-expression of SRF led to down-regulation 
of miR-1 biogenesis (Zhang et al., 2011). In another study it was shown that 
miR-1 targets cardiac hypertrophy inducing genes like ANP and β-MyHC (Wei 
et al., 2014). Consistent with these findings, our study also showed that in the 
absence of Akirin1, SRF protein level was up-regulated in the cardiac muscle 
(Figure 5.4). This increase in SRF might be leading to down-regulation of miR-1 
biogenesis due to which ANP and β-MyHC expression was up-regulated (Figure 
5.6). Re-expression of fetal genes like ANP and β-MyHC are proven to induce 
Akt signaling pathway in the cardiac muscle leading to increased sarcomeric 
protein synthesis and pathological hypertrophy (Kato et al., 2005). Thus it can be 
speculated that Akirin1 post-transcriptionally regulates SRF levels in cardiac 
muscle leading to pathological cardiac hypertrophy through miR-1. 
In summary, we have observed that Akirin1 regulates certain genes at 
transcription level and others post-transcriptionally. The exact mode of Akirin1 
action is yet to be elucidated and it is quite possible that many of the observed 
differences are due to redundant or indirect processes to which Akirin1 is the 
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contributing factor. For example, Akirin1 may be regulating these genes post-
transcriptionally either by affecting their RNA stability or through micro-RNAs 
that target the mRNA of the above genes and inhibit its translation. However, 
through this study, we have clearly established a striated muscle phenotype due 
to Akirin1 ablation, suggesting a novel role of Akirin1 in regulating metabolic 
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